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ABSTRACT  
 
 Adaptive immunity requires T cell responses to foreign pathogens to be 
counterbalanced with the need to limit collateral destruction of the host’s own tissues. 
Further, the presence of a substantial pool of lymphocytes capable of recognizing self-
antigen in the periphery poses a threat to the maintenance of peripheral tolerance and 
prevention of autoimmunity. Regulatory T cells (Treg) that can suppress potentially self-
reactive T cells are critical regulators of peripheral tolerance as well as initiation of 
immune responses. Treg cells employ several context-dependent mechanisms to establish 
regulation. In this thesis, we describe two distinct pathways of regulation used by Treg 
cells involving negative costimulation by CTLA-4 and immunomodulation by the 
morphogen, TGFβ. 
 CTLA-4 is a co-inhibitory receptor on T cells essential for maintaining T cell 
homeostasis and tolerance to self. CTLA-4 expression is induced in conventional T cells 
following activation, whereas it is constitutively expressed in regulatory FOXP3+CD4+ 
regulatory T cells. Mice lacking CTLA-4 develop an early onset, fatal breakdown in T 
cell tolerance. Whether this autoimmune disease occurs because of the loss of CTLA-4 
function in regulatory T cells, conventional T cells, or both, is not known. We present 
evidence here that in addition to a critical CTLA-4 function in regulatory T cells, CTLA-
4 in conventional T cells is also necessary for controlling the consequences of abnormal 
T cell activation. CTLA-4 expression in activated conventional T cells only in vivo is 
unable to compensate for the impaired function of CTLA-4-less regulatory T cells that 
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results in systemic lymphoproliferation, but it can prevent the aberrantly activated T cells 
from infiltrating and fatally damaging non-lymphoid tissues. These results demonstrate 
that CTLA-4 has a dual function in maintaining T cell homeostasis: CTLA-4 in 
regulatory T cells inhibits inappropriate naïve T cell activation and CTLA-4 in 
conventional T cells can prevent the harmful accumulation of inappropriately activated 
pathogenic T cells in vital organs. 
 In addition, we have identified Disabled-2 (Dab2), a TGFβ signaling 
intermediate, as a FOXP3 target gene that is expressed exclusively in Treg cells and is 
critical for in vitro and in vivo regulation by Treg cells. During T cell development, 
DAB2 is also expressed in a Foxp3-independent manner in thymic precursor cells, and 
acts as a sensor of TGFβ signals that is required for programming normal TGFβ 
responsiveness in T cell progenies. Naïve CD4+ T cells that differentiate from Dab2-
deficient precursors favor Th17 cell generation at the expense of FOXP3+ Treg cells as a 
result of altered sensitivity to TGFβ. Importantly, retinoic acid can restore TGFβ 
signaling capacity of naïve CD4+ T cells generated from Dab2-deficient precursors, 
emphasizing the cooperative nature of retinoic acid and TGFβ signaling pathways in 
promoting Treg cell development and maintenance.  
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 CHAPTER 1 
INTRODUCTION 
 
There is no need to be a doctor or a scientist to wonder why the human body is 
capable of resisting so many harmful agents in the course of everyday life. 
Ilya Metchnikov, Nobel lecture, 1908. 
 
Disease and Immunity 
 The Merriam-Webster dictionary defines disease as “a condition of the living 
animal or plant body or of one of its parts that impairs its normal functioning and is 
typically manifested by distinguishing signs and symptoms”. Diseases can arise due to 
a myriad of factors including genetic or developmental defects, infections, poisons, 
nutritional deficiency or imbalance, toxicity, or unfavorable environmental 
conditions. The organism’s defense against these factors is called immunity (Latin: 
immunis) and the collection of mechanisms within an organism that function to 
provide this protection is called the immune system.  
 
 Over the course of history, there have been several indications of practices that 
were used to prevent and fight diseases. A formal demonstration of deliberate 
vaccination came in the late 18th century when Edward Jenner successfully used the 
harmless cowpox virus to immunize people against the smallpox causing vaccinia 
virus. However, most of the conceptual framework of the immune system was laid 
down much later in the 19th and early 20th century. In the words of Alfred Tauber, 
‘Immunology was born in the controversies of that fresh announcement that no 
1
 species, including our own, was a static entity; all were subject to change as a result 
of the vicissitudes of time and happenstance’ (1). Tauber refers, of course, to Charles 
Darwin’s On the Origin of Species, which was published in 1859 and generated 
intense furor in the scientific community. His evolutionary theory proposed an ever-
changing species in which favorable changes were inherited in successive generations 
of a reproducing organism. While this theory was vigorously opposed by several 
scientific and religious factions, it became apparent that the schema of an organism 
was not static, but was always adapting and evolving. In the backdrop of this 
revolutionary idea, several key discoveries were made that changed the way people 
thought about disease and immunity. 
 
 At the time, two lines of scientific inquiry existed- one that investigated the 
role of microorganisms as the primary cause of disease and the other that investigated 
host responses to these infectious agents. The former group was lead by Louis Pasteur 
who had decisively discarded the prevalent idea of ‘spontaneous generation’ and 
demonstrated, along with Robert Koch, that microorganisms were the agents 
responsible for disease. Medical practices were revolutionized by the contributions of 
Pasteur, Koch, Alexander Fleming and Joseph Lister to name a few, and the cause-
effect relationship between microbes and diseases was firmly established.  
 
 Ellie Metchnikoff, a Russian zoologist, was in the forefront of the second 
faction. Shortly after the publication of Origin, he performed the famous Messina 
experiments, a classic example of cellular immunology in which phagocytes from a 
starfish larvae punctured with a rose thorn would attempt to protect the larvae by 
2
 engulfing the intruding thorn tip. This was the first demonstration of a host cell 
population that was equipped to attack foreign potentially infectious agents and 
provide protective immunity. Around the same time, Paul Ehrlich and Emil von 
Behring, working with diphtheria toxin, elaborated the theory of ‘antigenicity’, which 
led to the idea that only certain substances can elicit the production of antibodies. 
Ehrlich also predicted the phenomenon of ‘horror autotoxicus’ or autoimmunity 
wherein, the host can, under certain conditions, make substances that can harm itself. 
Thus, by the beginning of the 20th century, two situations were defined that formed 
the fundamentals of immunity: ‘host identity’ or the ability of the host to distinguish 
between ‘self’ and ‘non-self’ and ‘host integrity’ or the ability of the host to 
counteract insults and injury. 
 
 Herein, I elaborate on these two concepts, beginning with a brief discussion on 
the ‘immune self’ and mechanisms of establishing self-tolerance, followed by a 
detailed review of the role of T regulatory cells in maintaining tolerance in the 
periphery.  Finally, I discuss the role of cytotoxic T lymphocyte antigen-4 (CTLA-4) 
and transforming growth factor β (TGFβ) as important effectors of immune regulation 
and T regulatory cell function. 
 
Immune Self and Tolerance 
 In the early 1940’s, immunologists, working with diverse experimental 
systems, introduced the concept of self-tolerance, which has since become one of the 
organizing concepts of Immunology. The term ‘self’ was first coined by Frank 
Macfarlane Burnet, a virologist, who postulated that the ‘self’ of the host body was 
3
 actively defined during its embryogenesis through interactions between cells of the 
immune system and other cells within the embryo (2). During this process, the 
developing immune system is taught to be tolerant to self, such that, upon antigenic 
challenge, it could mount a potent response against foreign, non-self antigen and 
leave host self-tissue untouched. This was experimentally demonstrated by Peter 
Medawar, Rupert Billingham and Leslie Brent who showed that neonatal or in utero 
injections of cells from mice of one strain (A) into a second strain (B) tolerized the 
strain B mice to donor A antigens when challenged in adulthood (3). Interestingly, 
Owen had already observed this phenomenon of tolerance when he was studying 
binovular twin cattle that shared a common placenta (4).  
 
 While there was a consensus among immunologists about the existence of 
self, the ‘nature’ of self was and still remains disputed. The cluster of genes that form 
the Major Histocompatibility Complex (MHC) can be considered as one of the main 
signatures of self. Pioneering work by Gorer and Snell identified these antigens as 
being responsible for the rejection of foreign engrafted tissue (5). However, while the 
MHC may be one identity of self, it is probably not the self itself. Classical 
experiments by Peter Doherty and Rolf Zinkernagel showed that the MHC was not 
the solution to the dilemma of self, but was an additional complexity to the immune 
system, because now the lymphoid cells did not simply have to deal with 
discriminating between self and non-self; it also had to distinguish between self and 
self plus MHC (6).  
 
4
  The current dogma is that the ‘immune self’ is not a static entity, but evolves 
during the life of an individual and the life of a species. While this idea challenges the 
simple reductionist approach that a single genetic criterion defines self, it serves better 
to explain the constant changes in an organism’s identity over ontogeny and 
evolution. More recent developments in the field have led immunologists to 
reconsider the necessity of self-non-self discrimination by the immune system. One 
emerging idea is that ‘dominant’ mechanisms of tolerance operate constantly and 
therefore, the immune system does not need to bother with self-recognition. Polly 
Matzinger is the protagonist of another school of thought, which completely discards 
the requirement of self-non-self discrimination for proper immune function. Her 
thesis instead proposes a “danger” model, wherein the host, instead of discriminating 
between what is self and what is foreign, now responds to the presence of ‘danger’- 
namely antigens secreted by damaged host tissues (7). A distinguishing feature of this 
theory is that the infectious agents themselves are not recognized as ‘dangerous’, but 
rather, the host tissues that are damaged in the process of infection, transmit the 
signals of damage.  
 
 Regardless of what self is, it is clear that the induction of self-tolerance 
requires the presence of antigen-sensitive cells that can ‘recognize’ antigen, a process 
which later impairs the cells’ capacity to respond to that antigen (8). Of the cells of 
the immune system, T and B lymphocytes have the ability for specific recognition of 
an enormous array of antigens by virtue of their expression of antigen-specific 
receptors, and are therefore, the key effectors of self-tolerance. The subsequent 
5
 discussions are restricted to the role of T cells in mediating and establishing immune 
tolerance.  
 
T cell tolerance 
 The T cell receptor (TCR) was identified in the late 1980’s using clone-
specific monoclonal antibodies to T cell lymphomas and hybridomas (9). TCRs are 
generated by random genetic rearrangements of the V, D and J elements that can give 
rise to up to 109 V-D-J genes in mice (10-12). The peripheral T cell repertoire is 
represented by an estimated 25x106 TCRs (13).  Due to this enormous diversity in the 
recognition capabilities of the TCR and the plasticity of antigen recognition by these 
TCRs, mechanisms must exist that protect the host from damage by self-reactive T 
cells. These mechanisms of T cell tolerance can be divided into two categories: 
central tolerance, operating in the thymus, and peripheral tolerance, operating in 
peripheral tissue and lymphoid organs. 
 
 Central tolerance broadly refers to the purging of the self-reactive repertoire 
as T cells develop in the thymus. T lymphocytes arise from multi-potent precursors in 
the bone marrow that are called haematopoietic stem cells (HSCs). Committed 
lymphoid progenitors migrate from the bone marrow to the thymus via the blood 
circulation. The earliest precursors to seed the thymus are the early T cell progenitors 
called ETPs, which are phenotypically characterized as Linlow (Lin: lineage markers), 
KIThi (Kit: receptor for the cytokine SCF, or stem cell factor), IL-7R+ and CD25- (IL-
2Rα) (14). They have multi-lineage potential and can differentiate into B cells, T 
cells, NK cells, and myeloid cells. ETPs then undergo ordered differentiation to 
6
 become DN2 (double negative, CD4-CD8-CD25+CD44+), DN3 (CD4-CD8-
CD25+CD44-) and DN4 (CD4-CD8-CD25-CD44-) cells (15) (Figure I-1). Myeloid, B 
and NK cell potential are lost at the DN2 stage, at which point these cells are 
committed to the T cell lineage. Expression of the recombinases, RAG1 
(Recombinase Activating Gene 1) and RAG2, leads to the rearrangement of the T cell 
receptor (TCR) γ, δ and β loci at the DN3 stage of development and the 
diversification into either the αβ or γδ lineage of T cells (16).  
 
 Signals emanating from a correctly assembled receptor are required for further 
survival and differentiation of developing thymocytes. For αβ T cells, this receptor is 
a complex of CD3, TCRβ and the invariant pre-TCRα chain (pTα). Assembly of a 
functional TCRβ/pTα complex, a process called beta-selection, leads to αβ lineage 
commitment, several rounds of proliferation and recombination of the TCRα locus to 
produce a mature αβ antigen receptor that is expressed on the cell surface. Following 
this, expression of pTα is lost and upregulation of CD8 and CD4 co-receptors 
commits precursors to the DP (double positive) stage of thymic development (17). 
The ligand specificity of the αβ receptor dictates whether that cell will proceed to the 
CD4 single positive (SP) or CD8SP stage. The first requirement for further selection 
is the expression of a TCR that can bind to either MHC class I or MHC class II. This 
process of screening for MHC restriction of T cells is called positive selection. While 
the numbers of αβ TCRs generated by random recombination is enormous, the 
generation of TCRs that can bind to MHC is quite infrequent, and as a result the 
majority of DP thymocytes are deleted despite expressing surface TCRs. As most 
7
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Figure I-1: T cell development in the thymus
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Figure I-1 T cell development in the thymus 
The earliest precursor cells that seed the thymus are the early thymic precursors or 
ETPs, which are phenotypically characterized as being CD4-CD8- (DN) CD44+CD25- 
and c-Kit+. These cells then undergo ordered differentiation to become DN2 (CD44-
CD25+cKit+), DN3 (CD44-CD25+) and DN4 (CD44-CD25-) cells. The γδ lineage of T 
cells arises from DN2 and DN3 precursors, while DN3 cells that express pre-Tα chain 
are committed to the αβ lineage of T cells. DN4 cells rapidly upregulate expression of 
CD4 and CD8 to become DP (CD4+CD8+) cells. DPs that express T cell receptors 
with appropriate affinity for self-MHC differentiate further to become either CD4SP 
(CD4+CD8-) or CD8SP (CD8+CD4-) cells. DP cells that express the transcription 
factor FOXP3 mature to become T regulatory cells. 
9
 MHC molecules display a self-peptide, thymocytes expressing TCRs that are MHC-
restricted also encounter self-antigen in the context of MHC. The quality and quantity  
of self-antigen that a thymocyte encounters will determine if it will be selected for 
further development or not. The ligands that induce positive selection of DP 
thymocytes have lower affinity and avidity to TCRs and are generally not stimulatory 
for mature T cells in the periphery. On the other hand, MHC-ligand complexes that 
bind with a high affinity to TCR are detrimental to T cells and signal for apoptosis of 
T cells. This process, called negative selection, is an extremely rapid and sensitive 
process and is a major mechanism preventing self-reactivity of T cells in the 
periphery. The DNA-binding transcriptional regulator, AIRE, is one factor that 
controls this process. AIRE regulates the thymic transcription of genes encoding 
peripheral tissue antigens that are displayed on medullary epithelial cells and thymic 
dendritic cells, and impaired presentation of self-peptides in the thymus of Aire-/- mice 
results in fatal autoimmunity in the periphery. The transcription factor ThPOK is 
essential for DP cells to transit to the MHC class II restricted CD4SP stage, while the 
transcription factor RUNX3 plays an important role in Cd4 gene silencing in MHC 
class I restricted precursors that become CD8SP (18). A small frequency of CD4SP 
cells is also positive for FOXP3, a transcription factor whose expression is initiated in 
certain DP precursor cells and maintained in cells that are called regulatory T cells 
(Treg). CD4SP, CD4SPFOXP3+ and CD8SP cells then exit the thymus, 
homeostatically proliferate and populate peripheral lymphoid organs.  
 
Peripheral tolerance  
10
  While intrathymic deletion of self-reactive T cells is an efficient way to ensure 
T cell self-tolerance, the diversity in antigen receptors and the random recombination 
events that generate this diversity make the process of deletion in the thymus 
imperfect. Incomplete presentation of antigens in the thymus and the plasticity of 
TCR recognition of antigen constitute an inherent danger to the maintenance of 
tolerance. It is clear that some self-reactive T cells do exit the thymus into the 
periphery. Additional post-thymic regulatory mechanisms are required to ensure that 
these auto-reactive T cells are not aberrantly activated in the periphery, and these 
constitute mechanisms of ‘peripheral tolerance’. 
 
 Several factors contribute to the maintenance of T cell tolerance to self-
antigen in the periphery. Antigen sequestration in immunologically privileged sites 
such as the eye (19), brain and the testes is one passive mechanism of tolerance by 
which T cells escape autoimmune activation . The quality and persistence of antigen, 
the maturation states of both the antigen presenting cell (APC) and the T cell, 
presence of regulatory cell populations and immuno-modulatory cytokines are some 
of the other key factors that regulate peripheral T cell tolerance. A description of all 
these mechanisms of maintaining peripheral tolerance is beyond the scope of this 
thesis and the subsequent discussions are restricted to mechanisms of dominant 
suppression utilized by T regulatory (Treg) cells. 
 
Autoimmunity 
 Failure of the immune system to recognize ‘self’ and subsequent loss in 
tolerance results in autoimmunity. This phenomenon, predicted as ‘horror 
11
 autotoxicus’ by Ehrlich in the late 1800’s, is a robust immune response against the 
host’s own tissues originating from inappropriate activation of lymphocytes to self-
antigen that results in considerable damage, and often times death, of the host. There 
are more than 80 described autoimmune diseases that range from systemic diseases, 
such as SLE (systemic lupus erythematosus), to tissue specific disease, such as Type 1 
Diabetes. While every person carries a circulating self-reactive T and B cell 
repertoire, certain individuals are predisposed to develop autoimmunity. There is a 
strong linkage between genes of the MHC and polymorphisms in cytokine and 
costimulatory molecules with autoimmune diseases. In addition, environmental 
factors like infections also predispose to precipitation of autoimmunity. 
 
Immune Homeostasis 
 To appreciate the consequences of a breakdown in peripheral tolerance and 
ensuing autoimmunity, it is important to understand how lymphocytes are sustained at 
relatively constant numbers in an antigen inexperienced host. Naive lymphocytes in 
the periphery are maintained as a non-proliferating population with a half-life of at 
least 6 months (20).  Peptide/MHC interactions and cytokine signals are two key 
factors that regulate the size and composition of the peripheral T cell pool. The 
common gamma-chain cytokines, IL-7, IL-15 and IL-2 are critical in maintaining 
peripheral T cell homeostasis. Il7-/- and Il7r-/- mice have severe defects in lymphocyte 
development in the thymus as well as maintenance of T cells in the periphery (21). 
Mice with gene knockouts (KO) of IL-2, IL-2Rα and IL-2/15Rβ all exhibit 
spontaneous activation of T cells and inflammatory disease, which leads to premature 
death (22-24). However, unlike Il7r-/- mice, the defect in these mice stems from the 
12
 lack of an important regulatory cell population that results in abnormal homeostatic 
regulation of lymphocytes in the periphery (25). In addition to receiving survival 
signals from cytokine receptors, T cells also constantly interact with MHC-ligand 
complexes through their T cell receptor. Whether this interaction is essential for T cell 
survival remains debatable.  In experiments with lymphopenic mice, Class II 
expression appears to be critical for the persistence of adoptively transferred CD4+T 
cells in vivo (26, 27). However, in lymphocyte sufficient mice, the same is not true 
and MHC Class II ligands seem to be dispensable (28-30). Interestingly, tonic self-
MHC class II and TCR interactions are essential to ensure functional sensitivity of T 
cells upon encounter with cognate peptide ligands (31). 
 
 Peptide ligands are presented to T cells on MHC molecules expressed on 
antigen presenting cells (APC) such as dendritic cells (DC). The context of T cell and 
APC interaction determines whether tolerance is maintained or an adaptive immune 
response is initiated. In a homeostatic environment, DCs are in an immature state and 
at a given time, about half of the lymph node DCs have high MHC Class II expression 
and express low levels of co-stimulatory ligands such as B7-2 and ICAM-1 (32, 33). 
In such steady-state conditions, immature DCs circulate between non-lymphoid and 
lymphoid tissue at a rapid rate, and have a half-life of <2 days (34-36). Although 
these DCs constantly scavenge tissues (37, 38), they have poor antigen processing 
capacities and much of their MHC is loaded with peptides derived from self-tissue 
(39). In fact, this persistent basal level of presentation of self-peptide is essential for 
maintaining tolerance, and T cells make short-lived tolerogenic encounters with DCs 
that result in abortive T cell activation. On the other hand, maturation of DCs results 
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 in increased formation of stable MHC-peptide complexes, higher expression of 
costimulatory molecules like B7-2, synthesis of cytokines and altered patterns of 
chemokine and chemokine receptor expression. Under such conditions, DCs can 
efficiently engage and activate T cells that lead to the initiation of an adaptive 
immune response. Thus, tolerogenic and immunogenic interactions between T cells 
and APCs are critical in maintaining the balance between tolerance and immunity. 
 
Maintaining tolerance in the periphery: Regulatory T cells 
 The immune system has evolved numerous ways to keep autoreactive T cells in 
check in the periphery. Probably the most prominent pathway of dominant regulation 
is mediated by the action of suppressor T cells. In the past few years there has been a 
tremendous growth in our understanding of these cells with respect to their 
development and function and their potential use as immunotherapeutic agents. It is 
interesting, however, that immunologists were introduced to this concept as early as 
1970 when Richard Gershon reported the presence of a specialized thymic-derived 
population of suppressor T cells (40). This idea was met with a lot of resistance and 
was summarily discarded for almost two and a half decades. One of the chief reasons 
for this skepticism stemmed from the inability of researchers to find the I-J locus, 
which was thought to encode for the so-called antigenic determinants expressed by 
suppressor T cells (41). Sadly, Richard Gershon died in 1983, long before the revival 
of T suppressor cells, and in an obituary by Baruj Benacerraf in the Journal of 
Immunology, one paragraph stands out- ‘Richard Gershon made one of the most 
important discoveries in Immunology in this century. In 1970 together with his 
student Kondo he established that thymus-derived lymphocytes are capable of 
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 exerting a specific negative regulatory effect in immune responses and called these 
cells suppressor T cells….When pioneer scientists endowed with vision make 
unexpected discoveries, as in the case of Gershon in 1970, they have a difficult time 
getting their discoveries to be taken seriously..’ (42). In 2002, Charlie Janeway Jr. 
wrote in the Annual Reviews of Immunology ‘(today)...we can infer the existence of 
the long-anticipated suppressor T cells. So you were right all along, Richard, and I 
personally apologize for years of my own skepticism’ (43). 
 
 An important early observation that influenced the resurrection of dominant 
suppression in the 1990’s was that mice thymectomized during the neonatal stage 
developed organ-specific autoimmunity and further, cells derived from an adult 
spleen could prevent this disease (44). Later, Juan Lafaille in Susumu Tonegawa’s 
laboratory demonstrated that TCR transgenic mice specific for the N-acetylated 
residue 1-11 of the myelin basic protein were completely protected from experimental 
autoimmune encephalitis (EAE) when injected with the peptide (45). However, if the 
TCR transgenic mice were crossed onto the RAG deficiency (to eliminate endogenous 
TCR gene rearrangement), these mice rapidly succumbed to overwhelming EAE upon 
peptide administration, suggesting the presence of a cell population that was present 
or induced in RAG sufficient mice that protected from disease. However, the first 
formal description of a naturally occurring regulatory T cell (Treg) population came 
from the work of Shimon Sakaguchi who showed that approximately 10% of 
peripheral CD4+ T cells in an antigen-inexperienced mouse expressed CD25, the IL-
2Rα chain. These CD4+CD25+ T cells behaved as suppressor T cells because transfer 
of CD25+ depleted CD4+ T cells into nu/nu (athymic mice/SCID, discussed later) 
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 mice resulted in severe autoimmunity, which could be prevented by the injection of 
CD4+CD25+ cells (46, 47). Interestingly, Fiona Powrie had already noted that transfer 
of purified naïve T cells lacking expression of activation and/or memory markers into 
immunodeficient hosts lead to autoimmunity in the form of Inflammatory Bowel 
Disease (IBD), and similar to Sakaguchi’s observation, addition of T cells that 
express low levels of OX-22, a memory T cell marker, prevents disease (48, 49).  
Finally, work from Ethan Shevach’s laboratory showed that purified CD4+CD25+ T 
cells could suppress the proliferation of responder T cells in vitro, and also described 
the IL-2 dependence of these Treg cells for their survival and proliferation in vitro 
(50).  
 
 These seminal papers underscored the fact that autoimmune pathology similar 
to existing human autoimmune diseases can be reproduced in mice by the depletion of 
a regulatory T cell population and convincingly resurrected the idea of suppressor T 
cells that exerted dominant regulation to maintain peripheral tolerance. Since their 
revival, sizeable insights have been made that provide irrefutable evidence towards 
the existence and indispensability of these Treg cells. 
 
Regulatory T cells 
 By definition, a regulatory T cell is a cell that a) has the capacity to modulate 
the quality and/or magnitude of an immune response or the lack of it, and b) the 
absence of such a regulatory cell population should result in pathologic immune 
dysregulation. However, the term has mostly come to be associated with some form 
of suppression of immune reactivity, whether it is activation to stimuli (self or 
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 foreign), production of effector cytokines or movement to sites of inflammation and 
tissue damage. Using these criteria, several subpopulations of Treg cells can be 
defined including CD4+CD25+ T cells (51), IL-10 producing Tr1 cells (52), TGFβ 
producing Th3 cells (53), CD8+ T suppressor cells (54), natural killer T (NKT) cells 
(55), CD4-CD8-T cells (56) and γδ T cells (57). 
 
 A detailed discussion of the CD4+CD25+ cells, which are relevant to this 
thesis, follows in subsequent sections. However, the other Treg cell subsets merit a 
few words here. The Tr1 cells were first described as a CD4+T cell subset that are 
distinct from effector Th1 and Th2 cells, and make copious amounts of IL-10 and 
TGFβ but little or no IL-2 and IL-4 (58). Naïve CD4+T cells can be induced to 
become Tr1 cells upon antigen priming in the presence of IL-10. CD8+ Tr1-like cells 
can also be generated in vitro by stimulating naïve CD8+T cells with activated 
plasmacytoid DCs (59) or IL-10 treated myeloid DCs (60). Tr1 cells do not normally 
express the transcription factor FOXP3 (61), which is a characteristic marker of 
CD4+CD25+ Treg cells. However, there are some instances when Tr1 cells do up-
regulate FOXP3 upon activation (62). IL-10 and TGFβ primarily mediate the 
suppressive function of Tr1 cells. These immunomodulatory cytokines act in part by 
inhibiting IL-2 production by T cells and down-regulating expression of 
costimulatory molecules and suppressing cytokine production by APCs. An important 
point to note here is that natural Treg cells (CD4+CD25+FOXP3+) also produce IL-10, 
and the lack of specific Tr1 cells markers makes the distinction between these cells 
and natural Treg cells difficult. 
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  A regulatory T cell subset important in the induction of oral tolerance and 
maintenance of homeostasis in mucosal tissues is the TGFβ secreting Th3 cells. Oral 
tolerance is the specific suppression of cellular and/or humoral responses to an 
antigen by prior oral administration of the antigen. This is a major pathway of 
maintaining tolerance to food antigen and commensal bacteria resident in the mucosal 
surface of the gut. There are two pathways to the induction of tolerance - the 
generation of regulatory cells and clonal deletion/anergy. Low antigen doses favors 
the generation of regulatory T cells whereas high dose antigen favors the induction of 
anergy. Th3 cells, also called ‘adaptive’ Treg cells, are induced by antigen stimulation 
in the periphery, as opposed to ‘natural’ Treg cells that are thymus derived. Th3 cells 
function by the secretion of immunosuppressive cytokines like TGFβ that can 
modulate APC function as well as effector T cell differentiation. CD8+ T cells can 
also be converted to Th3 cells (63), which can mediate bystander suppression in vivo. 
 
 Besides conventional αβ T cells, non-conventional T cells like the γδ T cells 
and NKT cells have been shown to have immunoregulatory function. Unlike αβ T 
cells, most γδ T cells and NKT cells do not undergo negative selection, but are 
positively selected by engagement of autoantigens during development (64-66). 
Although the antigen receptor specificity of these cells is unknown, it is clear that the 
absence of these cell subsets in mice leads to immune dysfunction. γδ T cell-deficient 
mice present with exaggerated immune responses and exacerbated pathology to 
infections with Klebsiella, Mycobacteria and Listeria (67-69). The αβ T cell 
associated lupus-like autoimmunity in MRL/LPR mice is worsened on the γδ-
deficient background (70). These studies and others implicate γδ T cells in regulating 
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 aspects of αβ T cell function that can lead to autoimmunity and pathology particularly 
in intra-epithelial tissues of the gut and skin.  
 
 CD4+CD25+ Treg cells 
 It is well established that of the numerous subsets of Treg cells, the 
CD4+CD25+ Treg cells are the most crucial regulators of peripheral tolerance. The IL-
2Rα chain or CD25 was the first molecule to be identified as an important cell-
surface marker of Treg cells (46). This is a useful marker to identify Treg cells in an 
antigen-inexperienced, relatively naïve mouse. However, activated T cells also 
express CD25, and the utility of CD25 as a marker of Treg cells during an ongoing 
immune response becomes questionable. Further, CD25 is not simply a marker of 
activation on Treg cells but is important for Treg cell development and maintenance. 
Evidence for this comes from the severe autoimmune phenotype of Il2-/- and Il2Rβ-/- 
mice. These strains have a dramatic decrease in the frequency of Treg cells, both in 
the thymus and periphery. STAT5 (Signal Transducer and Activator of Transcription) 
is an indispensable signal transducer of common-gamma chain cytokines including 
IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. While STAT-5 deficient mice (conditional 
deletion using Cd4CreTg mice) have a severe block in thymic development, they also 
have a significant reduction in the frequency and numbers of CD4+CD25+FOXP3+ 
Treg cells, and it was shown that STAT5 plays an essential regulatory function in 
Foxp3 gene transcription downstream of IL-2 (25, 71, 72).  
 
 An important development in the field was the identification of FOXP3 
(Forkhead Box Protein P3) as a transcription factor that is expressed exclusively in 
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 Treg cells. FOXP3 belongs to the ‘forkhead’ family of transcription factors that have 
diverse roles in the immune system. 
 
FOX proteins in immune function 
 FOX  (forkhead) proteins were first identified in Drosophila melanogaster, 
where they are involved in terminal pattern formation in the embryo (73). They are a 
large family of transcriptional regulators and typically contain a sequence of 80-100 
amino acids that form the DNA binding forkhead domain. This motif is also referred 
to as the winged-helix domain due to the butterfly-like appearance of the loops in the 
protein structure. There are more than 100 forkhead containing proteins that can be 
divided into 15 classes based on structural homology (74). FOX proteins play 
important roles in regulating expression of genes involved in cell growth, 
proliferation, differentiation, longevity and embryonic development. Several FOX 
family members regulate different aspects of immune system development and 
function. Mutations in Foxn1 are responsible for the nude/SCID (nu) phenotype in 
mice, rats and humans that results in the lack of hair, abnormal epidermis 
development and the absence of the thymus (75, 76). Athymia has been attributed to a 
block in the development of thymic epithelial cells (TEC) in Foxn1 deficient mice 
(77). FOXJ1 is a protein that regulates Th1-Th2 effector cell differentiation. Foxj1 
knockout mice are embryonic lethal as FOXJ1 has crucial roles in the development of 
ciliated cells like pulmonary epithelial cells. However, in fetal-liver chimera 
experiments, while lymphocyte development is normal, peripheral CD4+T cells have 
an activated phenotype and are prone to producing more IFNγ and IL-2. These cells 
also have up-regulated expression of t-bet, a Th1 skewing transcription factor, 
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 suggesting that FOXJ1 is a negative regulator of Th1 differentiation (78). FOXO3A is 
a regulator of NF-κB activity and its importance in immune cells came from the 
evidence that older Foxo3a-/- mice suffered from late-onset autoimmunity leading to a 
dramatic loss in immune homeostasis, lymphoproliferation and multi-organ 
lymphocyte infiltration (79). One proposed molecular mechanism of FOXO3A 
function is by regulating the activity of the cell cycle inhibitor, p27kip1 (80), which is 
a regulator of T cell anergy (81). While these FOX family members regulate 
significant aspects of immune function, probably the most vital forkhead transcription 
factor for the immune system is FOXP3.  
 
FOXP3 and Treg cells 
 The history of FOXP3 can be traced back to 1949, when the scurfy mutation 
arose spontaneously in the inbred MR mouse strain at the Oak Ridge National 
Laboratory (82). The defect was mapped to a X-linked recessive mutation with 
lethality in hemizygous males. The affected males (sf/Y) suffered from acute 
autoimmunity leading to ear thickening, scaling of the ears, eyelids, feet and tail. The 
mice were severely runted and died by three weeks of age because of massive 
lymphoproliferation. A frameshift mutation in exon 8 of the Foxp3 gene that 
generated a protein that lacked the forkhead DNA-binding domain was determined to 
be the cause of the phenotype of these mice (83, 84). A similar disease is seen in 
IPEX (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked) patients 
who present with watery and often times bloody diarrhea in infancy, and multi-organ 
autoimmunity including atopic dermatitis, thyroiditis and Type 1 Diabetes (85). 
Affected individuals usually develop symptoms early in childhood and die by 2-3 
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 years of age. The gene defect responsible for IPEX syndrome was also mapped to 
mutations in the Foxp3 gene (84, 86, 87). Heterozygous females carrying a single 
mutant scurfy allele (sf/X) were protected from disease despite random inactivation of 
one X-chromosome, suggesting the existence of a subset of ‘Foxp3 wt’ cells that 
regulate autoimmune activation of lymphocytes in trans. These cells that expressed 
Foxp3 and could regulate in trans were identified to be the same CD4+CD25+ Treg 
cells described by Sakaguchi et al in 1995 (88-90).  
 
 A bulk of literature now exists that suggests that FOXP3 is necessary and 
sufficient for the development and function of Treg cells. The first evidence came 
from the similar autoimmune phenotype of Foxp3 knock out mice and scurfy mice, 
both of which are a result of a lack of Treg cells in these mice. There are some 
indications that FOXP3 may play a role in thymic epithelial cell function (91, 92); 
however, conditional deletion of Foxp3 in CD4+ T cells using Cd4CreTg mice results 
in a similar breakdown in tolerance as Foxp3-/- mice, ruling out the role of TECs in 
the observed phenotype (93, 94). Secondly, mixed bone marrow (BM) chimera 
experiments with wt and Foxp3-/- BM shows that only wt BM can contribute to the 
CD4+CD25+ Treg compartment in the thymus and periphery, suggesting that Foxp3 is 
necessary for the development of Treg cells (89). Third, the generation of Foxp3 
reporter mice allowed the purification of Treg cells independently of CD25, and 
functional assays showed that FOXP3 expression is sufficient for in vitro suppression 
while CD25 is dispensable (93, 95). Notably, enforced expression of FOXP3 by 
retroviral infection of conventional CD4+CD25- cells imparts regulatory function to 
these cells and they can suppress proliferation of uninfected responder cells in vitro as 
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 well as regulate various autoimmune diseases (autoimmune gastritis, colitis) in 
adoptive transfer models in vivo (88, 89).  
 
 More recently, however, the field has begun to question the role of FOXP3 as 
the ‘master’ regulator of Treg development and function. One key observation leading 
to this is the fact that human CD4+T cells can up-regulate FOXP3 expression during 
the normal course of their activation (96). This was the first suggestion than FOXP3+ 
Treg cells can be induced de novo upon TCR stimulation. Whether the FOXP3 
expression in activated human T cells results in the gain of suppressive function is 
controversial. It has been suggested that only those cells that can maintain stable, high 
expression of FOXP3 have the capacity to become suppressor cells. In the mouse 
system, it has been shown that conventional CD4+CD25-FOXP3- cells can be induced 
to express FOXP3 upon activation in the presence of TGFβ (95, 97, 98). One 
characteristic of these de novo generated FOXP3+ cells is the instability of FOXP3 
expression. ‘Natural’ thymic derived Treg cells maintain FOXP3 expression and 
suppressive function and constitute a stable Treg lineage. On the other hand, induced 
Treg cells in both mice and humans appear to have distinct requirements for 
maintaining FOXP3 expression, and only those cells that sustain high FOXP3 
expression acquire regulatory function (99, 100). This suggests that FOXP3 
expression by itself is not indicative of a cell with suppressor activity. In addition to 
in vitro data on induced FOXP3+ cells, the phenotype of GFP-knockin-Foxp3-
knockout mice suggests that there may be a regulator upstream of FOXP3 that 
determines Treg lineage fate (101, 102). In this system GFP was used to functionally 
inactivate the FOXP3 protein and also serve as a reporter of Foxp3 transcriptional 
23
 activity. Interestingly, GFP+Foxp3null cells were phenotypically identical to wt Treg 
cells, were anergic and expressed a number of Treg signature genes, such as Ctla4, 
Gitr and Cd44. However, these cells were not functional and failed to suppress 
proliferation of responder cells in vitro and in vivo. These data suggest that while 
FOXP3 may be necessary for Treg cell function, it is not the ‘master’ regulator of the 
Treg lineage, but may serve to reinforce the Treg phenotype, in part by amplifying its 
own expression.  
 
Regulation of FOXP3 expression 
 The specific biochemical and molecular factors that regulate Foxp3 expression 
are not known. While there are several known regulators of Foxp3 expression, these 
factors also regulate Treg cell survival and proliferation, making it hard to determine 
the precise regulatory circuits affecting Foxp3 transcription per se. CD28 
costimulation, IL-2 and TGFβ are three important inducers of Foxp3. The role of 
TGFβ in regulating Foxp3 expression and Treg cell function is discussed in detail in 
later sections. Mice lacking Cd28 and Il2 have a drastically decreased frequency of 
FOXP3+ cells in the thymus and periphery, suggesting a role for these molecules in 
the development of Treg cells in the thymus (103, 104). However, both CD28 and IL-
2 are also required for the survival of Treg cells in the periphery, as well as their 
proliferation upon TCR stimulation. In addition to costimulation, TCR/MHC 
interactions are also critical for the development of FOXP3+ cells in the thymus. 
Analysis of Foxp3-GFP knockin (Foxp3gfp) mice revealed that the majority of mature, 
CD24lo GFP+ cells are CD4SP while a few are DP or CD8SP. The development of 
DPGFP+ and CD8+GFP+ cells was severely inhibited in Foxp3gfpMHCI-/- (b2m-/-) 
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 mice, and similarly, the development of CD4+GFP+ cells in Foxp3gfpMHCII-/- (Abb-/-) 
mice was blocked. No Treg cells developed in Foxp3gfpMHCI-/-MHCII-/- (b2m-/-Abb-/-) 
mice, indicating that TCR/MHC interactions drive Treg cell development (93). In 
addition, TCR transgenic mice on the Rag-/- background do not develop Treg cells 
while those that express RAG protein and can rearrange endogenous TCR genes do 
have varying numbers of Treg cells (105). There is a further increase in the Treg cell 
frequency if the TCR-transgenic mice are crossed with transgenic mice expressing the 
cognate antigen for the particular TCR (106-109). However, the same is not observed 
with a TCR having lower affinity for the same antigen. Increasing the quantity of 
agonist peptide also increases the frequency of Treg cells; however, there is also a 
simultaneous decrease in the numbers of conventional T cells as a result of their 
inability to be selected (110). Two insights are gained from these observations. First, 
Treg cells are most likely selected on high-affinity self-interactions in the thymus. 
Second, Treg cells are less susceptible to signals leading to death by negative 
selection. An important interpretation of these studies is that Treg cell development in 
the thymus is instructive- i.e. the ability of a thymocyte to develop into a Treg cells is 
determined by the strength of the TCR signal it perceives. However, this does not rule 
out the existence of a ‘precursor’ population that is fated to become a Treg cell, and it 
may well be that a ‘master regulator’ upstream of FOXP3 directs Treg cell lineage 
commitment. 
 A major quandary in the field is the lack of information on the antigen 
specificities of the TCRs on Treg cells. Several studies have been undertaken to 
address this issue. One approach has been to clone TCRs that are unique to either 
CD4+CD25+ Treg cells or CD4+CD25- conventional T cells (Tconv) and express them 
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 by retroviral transduction in RAG-deficient TCR transgenic T cells. Upon transfer of 
these cells into lymphopenic hosts, T cells that are transduced with the Treg cell 
specific TCRs appear to expand more, consistent with the notion that Treg cells 
express TCRs with higher avidity for self-ligands (111).  Another method that has 
yielded some contradicting results is the one used by Pacholczyk et al. They 
generated a mouse model in which the T cells express a single transgenic TCRβ chain 
and a variety of TCRα chains derived from an unarranged TCRα minilocus (112). 
This allowed for some endogenous diversity but also restricted the enormous variety 
that would be generated from an intact TCRα locus. Analyses of these mice revealed 
that there is considerable overlap between the TCR repertoire usage of Treg cells and 
Tconv cells, arguing against the idea that Treg cells are selected on high-affinity 
interaction. In another report, the same group has shown that, in fact, Treg cells 
mostly recognize non-self antigens and this recognition as opposed to recognition of 
self-antigen, is the reason for the wasting disease in an adoptive transfer model of 
Treg function (113). Based on these experimental evidences, an emerging idea in the 
field is that developing Treg cells in the thymus are not selected on high-affinity self 
ligands, but that there are specific ligands that select for Treg cells, which do not 
necessarily have to deliver a strong TCR signal (114).  
 
 Little is known about the molecular mechanisms regulating Foxp3 
transcription. The Foxp3 gene is highly conserved across different mammalian 
species including human, chimpanzee, mouse, rat and dog and contains 11 exons and 
three highly conserved non-coding sequences (CNS). The Foxp3 promoter by itself 
has weak activity in FOXP3+ mouse lymphoblast EL4 cells. A recently identified 
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 evolutionary conserved enhancer region that contains NFAT and SMAD binding sites 
confers strong activity to the promoter (115). The human basal Foxp3 promoter 
contains six NFAT and AP1 binding sites that are important for TCR-mediated 
regulation of the gene (116). NFAT can directly or indirectly induce Foxp3 
expression. Evidence for this is that human T cells can be induced to express FOXP3 
upon TCR stimulation in the absence of TGFβ, an event that can be inhibited by the 
calcineurine inhibitor, Cyclosporine A (116). The fact that Stat5a/b knockout mice 
have a reduced frequency of FOXP3+ cells prompted the investigation of STAT5 
regulation of Foxp3 expression. A search for STAT binding sequences revealed 
tandem consensus STAT-binding motifs in the first intron of the Foxp3 gene. 
Consequently, it was shown that activated STAT5 and STAT3 (downstream of IL-2R 
signaling) could bind to these GAS (interferon-gamma activated sequence) motifs 
(71, 72). In addition to the NFAT, AP-1 and STAT binding sites, the CNS region also 
contains a putative CREB-ATF (cyclic-AMP response element binding 
protein/activating transcription factor) binding motif. As CpG methylation inhibits 
CREB binding, the identification of this motif led to the speculation that Foxp3 
expression may be regulated by DNA methylation. Indeed, a decrease in Dnmt1 
(DNA methyltransferase) expression by RNA-interference (RNAi) in CTLL-2 cells 
led to an increase in Foxp3 mRNA and protein expression (117). Similarly, in vitro 
treatment of naive TCR transgenic CD4+CD25- cells with a DNA hypomethylating 
agent, Azacytidine (Aza), induced de novo expression of Foxp3, even in the absence 
of TGFβ (118). Consistent with this, one group identified another CNS upstream of 
exon-1 that possessed transcriptional activity and was also completely demethylated 
at all CpG motifs. This region, called the Treg-specific demethylated region (TSDR), 
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 is associated with modified histones and is suggestive of epigenetic imprinting of the 
Foxp3 locus (119). Further, while stable Foxp3 expression in natural Treg cells has 
been linked to the demethylation of the CNS (120), TGFβ induced Treg cells, which 
are notorious for their instability in maintaining FOXP3 expression, were shown to 
harbor intermediate/partial methylation of the CpG motifs within the Foxp3 locus 
(119). Thus, while methylation may regulate expression of FOXP3, it remains to be 
determined if chromatin remodeling at the Foxp3 locus and expression of Dnmt1 are 
necessary for the epigenetic modifications that could provide a basis for Treg lineage 
determination. 
 
 While information on the transcriptional regulation of Fopx3 expression is far 
from complete, much more is known about FOXP3 mediated regulation of target 
genes. It is clear that FOXP3 can act both as a transcriptional activator and a repressor 
(82) and can regulate the expression of a large number of genes. Co-stimulatory 
signals from CD28 leads to the activation of AP1 and subsequent binding with NFAT 
(activated by TCR signals) which cooperatively initiates the transcription of the Il2 
gene. FOXP3 cooperatively binds to NFAT (121) and is involved in a regulatory 
circuit involving a transcriptional switch, whereby NFAT-AP1 binding to the Il2 gene 
is replaced by NFAT-FOXP3 binding. FOXP and AP1 occupy the same DNA region 
on the Il2 promoter but interact with different residues on NFAT. Further, NFAT-AP1 
complexes activate, while NFAT-FOXP3 complexes repress Il2 expression. 
Conversely, NFAT-FOXP3 complex binding to the promoter regions of Ctla4 and 
Cd25 acts as a transcriptional activator, and binding of this complex to these sites is 
enhanced by TCR stimulation, consistent with the idea that Treg cells need to be 
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 activated through their TCR to initiate their regulatory program. Another 
transcriptional partner of FOXP3 is RUNX1. The Il2 promoter contains three RUNX 
consensus sites and both RUNX1 and RUNX3 can bind and positively regulate Il2 
gene transcription (122, 123). Interestingly, RUNX1 and RUNX3 can also bind to 
FOXP3 and act as transcriptional repressor of the Il2 gene. It has been suggested that 
FOXP3-NFAT-RUNX1 can form a higher order complex and cooperatively regulate 
gene transcription. This would be possible because while NFAT and FOXP3 interact 
by direct contact between their DNA-binding domain, FOXP3 and RUNX1 interact 
through regions distinct from their DNA-binding domains on sites that are widely 
separated on the genome (121). The N-terminal domain of FOXP3 is unique in that it 
lacks the CtBP (transcriptional repressor) binding motif that is present in all other 
FOXP family members (124). 
 
 In the search for FOXP3 regulated genes, two groups reported that FOXP3 
could bind to approximately 1200 genomic regions (125, 126). FOXP3 regulated 
genes are primarily modulators of T cell activation and consist of transcriptional 
regulators, intracellular signaling and cell surface receptors. The promoters of genes 
expressed in Treg cells, such as Il2, Cd25, Gitr, Ctla4, Il7ra, Icos, Pde3b and Ccr4, 
are bound by and regulated by FOXP3. Interestingly, direct FOXP3 target genes 
comprise only 6% of the entire program of FOXP3 dependent gene expression, 
suggesting that FOXP3 may regulate other transcription factors that regulate further 
transcriptional regulation. A few such unique transcription factors that are expressed 
in both the thymic and peripheral Treg cells are Prdm1, Crem, Zfn1a2 and Irf6; and 
transcription factors that are differentially expressed only in thymic Treg cells are 
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 Stat5, Irf4, Hif1a and Stat4. In addition, FOXP3 regulates expression of a few 
noncoding RNA sequences, of which mir155 is the most prominent. 
 
Mechanisms of function of Treg cells  
 FOXP3+Treg cells can be divided into two subsets- natural Treg cells (nTreg) 
that develop in the thymus and induced Treg (iTreg) cells that are generated from 
conventional cells in the periphery. Both these subsets utilize multiple mechanisms to 
exert immune regulation (Figure I-2). However, these pathways of regulation are 
highly context dependent and different experimental readouts of Treg function reveal 
different mechanisms utilized by Treg cells. The commonly used method to test Treg 
cell function is the in vitro suppression assay, in which TCR-stimulated Treg cells are 
co-cultured with responder cells (naïve CD4+CD25- T cells or splenocytes) in the 
presence of irradiated APCs. The ability of Treg cells to suppress the proliferation of 
responder cells upon their activation is used as a measure of Treg cell activity. In 
addition, another popular in vivo measure of Treg function is the ability of Treg cells 
to prevent colitis that is induced in mice by the transfer of Treg depleted, naïve 
CD4+CD25-CD45RBhi conventional T cells. Both these assays are extremely artificial 
in that neither represents any physiologically relevant scenario where Treg cells might 
really be important. However, much of the mechanistic insights into Treg function 
have utilized these assays and they are discussed below. 
 
Immunomodulatory cytokines 
 Treg cells can function by the production of immunosuppressive cytokines 
like IL-10 and TGFβ. The role of TGFβ in Treg function is discussed in detail later. 
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Figure I-2: Mechanisms of Treg cell function
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Figure I-2 Effectors of Treg cell function 
FOXP3+ Treg cells utilize multiple context dependent mechanisms to regulate 
immune responses. a) Treg cells can secrete immunosuppressive cytokines such as 
IL-10, TGFβ and IL-35 that inhibit various aspects of T cell function as well as those 
of innate cells and antigen presenting cells. b) Treg cells can directly lyse target cells 
by a perforin dependent mechanism and also by secretion of Granzyme A or B. Other 
mechanisms of suppression by Treg cells include c) direct cell-to-cell transfer of 
cAMP via GAP junctions that can inhibit activated T cells by blocking IL-2 
production and d) by acting as a ‘sink’ for the T cell cytokine, IL-2, by virtue of their 
high expression of CD25. e) Treg cells can also modify antigen presenting cells 
(APCs) such that they are rendered ineffective in activating T cells. 
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 While FOXP3-CD4+ T cells (Tr1 and Th3 cells) also produce IL-10 and TGFβ, 
natural Treg cells arising in the thymus have been shown in different circumstances to 
depend on these cytokines for their function (127). IL-10 and TGFβ are not required 
for in vitro suppression by Treg cells, as the addition of neutralizing antibodies to IL-
10 and TGFβ (128, 129) or the use of Treg cells from Il10-/- T cells (50) does not 
affect suppression in co-culture assays in vitro. However, the role of IL-10 in 
mediating some aspects of Treg function in vivo is indisputable. The clearest 
experimental evidence comes from the conditional deletion of Il10 in FOXP3+ cells 
using CRE transgenic mice in which the Foxp3 promoter drives CreTg expression in 
Treg cells (130). In these mice, Treg cell produced IL-10 was not required for the 
control of systemic autoimmunity but was required to maintain immune homeostasis 
at sites of environmental interface. The Il10flox/floxFoxp3Cre mice displayed a specific 
loss of tolerance at mucosal surfaces with severe inflammation and immune pathology 
of the colon and the lungs. These findings agree with the earlier studies showing that 
IL-10 (and TGFβ) is necessary to control airway allergic responses by Treg cells 
(131). IL-10 is also important for the prevention of colitis in mouse models of IBD 
(inflammatory bowel disease) (132). In addition to controlling autoimmunity, Treg 
cell derived IL-10 is also important for the control of various infections such as 
Mycobaterium (133) and Leishmania (134).  
 
 In addition to IL-10, a new inhibitory cytokine called IL-35 that is formed by 
the pairing of IL-12α (p35) with the Epstein Barr virus induced gene-3 (Ebi3), is also 
important for Treg cell function. Expression of IL-35 is increased in Treg cells after 
activation and is required for maximal suppression by Treg cells (135). While Ebi3-/- 
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 mice do not suffer from overt autoimmunity, Treg cells from Ebi3-/- mice function 
very poorly to control autoreactive T cells in a colitis model and a homeostatic 
proliferation model of Treg function. The mechanism of IL-35 function remains to be 
determined. 
 
Cytotoxicity of Treg cells 
 Although cytotoxic killing is primarily associated with the activity of NKT 
cells and CD8+ T cells, human and mouse Treg cells have been shown to up-regulate 
expression of Granzyme A and B respectively, and perforin after activation (136, 
137). Granzyme B deficient mice can clear tumor cells more efficiently than wt mice 
and transfer of wt Treg cells into Granzyme B deficient mice restores their 
susceptibility to tumor growth. This suggests that one mechanism by which Treg cells 
could maintain a suppressive tumor microenvironment was by Granzyme B mediated 
killing of effector T cells (138). Indeed, Treg cells from Granzyme B-deficient mice 
have compromised suppressive activity in vitro (138, 139). A role for Granzyme B in 
Treg mediated function is further supported by the fact that over-expression of a 
Granzyme B inhibitor in responder T cells makes them immune to suppression in 
vitro (140).  
 
Cytokine deprivation and disruption of metabolic function 
  Treg cells constitutively express high levels of the IL-2Rα chain, CD25, on 
their surface. Because of this, Treg cells have been proposed to serve as an IL-2 
‘sink’, depriving other responding T cells in the vicinity of IL-2 and thus limiting 
their proliferation (50, 141) and inducing apoptosis (142). Cyclic adenosine 
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 monophosphate (cAMP) is an important second messenger that is a potent inhibitor of 
T cell proliferation and differentiation (143). It was recently shown that Treg cells 
could directly transfer cAMP into effector T cells though membrane GAP junctions 
(144). Expression of the ectoenzymes, CD39 and CD73 generates pericellular 
adenosine by Treg cells, which suppresses effector T cell function by the activation of 
the adenosine receptor 2A (A2AR) (140).  
 
Suppression of DCs 
  In addition to having a direct effect on effector T cells, Treg cells can also 
modulate dendritic cell function, which can then affect function of responding T cells. 
Intravital studies have revealed that Treg cells directly interact with DCs in vivo (145, 
146). Further, upon TCR stimulation, highly motile Treg cells preferentially aggregate 
around DCs in an LFA-1 dependent manner. Upon aggregation, Treg cells 
specifically down-regulate the expression of B7-1/86 but not CD40 and MHC class II 
on DCs (147). Much of the modulation of DC function has been linked to CTLA-4 
expression on Treg cells, and the essential role of CTLA-4 in addition to DC 
regulation in Treg function is discussed in detail below. 
 
 Intensive investigations are currently in progress to understand the 
complexities of Treg function. The original idea that Treg cells function by cell-
contact dependent mechanisms clearly needs to be revised. Further, as more insight is 
gained into the Treg cell functional arsenal, the redundancy in Treg cell function is 
becoming more apparent. This is demonstrated by the fact that none of the 
molecules/pathways described above result in a complete lack in regulatory activity 
35
 when blocked or disrupted, the consequences of which would lead to a scurfy-like 
phenotype. However, there are two mouse models of gene deletion that closely 
resemble the phenotype of Foxp3-/- and scurfy mice. Similar to Foxp3-/- mice, both 
Ctla4-/- and TGFβ-/- mice suffer from early onset autoimmunity, leading to multi-
organ lymphocyte tissue infiltration and death by 3-4 weeks of age. While both mouse 
models do generate FOXP3+ cells, whether these cells are functional or are the cause 
of dysregulated immunity in these mice remains unknown. A literature review of 
these two molecules and their relationship with Treg cells follows in the subsequent 
sections. 
 
CTLA-4 and peripheral tolerance 
 Peripheral T cells express TCRs with affinity for self-peptides as a result of 
positive selection in the thymus. The requirement for two signals for optimal T cell 
activation has been shown to be critical for the maintenance of peripheral T cell 
tolerance. The balance between positive and negative signals from different 
costimulatory ligands determines the ultimate outcome of T cell encounter with 
antigen to generate an immune response or prevent autoimmunity. 
 
Two-signal model of T cell activation 
 One important mechanism of maintaining the fidelity of immune responses 
and avoiding aberrant self-reactivity is the requirement of two signals for T cell 
activation. In 1959, Lederberg first proposed the idea of two qualitatively different 
signals perceived by a lymphocyte that resulted in either tolerance or activation (148). 
He postulated a temporal model of lymphocyte signaling in which TCR binding to 
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 cognate antigen was identical in immature and mature cells, but the signal 
transduction pathway differed with the state of maturity resulting in two biologically 
different outcomes. Bretscher and Cohn modified this theory to explain B cell 
tolerance by suggesting that lymphocyte activation required 2 signals (148).  Signal 
one was the occupancy of the antigen-specific receptor, which by itself led to 
inactivation of B cells. If however, the B cell received a second signal in conjunction 
with the antigen receptor signal, this would lead to its activation and antibody 
production. They proposed that the second signal in their model came from T cells 
that provided  ‘help’ to B cells.  
 
 To explain why certain stimuli induced a state of unresponsiveness in T cells 
while others activated them, Jenkins and Schwartz refined the original 2-signal model 
to apply to T cell activation. They showed that peptide-MHC complexes (Class II Ia) 
on planar lipid membranes alone in the absence of accessory cells failed to activate T 
cells and induced a state of proliferative unresponsiveness in them (149). Similarly 
chemically modified splenocytes also induced antigen-specific unresponsiveness in 
vitro and in vivo (150). Today, an enormous body of literature exists which clearly 
demonstrates that optimal T cell activation requires an antigen specific signal from 
the TCR that interacts with MHC-peptide complexes on APCs, and a second, antigen 
independent signal called the co-stimulatory signal also provided by mature APCs. 
TCR signals alone in the absence of co-stimulation leads to the induction of anergy in 
naïve T cells. 
 
CD28 costimulation 
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  A prominent costimulatory molecule for naïve T cells is CD28 (151-153), 
which is constitutively expressed on most circulating T cells in mice and humans. 
Although additional costimulatory pathways exist, including CD40/CD40L, 
Ox40/Ox40L, and LFA-1/ICAM-1, the CD28 pathway is the most potent and well 
studied amongst them. The ligands for CD28 are B7-1 (CD80) and B7-2 (CD86), 
which are upregulated on APCs during their differentiation induced by various 
stimuli, and are also upregulated on T cells after activation (154). CD28 binds to these 
molecules with relatively low affinity and very fast association and dissociation rate 
constants (155). While CD28 binds to B7-1 with approximately 10-fold higher 
affinity than B7-2, B7-2 is the preferred ligand for CD28 in vivo. Under steady-state 
conditions, CD28 mediates cell-cell adhesion and facilitates conjugate formation and 
T cell interaction with APC. Because of the relative high density of CD28 expression 
and the rapid dynamic nature of its interaction with its ligands on APCs, CD28 on T 
cells helps TCRs scan APCs for rare ligands and plays a role in the initiation of T cell 
responses. 
 
 CD28 binding to its ligands, B7-1 and B7-2, initiates a signaling cascade, 
which results in increased IL-2 receptor expression, IL-2 transcription and mRNA 
stabilization, induction of anti-apoptotic proteins like Bcl-xL (156) and enhanced 
glucose metabolism (157) in T cells. In addition, CD28 signals decrease the threshold 
of T cell activation by the formation of stable immunological synapses. CD28 signals 
by themselves cannot induce T cell activation and proliferation, and it is generally 
thought that CD28 functions primarily to potentiate TCR signals. 
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Cytotoxic T lymphocyte Antigen-4 (CTLA-4) 
 Ctla4 was identified by differential screening of a murine CTL (cytotoxic T 
lyphocyte) cDNA library as a gene involved in the function of CTLs (158). It encodes 
for a 2kB transcript that translates a 223 amino acid protein whose expression is 
restricted to lymphocytes. It was quickly established that CTLA-4 was closely related 
to CD28 in terms of sequence, message expression, gene structure and chromosomal 
location and it was hypothesized that CTLA-4 arose as a result of a gene duplication 
event (159). Indeed, the Ctla4 and Cd28 genes are separated by only 25-150 kilobases 
(160). Further, a soluble version of the CTLA-4 ectodomain fused to an 
immunoglobulin tail (CTLA-4-Ig) bound to B7-1 and B7-2 on APCs similar to CD28 
but with considerably higher affinity (161). It was also shown that CTLA-4-Ig worked 
as an immunosuppressive agent in vivo (162) and promoted donor-specific tolerance 
and survival of xenogeneic islet grafts (163) by preventing T cell activation. 
 
 The first hints at the function of CTLA-4 in regulating T cell responses came 
with the generation of CTLA-4 monoclonal Abs. However, while the anti-CTLA-4 
mAb efficiently bound to CTLA-4, it was unclear if the antibody blocked CTLA-4 
signals or cross-linked the receptor to transmit a CTLA-4 signal. As a result, the 
earliest studies misinterpreted the increased proliferation observed upon the addition 
of anti-CTLA-4 Ab in conjunction with anti-TCR and anti-CD28 Abs, and concluded 
that ‘CTLA-4 (with CD28) cooperatively regulates T cell adhesion and activation by 
B7’ (164). The first suggestion that CTLA-4 may be an inhibitory receptor on T cells 
came from the studies comparing the effects of intact and monovalent fragments of 
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 the CTLA-4 mAB. While both intact and monovalent fragments of mouse anti-
CTLA-4 mAb enhanced T cell responses in allogeneic MLR reactions, only the intact 
Ab inhibited proliferation under conditions where Fc receptor cross-linking was 
provided (165). This was confirmed in experiments where cross-linking of the anti-
CTLA-4 mAb was achieved using a secondary anti-hamster Ab (166). Finally, in vivo 
studies revealed that anti-CD28 blocking antibodies inhibited whereas anti-CTLA-4 
blocking antibodies enhanced T cell responses (167, 168), suggesting that CD28 and 
CTLA-4 have opposing effects on T cell activation. 
 
Ctla4-/- mice 
 The phenotype of Ctla4 knockout mice is the most conclusive demonstration 
of the inhibitory function of CTLA-4. Ctla4-/- mice develop a severe 
lymphoproliferative disorder and die by 3-4 weeks of age (169, 170). The majority of 
data suggest that CTLA-4 deficiency does not affect thymic development (170, 171), 
although there is one report that suggests that negative selection may be altered (172). 
The disease in Ctla4-/- mice appears to result primarily from a defect in peripheral T 
cell tolerance and homeostasis (169, 171, 173). Although both CD4 and CD8 T cells 
are affected, aberrant CD4+ T cell activation that begins early at 5 days after birth is 
considered to be the initiating factor for the lymphoproliferative disease. Massive 
tissue destruction with severe myocarditis and pancreatitis, lymphadenopathy and 
splenomegaly ultimately result in death of these mice. Ctla4-/- mice expressing a TCR 
transgene on a RAG-deficient background are protected from disease (170, 174) 
suggesting that T cells become activated to self-antigen in the periphery of Ctla4-/- 
mice. In addition, B7-CD28 interactions are necessary for the development of disease 
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 in Ctla4-/- mice since T cells from Ctla4-/-Cd28-/- mice and Ctla4-/-B7-/- mice are naïve 
and the mice are healthy (175). Blocking B7 costimulation by CTLA4Ig treatment of 
neonatal Ctla4-/- mice also prevents the development of disease (175, 176).  
 
CTLA-4 protein: isoforms and expression 
 The Ctla4 gene consists of four exons: Exon 1 encodes the leader peptide 
sequence, exon 2 contains the ligand-binding site, exon 3 encodes the transmembrane 
region and exon 4 codes for the cytoplasmic tail (177, 178). Human and mouse 
CTLA-4 undergo differential alternative splicing to generate CTLA-4 isoforms 
(Figure I-3A). Humans express the full-length mRNA containing exons 1-4, a 
transcript encoding a soluble form of CTLA-4 that lacks the trans-membrane domain 
encoding exon 3, and a transcript encoding only exons 1 and 4. Mouse T cells can 
express an additional transcript, the ligand-independent isoform that lacks the B7 
binding domain encoded by exon 2 (158, 177-182). The expression of different 
isoforms of CTLA-4 has been associated with susceptibility to autoimmune diseases 
in humans and mice.  
 
 An understanding of the precise transcriptional regulation of CTLA-4 
expression is lacking. NFAT is one regulator of CTLA-4 transcription as modulation 
of NFAT levels by Cyclosporine A correlates directly with CTLA-4 expression (183, 
184). There are several additional transcriptional regulatory elements in the 5’ UTR of 
the Ctla4 gene, including sites for AP-1, STAT, GATA-1, NF-κB and Oct-1 binding 
(178, 184, 185). cAMP also upregulates CTLA-4 expression and may be involved in 
directly regulating Ctla4 transcription (186). 
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Figure I-3 CTLA-4 isoforms and expression pattern in thymocytes 
A. The Ctla4 gene consists of four exons: Exon 1 encodes the leader peptide 
sequence, exon 2 contains the ligand-binding site, exon 3 encodes the transmembrane 
region and exon 4 codes for the cytoplasmic tail. Alternate splicing of mRNA results 
in the generation of four isoforms of CTLA-4: full-length mRNA containing exons 1-
4, a soluble form of CTLA-4 that lacks the trans-membrane domain encoding exon 3, 
a transcript encoding only exons 1 and 4 and a ligand-independent isoform that lacks 
the B7 binding domain encoded by exon 2. The ligand-indepndent isoform is only 
detected in mice and not in humans.  
B. Flow cytometric analysis of CTLA-4 expression in T cell subsets was performed 
on thymocytes from 3-4 weeks old C57/BL6 mice. Intracellular CTLA-4 was 
expressed in early precursors cells at the DN3 stage of thymocyte development. 
CTLA-4 expression was lost in developing αβ T cells and was re-expressed only in 
Treg cells that were CD4+FOXP3+. CD8SP and CD4SPFOXP3- cells did not express 
detectable intra-cellular CTLA-4. (DN1: CD4-CD8-CD44+CD25-, DN2: CD4-CD8-
CD44+CD25+, DN3: CD4-CD8-CD44-CD25+, DN4: CD4-CD8-CD44-CD25-, DP: 
CD4+CD8+, CD8SP: CD4-CD8+, CD4SP: CD4+CD8-) 
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 Despite the significant structural homology, CD28 and CTLA-4 proteins have 
very different lifestyles. While CD28 is constitutively expressed on T cells, with little 
change in expression even upon activation (187), CTLA-4 expression is differentially 
regulated in naïve and activated T cells. Further, the expression pattern of CTLA-4 
isoforms also varies between cell subsets. Full-length (fl) CTLA-4 expression can be 
first detected in early DN3 thymic precursors cells (158, 188) (Jain N unpublished 
observations, Figure I-3B). DP cells do not express detectable flCTLA-4 protein and 
CTLA-4 is re-expressed only in CD4SP cells that are FOXP3+. Activated thymocytes 
can also upregulate CTLA-4 mRNA expression (189). Treg cell restricted expression 
of CTLA-4 is also seen in peripheral lymphoid organs (159, 185, 190, 191). Naïve T 
cells (both CD4+ and CD8+) do not express CTLA-4 mRNA and protein. However, 
upon TCR stimulation, CTLA-4 mRNA is rapidly induced within 1 hour (159, 185, 
190), and CTLA-4 protein can be detected by 24 hours after activation, with peak 
expression at 36-48 hours. CD28 co-stimulation and IL-2R signaling are necessary for 
CTLA-4 mRNA stabilization and protein expression (184, 192). The half-life of 
CTLA-4 mRNA is 4.6 hours under conditions of TCR stimulation alone, which 
increases to 8.9 hours with CD28 co-stimulation. Previously activated/memory T cells 
have a relatively large pool of intracellular CTLA-4, which is rapidly cycled to the 
cell surface upon activation (193). Compared to naïve T cells, memory T cells can 
sustain surface CTLA-4 expression for a longer time. The ligand-independent (li) 
CTLA-4 isoform is expressed at high levels in resting/memory T cells and expression 
is rapidly downregulated upon activation (180). Besides T cells, CTLA-4 gene 
expression can be detected in various other cell types such as B cells (194), 
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 granulocytes, CD34+ stem cells, placental fibroblasts (195), and mouse embryonic 
stem cells (196). However, the significance and functional consequences of CTLA-4 
expression in these cells is unknown. 
 
 The bulk of CTLA-4 protein remains in intracellular vesicles that localize 
close to the microtubule organizing center (MTOC) (192, 197). Surface CTLA-4 
expression is highly dynamic and tightly regulated by endocytosis. The cytoplasmic 
tail of CTLA-4 contains a tyrosine-based intracellular localization motif that results in 
rapid endocytosis of CTLA-4 protein from the surface to endosomal compartments as 
well as targeting of some CTLA-4 to lysosomes for degradation. The half-life of 
CTLA-4 protein is only about 2 hours in activated T cells (192, 198, 199). The 
clathrin-coated pit adaptor protein, AP-2, plays a role in this endocytosis process. 
CTLA-4 expression on the surface is stabilized by tyrosine phosphorylation (by LCK 
and ZAP-70 dependent mechanisms) of the endocytosis motif that inhibits AP-2 
binding. The cytoplasmic domain of CTLA-4 protein is 100% conserved across 
species and endocytosis and control of surface CTLA-4 expression may be an 
important aspect of biological effects mediated by CTLA-4 (200). No functions have 
been attributed to intracellular flCTLA-4 as yet. 
 
 CTLA-4 is expressed as a homodimer on the cell surface (200). The crystal 
structure of CTLA-4 bound to B7-1 suggests that the bivalent binding of CTLA-4 to 
B7-1 dimers leads to the formation of lattice structure of alternating CTLA-4/B7 
molecules (201, 202). Upon T cell-APC interaction, CTLA-4 accumulates at the 
immunological synapse (IS) via lipid rafts (203). The amount of CTLA-4 in the IS is 
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 directly proportional to the strength of the TCR signal (204) and CTLA-4 interaction 
with B7-1 (205). 
 
CTLA-4 polymorphisms and disease susceptibility 
 As discussed previously, CTLA-4 expression in different T cell subsets is 
tightly regulated at the transcriptional, translational and post-translational levels. 
Thus, even subtle alterations in expression of CTLA-4 may have serious 
immunological consequences. Four main polymorphisms of the Ctla4 gene have been 
identified that have repercussions on CTLA-4 expression and subsequent disease 
susceptibility. Single nucleotide polymorphisms have been noted in human CTLA-4 
at positions -1722, -1661 and -318 in the regulatory/promoter region of the gene, and 
one at position +49 in exon 1. The T-1772C and A-1661G polymorphisms are not 
well characterized. The A49G polymorphism is the only polymorphism that changes 
the primary amino acid sequence of CTLA-4, causing an alanine to threonine 
substitution (200). This mutant form of CTLA-4 is aberrantly processed in the 
endoplasmic reticulum, leading to decreased surface expression (206). In contrast, the 
C-138T polymorphism has been associated with increased promoter activity that 
results in increased CTLA-4 expression (207). An additional dinucleotide (AT) repeat 
polymorphism in the 3’UTR of the Ctla4 gene has been identified. Patients with 
longer AT repeats have T cells with higher proliferative potential upon TCR and 
CD28 stimulation (208). There are several reports correlating Ctla4 polymorphisms 
with susceptibility to autoimmune diseases such as autoimmune thyroid disease 
including Graves’ disease and Hashimoto’s thyroiditis, myasthenia gravis, multiple 
scelorsis and systemic lupus erythematosus (209). However, the data are contentious 
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 and the precise mechanisms by which these polymorphisms affect CTLA-4 
expression are unclear.  
 
 The role of CTLA-4 in Type 1 diabetes (T1D) is better understood. Short-term 
therapy with anti-CTLA4 mAbs of a diabetogenic TCR transgenic mouse strain 
results in insulitis and β-cell destruction (210). The genetic association between T1D 
and CTLA-4 in humans and mice (NOD) has been well established. CTLA-4 
(identified as disease susceptibility locus Idd5.1) is the only costimulatory molecule 
directly linked to T1D at the genetic level in both species. A polymorphism at 
position +77 in exon 2 of the Ctla4 gene that results in the expression of the liCTLA-
4 isoform has been detected in mice and is linked to diabetes susceptibility (179, 180). 
In diabetes resistant mice, base 77 is an adenine that allows for alternative splicing 
and generation of the liCTLA4 isoform. In diabetes susceptible mice, the adenine is 
replaced with a guanine that favors the inclusion of exon 2 in the final transcript. This 
liCTLA-4 is expressed at lower levels in NOD T cells and can inhibit T cell activation 
in vitro.  Human CTLA-4 contains a threonine at base 77 instead of adenine, which is 
probably why humans do not express the liCTLA-4 isoform. 
 
CTLA-4 mechanisms of action 
 Numerous mechanisms have been proposed for CTLA-4 function and it is 
quite likely that CTLA-4 utilizes multiple mechanisms operating at different levels to 
regulate peripheral T cell tolerance (Figure I-4). 
 
Ligand competition 
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Figure I-4: Mechanisms of CTLA-4 regulated inhibition of T cell activation  
CTLA-4 is a negative costimulatory molecule and can inhibit T cell activation in 
several ways. Some of them are: 
A. CTLA-4 can compete with CD28 for binding to the ligands B7-1 and B7-2 on 
antigen presenting cells. CTLA-4 binds to these ligands with higher affinity than 
CD28 and bivalent binding of CTLA-4 to B7 molecules can result in the formation of 
a lattice-like structure that can disrupt the immunological synapse. 
B. CTLA-4 binding to B7 can initiate an inhibitory signal transduction pathway 
involving Cbl-b, which can inhibit TCR signals. Recruitment of phosphatases such as 
PP2A can also inhibit TCR and CD28 signals.  
C. CTLA-4 expressed on Treg cells and/or activated T cells can generate a ‘reverse’ 
signal into APCs through B7 binding that leads to the production of indoleamine 
deoxygenase (IDO). IDO can catalyze the breakdown of tryptophan resulting in 
altered dendritic cell function and inhibition of T cell activation. 
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  CD28 and CTLA-4 both bind the same receptors, B7-1 and B7-2 on antigen 
presenting cells. However, CTLA-4 binds to both these ligands with much higher 
affinity compared to CD28, with an even greater preference for B7-1. Therefore, in a  
ligand limiting condition, as is the case in homeostatic conditions or during the very 
early phases of inflammation, CTLA-4 will preferentially bind to B7 molecules 
depriving T cells of positive costimulation. Support for this ligand competition model 
comes from the fact that transgenic expression of a tailless form of CTLA4 (lacking 
the cytoplasmic domain) can completely ameliorate the fatal lymphoproliferative 
disease of Ctla4-/- mice (172, 211). While the lymphocytic infiltration into tissues that 
is characteristic of Ctla4-deficiency is absent, the mice do exhibit lymphadenopathy 
and increased T cell numbers. Some have taken this as evidence that CTLA-4 inhibits 
T cell activation to self-antigen by competing with CD28 for ligand binding, and thus 
inhibiting the delivery of a positive costimulatory signal.  
 
 While ligand sequestration is a simple model to explain CTLA-4 mediated 
inhibition of naïve T cell activation, its relevance in vivo is questionable and it is 
unlikely to be the primary cause of aberrant T cell activation seen in Ctla4-/- mice. 
Firstly, this model is dependent on surface CTLA-4 expression on naïve T cells, while 
naïve T cells in vivo barely express CTLA-4 mRNA, let alone surface CTLA-4 
protein. Further, T cells in the tailless Ctla4TgCtla4-/- mice still display an activated 
phenotype and proliferate. So clearly, ligand competition with CD28 is not involved 
in the regulation of initiation of T cell activation. However, it may play a role in 
inhibiting CD28 signals that lead to tissue migration, and this is discussed in 
subsequent sections. 
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Inhibitory signaling 
 In addition to inhibiting the delivery of a positive costimulatory signal via 
CD28, CTLA-4 can also deliver an inhibitory signal though its cytoplasmic tail. Early 
studies showed that antibody cross-linking of CTLA-4 during T cell activation could 
inhibit IL-2 production and proliferation. However, these studies did not take into 
account the presence of Treg cells in the cultures that could inhibit T cell activation. 
Although one argument against the effect of Treg cells in these assays is that TCR 
transgenic T cells, that are not contaminated with Treg cells are also inhibited by 
CTLA-4 crosslinking, and more pronounced effects of antibody crosslinking are seen 
on previously activated T cells that express more CTLA-4 on their surface.  
 
 While the precise inhibitory signals delivered by CTLA-4 are not clear, it has 
been proposed to function at three levels: a. CTLA-4 inhibits early events in TCR 
signaling, b. CTLA-4 directly inhibits CD28 signaling and c. CTLA-4 inhibits 
downstream target of TCR and CD28 signals. In support of this, CTLA-4 has been 
shown to recruit phosphatases to the TCR complex and abort early TCR signaling 
events like ZAP-70 phosphorylation (212). The ligand-independent isoform of 
CTLA-4 can also bind to and dephosphorylate the TCRζ chain (180). Further, CTLA-
4 signaling downregulates cytokine production by inhibiting the accumulation of AP-
1, NF-κB and NFAT in the nucleus (213, 214).  
 
 Again, although a negative signal transduction pathway from CTLA-4 is an 
attractive model for inhibition of T cell activation by CTLA-4, it does not explain the 
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 dysregulated T cell activation in Ctla4-/- mice. Naïve T cells lack surface CTLA-4 
expression and since TCR signals are usually transmitted within the first few minutes 
to hours of initial T-APC interaction, it is difficult to envision how CTLA-4 could 
inhibit these early signaling events. 
 
IDO/tryptophan metabolism 
 B7 molecules can control immune responses by reverse signaling into APCs. 
Ligation of B7-1 and B7-2 by CTLA-4, and possibly CD28, delivers a ‘back’ signal 
into APCs that activates an immunosuppressive pathway of tryptophan metabolism 
(215). Treatment of DCs with CTLA4Ig leads to the upregulation of IDO 
(indoleamine 2, 3-dioxygenase) via an IFNγ dependent pathway that utilizes the 
signaling adaptor DAP12 and the transcription factor IRF-8 (interferon regulatory 
factor-8) (216). IDO is responsible for the breakdown of tryptophan to byproducts 
that inhibit T cell proliferation. Therefore, one mechanism by which CTLA-4 could 
regulate immune responses is by modulation of APCs (217). While this model is 
attractive in that it can account for regulation of peripheral tolerance under 
homeostatic conditions via CTLA-4 expressing Treg cells, it is not clear how CTLA-4 
ligation specifically, and not CD28, can lead to the induction of IDO, considering 
they both bind B7. Further, the pathway of suppression initiated by IDO is not well 
characterized, and whether this is a mechanism used by CTLA-4 on Treg cells or 
activated T cells is not understood. 
 
Homing 
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  CTLA-4 can also modulate T cell interaction with APCs, although the data in 
this regard is somewhat conflicting. It was shown that CTLA-4 could alter the 
expression of adhesion molecules such as LFA-1 (218). Consistent with this, CTLA-4 
sufficient T cells adhere much more strongly to ICAM1 expressing substrates than 
CTLA-4 deficient T cells, suggesting that CTLA-4 promotes stable T-APC 
interaction. In contrast, CTLA-4 has also been shown to increase the motility of T 
cells when they are stimulated through their TCRs, such that these cells can only 
make short-lived contacts with APCs that results in abortive activation (219). One 
major caveat to the interpretation of these studies is that surface CTLA-4 is expressed 
very late in the T cell activation process, and it is unlikely that this altered interaction 
with APCs would influence early activation events. However, in a homeostatic 
environment, interactions between APCs and Treg cells, which constitutively express 
CTLA-4, might influence whether an immune response is induced.  
  
CTLA-4 and Treg cells 
 Suggestions that CTLA-4 may function in a cell autonomous manner to regulate T 
cell activation  came from early studies of mixed bone marrow (BM) chimeras of wt 
and Ctla4-/- BM. CTLA-4 sufficient wt BM could prevent the activation of Ctla4-/- T 
cells in these chimaeras and the mice could be maintained in a healthy state 
indefinitely (220). In un-manipulated mice, expression of CTLA-4 is mostly restricted 
to Treg cells. Therefore, one interpretation of the mixed BM chimera data is that 
CTLA-4 is primarily required for Treg cell function and/or maintenance and the 
lymphoproliferation observed in Ctla4-/- mice is primarily a consequence of defective 
Treg cells. The fact that the phenotype of Ctla4-/- mice closely resembles that of 
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 Foxp3-/- mice supports this theory. However, unlike Foxp3-/- mice that completely 
lack Treg cells, Ctla4-/- mice do have FOXP3+ cells in peripheral lymphoid organs, 
suggesting that CTLA-4 is not required for the development of these cells in the 
thymus. Interestingly, transgenic expression of FOXP3 in Ctla4-/- mice can extend the 
lifespan of Ctla4-/-  mice to up to 6 months (90) (Khattri R, NI 2003), suggesting that 
CTLA-4 may not be required for Treg cell function and that FOXP3 expression alone 
is sufficient. However, FOXP3 can regulate several genes involved in activation and 
cell cycle progression. Therefore, a rescue of phenotype of Ctla4-/- mice by over-
expression of FOXP3 does not rule out a role for CTLA-4 in Treg function. 
 
 Until recently, the role of CTLA-4 in mediating Treg cell function was 
controversial. Adoptive transfer of naïve (CD25-) CD4+ T cells into lymphopenic 
hosts rapidly leads to colitis unless FOXP3+ CD4+CD25+ Treg cells are also 
transferred.  Protection from colitis is abrogated by injection of blocking Ab against 
CTLA-4 suggesting that CTLA-4 is necessary for immune regulation in this model 
system (221). While the relevant target of Ab blockade (e.g. CTLA-4 on effector T 
cells or Tregs) in this model was unknown, it has been shown that CTLA-4 blockade 
variably disrupts the control of colitogenic B7-deficient (Cd80-/-Cd86-/-) Clta4-/- T 
cells by wt (CTLA4+) Treg cells, suggesting that CTLA-4 on Treg cells is 
functionally relevant for initiating and/or maintaining regulation.  However, the 
situation remained uncertain since experiments utilizing Ab-mediated blockade of 
CTLA-4 have given inconsistent results in the same model system and Treg cells 
from Ctla4-/- mice have also been reported to prevent the progression of colitis. The 
most conclusive demonstration so far about the role of CTLA-4 in Treg cell function 
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 has come from the recent generation of conditional Ctla4-/- mice. Ablation of CTLA-4 
in Treg cells by CRE expressed from a Foxp3 promoter (Foxp3-Cre), results in a 
breakdown of tolerance similar to that in Ctla4-/- mice, leading to death of mice by 6-
10 weeks of age (222). However, the phenotype of the mice does not faithfully 
phenocopy that of Ctla4-/- mice, and additional complexities and requirements of 
CTLA-4 in Treg cells and conventional T cells need to be investigated. 
 
Transforming Growth Factor-beta (TGFβ) and peripheral tolerance 
 TGFβ is a plieotropic morphogen that has several functions in the immune 
system. One critical role for TGFβ is in the maintenance of peripheral T cell 
tolerance. The following sections outline this aspect of TGFβ function. 
 
Morphogens and TGFβ  
 TGFβ belongs to a class of proteins called morphogens that primarily function 
in orchestrating developmental decisions in several species. Morphogens were first 
identified in the fruit fly, Drosophila melanogaster, in the early 20th century by 
Thomas Hunt Morgan. In 1969, Lewis Wolpert, in his famous French Flag Model, 
conceptualized how the concentration of morphogens in the environment could 
subdivide a tissue into domains of different gene expression (223). A working 
definition of a morphogen based on several years of study is that it is a substance that 
works in a concentration gradient dependent manner to specify cell fate and govern 
the pattern of tissue development by providing positional cues. Morphogens can be 
either transcription factors that directly affect gene expression, or secreted proteins 
that signal between cells. The first morphogen to be identified was Bicoid, a 
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 transcription factor regulating the development of the Drosophila syncitial embryo. 
Another secreted morphogen described around the same time was Decapentaplegic, 
the product of a gene locus that governs the development of the 15 major imaginal 
discs in D. melanogaster larvae. The mammalian homologue of Decapentaplegic is 
the Transforming Growth Factor-beta (TGFβ), which plays pleiotropic roles in 
regulating cell proliferation, lineage determination, differentiation, motility, adhesion 
and death.  
 
 There are several TGFβ family members, and they can be divided into three 
major groups: TGF proteins themselves, bone morphogenetic proteins (BMPs) and 
Activin (224). In mammals three isoforms of TGFβ are expressed that can have 
positive and negative influences on a variety of cellular processes. These are TGFβ1, 
TGFβ2 and TGFβ3, with TGFβ1 being the most relevant for the immune system 
(225). However, TGFβ1 also plays a role in the regulation of differentiation and 
homeostasis of cardiomyocytes, pancreatic β-islet cells and blood vessel endothelium 
(226-228). TGFβ2 and 3 are predominantly expressed in mesenchymal tissues and 
bones where they have various functions in bone development and murine palate 
formation. The expression of TGFβ2 and TGFβ3 is mostly under the control of 
developmental or hormonal signals. TGFβ2 and TGFβ3 knockout mice are embryonic 
lethal and have major developmental defects resulting in malformation of bones and 
internal organs (229). 
 
Cellular sources of TGFβ1 
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  Tumor cells are major secretors of TGFβ1 (230), which regulates the tumor 
microenvironment partially by recruiting immune cells and coordinating their 
function (231, 232). Innate cells such as neutrophils, NK cells, monocytes and 
monocyte-derived macrophages also contribute to the accumulation of TGFβ1 in the 
tumor environment. Under homeostatic conditions, certain subsets of dendritic cells 
synthesize TGFβ. It has been reported that TGFβ1 produced by Peyer’s Patch DCs 
and lung DCs can regulate the differentiation of effector T cells in these tissues and 
lead to either suppression or exacerbation of immune responses (233). Similarly, 
TGFβ1 secreted by tumor-infiltrating DCs also influences effector T cell lineage 
commitment. In addition, activated T cell subsets themselves produce TGFβ1 (234). 
As discussed previously, Th3 cells that are induced during the process of oral 
tolerance secrete TGFβ1, which then mediates immune suppression. CD4+Foxp3+ 
natural Treg cells also express surface TGFβ1 (235, 236); however whether this is 
relevant for their suppressive activity remains debatable.  
 
 TGFβ1 transcripts can be detected in a variety of lymphocytes including early 
thymic precursors such as DN2 and DN3, mature SP thymocytes and peripheral T cell 
subsets. However, in most cases, TGFβ1 message levels do not correlate with the 
amount of secreted protein, suggesting post-transcriptional and/or post-translational 
regulation of TGFβ1 expression (237). The transcriptional regulation of TGFβ1 
expression is relatively unknown. The TGFβ1 promoter contains activator protein 
(AP-1) binding sites where c-jun and c-fos, induced by TGFβ itself can bind to and 
stimulate more TGFβ1 expression. Thus TGFβ1 can function in an auto-feedback 
loop and amplify its own production (229). 
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TGFβ signaling 
 TGFβ is synthesized as a pre-pro precursor protein. The pre region of the pre-
pro-TGFβ precursor contains a signal peptide while pro-TGFβ is processed in the 
Golgi by a furin-like peptidase that removes the N-terminus of the immature protein 
(229). Homodimerization of this new protein, now called Latency associated protein 
(LAP), and subsequent noncovalent binding with a homodimer of mature TGFβ result 
in the formation of latent TGFβ or small latent complex (SLC). This complex can be 
secreted out by itself or in association with latent TGFβ-binding protein (LTBP) that 
plays a role in targeting TGFβ to the extracellular matrix. Proteolytic cleavage or a 
conformational change resulting in the release of TGFβ from LAP and LTBP allows 
mature TGFβ to bind to its receptors.  
 
 Biological effects of TGFβ1 are mediated by its binding to type I and type II 
trans-membrane serine/threonine kinase receptors (238). There are five type I 
receptors (also called activin receptor like kinase family ALK family), and seven type 
II receptors. TGFβ1 binds to ALK5 and TGFβ-receptor II (TGFβRII). TGFβRII exists 
in a basally phosphorylated state (239). Binding of mature TGFβ ligand to 
homodimeric TGFβRII results in the recruitment of TGFβRI and formation of a 
heterotetrameric complex. Ligand binding does not increase the phosphorylated state 
of TGFβRII, but allows it to catalyze the phosphorylation of TGFβRI at several serine 
and threonine residues. It is thought that TGFβRII acts as a constitutively active 
kinase, which upon ligand binding, can access its substrate, TGFβRI, and initiate 
signaling. SMAD (mothers against decapentaplegic homologue) proteins transduce 
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 the signals from the TGFβRI to the nucleus. Although SMAD proteins bind weakly to 
DNA (240), their activity is mediated by interaction with a large number of 
transcriptional partners to regulate the TGFβ induced gene expression profile. There 
are also SMAD-independent signaling pathways that involve mitogen-activated 
protein kinase (MAPK), PI3K kinase, PP2A phosphatase and Rho proteins (241).  
 
 The activated TGFβR complex undergoes endocytosis via two pathways- one 
leading to accumulation of activated complexes in endosomes where SMAD 
activation takes place, and the other to caveolin-coated vesicles from where the 
complex is targeted for proteasome-dependent degradation regulated by SMURF 
(SMAD ubiquitylation regulatory factor) E3 ubiquitin ligases (239, 242). The balance 
between these two pathways affects the strength of the TGFβR signal and subsequent 
biological consequences. 
 
 Vertebrate TGFβ signal transduction involves eight SMAD proteins that can 
be divided into three functional classes: receptor associated SMADs or R-SMADs 
including SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8; co-mediator SMADS or 
co-SMADs such as SMAD4; and inhibitory SMADs or I-SMADs such as SMAD6 
and SMAD7. Only SMAD2 and SMAD3 can be activated by TGFβRI signaling 
(238). R-SMADs are associated with the membrane-anchored protein, SARA (SMAD 
anchor for receptor activation), which is abundant in endosomes where SMAD 
activation by TGFβRI takes place and also on the plasma membrane. R-SMAD 
phosphorylation/activation destabilizes its interaction with SARA, leading to the 
association of R-SMADs with SMAD4, followed by nuclear translocation. SMAD 
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 proteins are rapidly dephosphorylated in the nucleus and shuttled back into the 
cytoplasm, thereby allowing for the dynamic regulation of TGFβ1 signaling to 
extracellular stimuli. Inhibitory SMADs suppress TGFβ signaling by two 
mechanisms- firstly by competing with R-SMADs for binding to TGFβRI and 
secondly by recruiting SMURF E3 ubiquitin ligases for the degradation of TGFβRI 
(243, 244). As mentioned earlier SMADs bind DNA very weakly. Coupled with the 
fact that the SMAD binding motif, CAGAC, is usually present only in a single copy 
in the promoter elements of SMAD-responsive genes, SMADs have to recruit 
additional co-factors and co-activators to regulate gene expression. 
 
TGFβ and DAB2 
 DAB2 is an adaptor protein in the TGFβ signaling pathway and was initially 
identified in a screen for proteins involved in growth factor signal transduction in 
macrophages (245). There are three alternatively spliced products of Dab2 mRNA: 
the full-length p96 isoform, the p93 isoform and the p67 isoforms. Dab2 is expressed 
in several tissues such as heart, lung, liver, skeletal muscle and kidney (246).  
However, the precise expression pattern of Dab2 and its isoforms in the immune 
system is not known.  
 
 DAB2, also known as DOC-2 (Differentially expressed in Ovarian 
Carcinomas-2), is the mammalian homologue of the Drosophila Disabled protein 
(247). It contains a phosphotyrosine interacting domain (PID or PTB) and a proline 
rich SH3-binding domain that mediate its role as an adaptor protein. DAB2 binds to 
both SMAD2 and SMAD3 via its N-terminal PTB domain. It can also bind to both 
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 TGFβRI and TGFβRII and it has been suggested that DAB2 serves to bridge the 
TGFβR complex to the SMAD signaling pathway (248). In addition, DAB2 can also 
associate with the mitogen activated kinase kinase kinase (MAPKK), TAK1, which 
can trigger the SMAD-independent TGFβR signaling pathway through JNK 
activation (249). 
 
TGFβ and T cell development 
 TGFβ regulates the development and function of immune cells at multiple 
stages (Figure I-5). Early studies investigating the role of TGFβ in T cell 
development primarily relied on the use of in vitro cultures and fetal thymic organ 
cultures (FTOCs). First, TGFβ was shown to inhibit the IL-7 induced proliferation of 
total thymocytes in vitro (250, 251). TGFβ could also induce CD8 expression on 
CD25+TN (CD3-CD4-CD8-) precursor cells, suggesting that it may be involved in the 
regulation of thymic CD8+ T cells (252). In addition, TGFβ1 produced by thymic 
epithelial cells could regulate the differentiation of CD4-CD8lo αβ precursor cells into 
CD4+CD8+ DP thymocytes (253). TGFβ also inhibits the differentiation of precursor 
cells into CD4+CD8+ DP cells with a more pronounced inhibition of CD4SP cell 
generation. CD8SP cells can develop normally in the presence of TGFβ, however 
these cells have higher expression of CD8β, TCRβ and CD3 (254). While these were 
indications that TGFβ does influence T cell development, additional insights were 
only gained once the TGFβ1 knockout mice were made. 
 
 The first study of a Tgfβ1-/- mouse reported intrauterine lethality of ~50% of 
Tgfβ1-/- mice (reaching 100% on the C57/BL6 background) (255, 256). This is not 
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Figure I-5: TGFβ regulates the development and function of immune cells. 
TGFβ is a plieotrpic morphogen than regulates several aspects of immune cells 
development and function. In the thymus, TGFβ is required for the development of 
NKT cells and CD8SP cells. The role of TGFβ in thymic Treg cell development 
remains questionable.  
In the periphery, TGFβ is required for the homeostatic maintenance of Treg cells. 
TGFβ produced by Treg cells, dendritic cells and non-immune cells is required for the 
control of conventional CD4+ and CD8+ T cell autoreactivity. TGFβ made by 
dendritic cells is also crucial for regulating homeostasis in the gut as well as for the 
control of APC function and antigen presentation capacity.  
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 surprising because TGFβ1 is required for a number of developmental processes, 
including haematopoiesis (257). However, the few mice that are born have a severely 
attenuated life span and survive only until 3-5 weeks of age (255, 258). A rapidly 
progressing, spontaneous autoimmunity beginning at around 17 days of age results in 
massive CD4+ T cell activation (225, 259, 260), lymphocyte infiltration and death of 
these mice. This disease can be prevented by crossing the Tgfβ1-/- mice with SCID 
mice (260) or MHC-class II deficient mice (261); suggesting that T cells are the 
primary mediators of autoimmunity in Tgfβ1-/- mice. Because of the defects in 
multiple cell subsets in Tgfβ1-/- mice, the precise role of TGFβ1 in the immune system 
still remained unclear.  
 
 To investigate this, transgenic mice that express a dominant-negative 
TGFβRII from a T cell specific promoter that abrogates all TGFβ (1,2 and 3) 
signaling in T cells were generated. Two promoters were used, Cd4 (CD4-DNRII) 
(262) and Cd2 (CD2-DNRII) (263), that surprisingly, gave distinct results. The CD4-
DNRII mice survive to adulthood, but they develop an inflammatory disease 
characterized by organ infiltration and presence of circulating autoantibodies. The 
presence of activated/memory CD4+ T cells, in conjunction with previous 
observations with MHC-Class II deficient-Tgfβ1-/- mice, led to the conclusion that 
CD4+ T cells and not CD8+ T cells are the likely mediators and initiators of 
inflammation in Tgfβ1-/- mice. Contrary to this, the disease in CD2-DNRII mice is 
mediated by CD8+ T cells that proliferate indiscriminately, probably at the expense of 
CD4+ T cells, leading to enlarged secondary lymphoid organs. Interestingly, this 
CD8+ lymphoproliferation is not associated with typical inflammation. In both models 
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 however, thymocyte development is not affected. Several differences in the two 
models could account for this distinct phenotype. Firstly, the two promoters are 
expressed at different stages during T cell development. CD2 is expressed in early 
DN2 precursor cells resulting in abrogation of TGFβ signaling much earlier in 
ontogeny than CD4, which is expressed only at the DP stage of αβ T cell 
development. Thus, expression of the transgene in early precursors could potentially 
affect TGFβ responsiveness of multiple T cell lineages including NKT cells and γδ T 
cells. Further, it is possible that TGFβ signaling in precursor αβ T cells results in 
distinct developmental outcomes compared to TGFβ signaling in more mature 
thymocytes. In addition, the strength of the promoters may also vary, resulting in 
residual TGFβRII signaling in the weaker promoter model. Indeed, addition of 
exogenous TGFβ to CD4+T cells from CD4-DNRII mice in vitro, led to low but 
detectable nuclear translocation of SMAD2 and SMAD3 (264), suggesting some 
TGFβRI signaling in these T cells.    
 
 The first clear-cut evidence that TGFβ1 is essential for T cell development and 
homeostasis came from the generation of conditional TGFβRII knockout mice by two 
independent laboratories (264, 265). In both reports, deletion of TGFβRII using 
CD4Cre results in the lack of expression of TGFβRII in DP thymocytes and CD4 and 
CD8SP cells in the thymus and periphery. The phenotype of the CD4Cre:TGFβRII-/- 
mice recapitulates that of Tgfβ1-/- mice, and the mice die by 3-5weeks of age from 
severe inflammation. Both CD4 and CD8 T cells display an activated phenotype that 
precipitates into autoimmunity affecting multiple organs. However, while one study 
found a two-fold reduction in the frequency and numbers of conventional mature 
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 CD8+T cells (264), the other study reported normal CD8+ T cell development (265). 
The analysis of thymocyte development in mice lacking any aspect of TGFβ signaling 
is complicated by the severe immunopathology that can potentially affect T cell 
development. Thus, although both reports utilized young mice that do not display 
overt inflammation, differences in the two studies may result from subtle alterations 
in chemokine/cytokine patterns. To circumvent this problem, Ming Li has generated 
TGFβRII knockout mice on the H-Y TCR transgenic mouse background. 
Unpublished observations from this mouse model cited in (266) suggest that, in the 
absence of inflammation, CD8+H-Y Tg T cells are attenuated in the thymus and 
TGFβ signaling may play a role in promoting CD8+T cell development. Further, the 
use of TCR transgenic mice carrying the TGFβRII mutation has revealed a role for 
TGFβ in maintaining naïve T cell homeostasis. This observation comes from the fact 
that on a TCR transgenic background, TGFβ signaling deficient T cells can be 
indefinitely maintained in a naïve state (265, 267, 268). Further, a study of the TCR 
diversity in TGFβ1 deficient mice revealed that peripheral but not thymic CD4+T 
cells exhibited a nonpolyclonal distribution of the third complementarity determining 
region (CDR3) of TCR Vβ chains, suggesting death/loss of specific CD4+T cells in 
peripheral lymphoid organs (269). Thus, TGFβ1 maintains T cell homeostasis by 
regulating naïve T cell activation, proliferation and death. 
 
 TGFβ1 also affects the development of CD1d restricted NKT cells in the 
thymus and CD4Cre:TGFβRII-/- mice have sharply reduced thymic and peripheral 
NKT cell numbers. In addition, blockade of TGFβ signaling results in the 
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 development of a highly pathogenic T cell subset that exhibits characteristic features 
of NK cells that have elevated FasL, perforin, granzyme and IFNγ expression (265). 
  
TGFβ and natural Treg cells 
 Since the Tgfβ1-/- mice closely resemble the Foxp3-/- mice, it has been 
suggested that the loss of peripheral tolerance in Tgfβ1-/- is due to the lack of 
functional Treg cells. However, TGFβ signaling appears to be dispensable for Treg 
cell generation because two week old CD4Cre:TGFβRII-/- mice have normal perhaps 
even moderately higher frequencies of CD4+FOXP3+ cells in the thymus. However, 
the frequency of Treg cells in the spleen is significantly reduced, which could be due 
to improper maintenance of TGFβRII-/- Treg cells in the periphery, or because of 
massive expansion of conventional TGFβRII-/- CD4+T cells. Surprisingly, it was 
found that FOXP3+ cells in the spleen of CD4Cre: TGFβRII-/- mice incorporated more 
BrdU than littermate controls, suggesting an increased turnover rate of TGFβ 
signaling deficient Treg cells (264). This suggests that TGFβ may be essential for the 
survival and maintenance of Treg cells in the periphery, but may not be required for 
their development in the thymus. Contrary to this, another study that analyzed the 
phenotype of 3-5 days old neonatal LckCre:TGFβRII-/- mice (LckCre mediates 
deletion of TGFβRII in early DN2 cells in the thymus) showed a two-fold reduction 
in the frequency of FOXP3+ Treg cells in the thymus (270). However, as the mice 
age, there is a rapid increase in the frequency and numbers of Treg cells in the 
thymus, which is dependent on the increased IL-2 concentration in the thymus of 
LckCre:TGFβRII-/- mice. In addition, the Treg cells from LckCre:TGFβRII-/- mice are 
not functional and cannot suppress the proliferation of responder T cells in vitro. 
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 While the role of TGFβ in regulating Treg cell development and functionality 
remains uncertain, the development of autoimmunity in TGFβRII conditional 
knockout mice is probably not due to defective Treg cells. Transfer of wt Treg cells 
into neonatal CD4Cre: TGFβRII-/- mice cannot prevent the activation of TGFβRII 
deficient CD4+T cells or the autoimmune pathology, despite the robust maintenance 
of the wt Treg cells in these mice (264). These findings are consistent with an earlier 
study that showed that wt Treg cells could not control colitis induced by naïve CD4-
DNRII CD4+T cells in a mouse model of inflammatory bowel disease (IBD) (271). 
Mixed bone marrow chimera experiments also revealed that TGFβRII deficient T 
cells always exhibit a more activated phenotype than wt T cells (264, 265), suggesting 
that TGFβ may promote T cell tolerance by directly regulating both conventional and 
regulatory T cell populations. 
 
TGFβ and induced Treg (iTreg) cells 
 Another important mechanism of TGFβ mediated immune suppression is by 
promoting the generation of Treg cells in the periphery. Following TGFβ stimulation, 
regulatory activity can be induced in human naïve CD4+CD45RA+ T cells (272). 
Importantly, TGFβ can induce de novo expression of FOXP3 in naive conventional 
CD4+ T cells and confers suppressive function to these induced Treg cells (95, 97, 
98). Induction and maintenance of FOXP3 in iTreg cells requires high concentrations 
of TGFβ. This dose dependent regulation of immune effector responses is an 
important aspect of TGFβ biology. An elegant study showed that high concentrations 
of TGFβ is required to commit to the FOXP3+ Treg lineage and low concentrations of 
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 TGFβ lead to the generation of an alternate T cell subset producing pro-inflammatory 
cytokines such as IL-17 (273). In support of this, over-expression of TGFβ1 in islet 
cells of the pancreas causes the expansion of FOXP3+ Treg cells that protect NOD 
mice from diabetes (274). One in vivo environment that is characterized by high 
TGFβ1 concentration is the gut-associated lymphoid tissue (GALT). This mucosal 
niche is an important site for the generation if iTreg cells. Transfer of naïve 
polyclonal CD4+FOXP3- T cells into congenic wt recipients results in the conversion 
of a subset of these cells to iTreg cells that accumulate in the GALT (275). Further, 
CD103+ DCs have been implicated in assisting in this conversion to iTreg cells. 
Retinoic acid, a Vitamin A metabolite that is produced in high amounts by these DCs 
is responsible for this conversion, and also for the induction of gut-homing receptors 
such as α4β7 integrin and CCR9 on T cells (276). The role of retinoic acid in 
regulating iTreg cell conversion is discussed in greater detail below. Endogenous 
TGFβ at sites other than the mucosa can also induce expression of FOXP3 in 
conventional T cells. Steady-state dendritic cells pulsed with low doses of agonist 
peptide ligands can induce de novo generation of Treg cells from naïve T cells. This 
conversion is inhibited in CD4-DNRII mice in which T cells lack TGFβR signaling 
and display hyperproliferation (277). Since proliferation seems to be inversely 
correlated with the induction of FOXP3, one mechanism by which TGFβ could assist 
in the induction of FOXP3 is by limiting T cell division. 
 
 The molecular mechanism by which TGFβ1 regulates Foxp3 expression is still 
not fully understood. TGFβ1 signaling in T cells activates the R-SMADs, SMAD2 
and SMAD3, which together with co-SMAD, SMAD4, translocate to the nucleus to 
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 regulate gene expression. Development of FOXP3+ Treg in Smad3-/- mice has been 
difficult to study because of the lethal colorectal adnenocarcinomas that develop in 
these mice at 4-6 months of age (278). However, another Smad3 knockout mouse 
generated by the disruption of exon8, revealed a distinct phenotype. The disruption of 
Smad3 was primarily associated with impaired mucosal immunity and massive T cell 
activation and proliferation. Further, these T cells had diminished responsiveness to 
TGFβ mediated proliferative arrest (279). Although the role of Smad3-/- Treg cells in 
regulating T cell homeostasis was not addressed then, more recent evidence points to 
an important function of SMAD3 in inducing FOXP3 expression in Treg cells (115). 
TGFβ1 treatment of TCR and CD28 stimulated naïve T cells delivers a signal that 
results in recruitment of SMAD3 and NFAT to a conserved binding site on the Foxp3 
enhancer region. Synergistic action of SMAD3 and NFAT is required for histone H4 
acetylation of the enhancer region and initiation of Foxp3 transcription. SMAD2 and 
SMAD4 do not associate with the enhancer region and are not required for Foxp3 
expression in this particular system. Interestingly, however, defects in TGFβ signaling 
have no apparent effect on intrathymic development of FOXP3+ Treg cells. This is at 
odds with the requirement of TGFβ signaling intermediate, SMAD3, for Foxp3 
expression. One explanation is that additional TGFβ family members such as Activins 
and BMPs could initiate signaling through the SMAD pathway and activate SMAD3 
leading to Foxp3 expression in TGFβ1 knockout or TGFΒRII conditional knockout 
mice. There may also be SMAD3 independent pathways that could result in Foxp3 
expression in TGFβ1 deficient mice. 
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  SMAD4 has also been implicated in regulating Foxp3 expression upon TGFβ 
stimulation (280). Unlike Smad3-/- mice, Smad4-/- mice are embryonic lethal and die 
around embryonic day 6.5 (E6.5) due to lack of gastrulation (281, 282). Surprisingly, 
mice with a conditional deletion of SMAD4 in T cells by Cre-recombinase expression 
from the Cd4 promoter are healthy and have normal thymic αβ T cell development 
(280). This is incongruent with the fact that TGFβ signaling is critical for normal 
thymic development and that SMAD4 is an important transducer of TGFβ signals into 
the nucleus. In addition, the development of thymic derived FOXP3+ Treg cells in 
CD4Cre:Smad4fl/fl mice is also normal and these Treg cells appear to be functional in 
an in vitro suppression assay. Of interest is the fact that upon TGFβ1 treatment in 
vitro, Smad4-/- T cells do not convert as efficiently to the FOXP3+ Treg lineage as wt 
T cells. Their ability to convert to IL-17 producing Th17 cells, however, is normal. 
This suggests that SMAD4 may play a role in regulating Foxp3 expression upon 
TGFβ stimulation, but may be dispensable for Th17 lineage differentiation. 
  
TGFβ and helper T cell differentiation 
 Upon activation, CD4+ T cells differentiate into helper or effector T cells that 
can secrete different cytokines and chemotactic factors that mobilize other host cells 
to mount an immune response to specific invading pathogens (Figure I-6). There are 
several effector T cell lineages, which are characterized by their ability to produce 
signature cytokines. The best described helper T cells are the Th1 cells that secrete 
IFNγ and lymphotoxin to activate the cellular arm of adaptive immunity in response 
to intracellular pathogens, and the Th2 cells that produce IL-4, IL-5 and IL-13 and 
direct antibody production by B cells to extracellular pathogens. The differentiation of 
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Figure I-6: TGFβ controls effector T cell differentiation  
The differentiation of naïve CD4+T cells into effector lineages requires the concerted 
effort of skewing cytokines and growth factors (blue text) as well as the expression of 
specific transcription factors (green text). TGFβ can cooperate with other cytokines 
and orchestrate this differentiation, resulting in either the suppression of immune 
responses or the generation of an inflammatory response.  
TGFβ inhibits the differentiation of both Th1 and Th2 cells. However, in the presence 
of IL-4, TGFβ can direct the conversion of T cells into IL-9 producing Th9 cells. 
TGFβ alone or in concert with retinoic acid can differentiate naïve T cells into 
FOXP3 expressing Treg cells, but TGFβ in the presence of IL-6 can convert naïve T 
cells into IL-17 producing Th17 cells. TGFβ and IL-27 facilitates the development of 
Tr1 cells that produce IL-10 and IFNγ. Thus, TGFβ is central to the differentiation of 
several effector T cel lineages and can dictate the quality of the immune response that 
is generated in response to pathogenic stimuli. 
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 naïve T cells into these effector cells requires the expression of specific transcription 
factors that commit activated T cells to one lineage or the other. For Th1 cells, this is 
T-bet and STAT1/4, and for Th2 cells, it is GATA-3 and STAT6 (283).  
 
 A new lineage of helper T cells called Th17 cells that produced IL-17A and Il-
17F was described to develop from a pathway distinct from Th1 and Th2 cells (284). 
More interestingly, while TGFβ is vital for the induction of FOXP3 in naïve T cells, 
differentiation of Th17 cells from naïve CD4+ T cells also requires TGFβ (285-287). 
This reciprocal regulation of the generation of anti-inflammatory Treg cells and pro-
inflammatory Th17 cells by TGFβ is central to the outcome of several autoimmune 
diseases and infections. In addition to TGFβ signals, the differentiation of naïve CD4+ 
T cells to the Th17 lineage requires IL-6, a pro-inflammatory cytokine produced by 
innate cells upon stimulation via Toll-like receptors and C-type lectin receptors. Thus 
in the absence of inflammation, TGFβ induces the generation of FOXP3+ Treg cells, 
while IL-6 produced during inflammation tips the balance towards IL-17 producing 
Th17 cells and also actively inhibits the generation of Treg cells (285). IL-21 is 
another cytokine that can induce Th17 cells- however, TGFβ plus IL-6 treatment of 
IL21R-deficient T cells does induce the conversion of a small frequency of cells to 
Th17 lineage. Additionally, Th17 cells themselves produce copious amounts of IL-21, 
and it has therefore been suggested that IL-21 serves to reinforce the Th17 phenotype 
by amplifying IL-17 production (288-290). The role of IL-23 in Th17 cell 
differentiation has very recently been clarified. Contrary to initial observations that 
IL-23 could differentiate Th17 cells (291), it is now thought that IL-23 binding to its 
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 receptor IL-23R, which is induced by IL-6 and IL-21 on activated T cells (290), is 
required for the maintenance of Th17 cells (292). 
 
 The transcription factor RORγt is necessary and sufficient for differentiation 
of Th17 cells (293). In addition STAT3 activation by IL-6 signaling is also necessary 
for IL-17 production, and conditional deletion of Stat3 in T cells prevents the 
generation of Th17 cells (294). The regulation of iTreg cell versus Th17 cell 
generation at the transcriptional level is only now being elucidated. Interestingly, 
TGFβ stimulation can induce expression of both FOXP3 and RORγt simultaneously 
in TCR stimulated T cells in vitro (273). In fact, these double positive cells can also 
be found in the lamina propria tissue of the small intestines, and further investigations 
have suggested that FOXP3+ T cells can be differentiated into Th17 cells by pro-
inflammatory cytokines. On the contrary, if only TGFβ is present, FOXP3 can 
directly bind to RORγt and repress its transcriptional activity. In addition, DNA 
binding activity of FOXP3 is also essential for the inhibition of Il17 transcription 
suggesting a RORγt independent pathway of regulation by FOXP3. In the presence of 
IL-6, the inhibitory effects of FOXP3 on RORγt expression are relieved, perhaps by a 
STAT3 dependent mechanism. More recently, RUNX1 was shown to regulate Il17 
transcription by inducing RORγt expression. RUNX1 further physically associated 
with RORγt on a CNS region of the Il17 promoter and initiated Il17 transcription 
(295). On the other hand, RUNX1 also bound FOXP3 and this interaction was 
important for the negative effect of FOXP3 on Th17 differentiation. Thus, RUNX1-
FOXP3 complex acts as a transcriptional repressor of Il17 expression and RUNX1- 
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 RORγt acts as a transcriptional activator, indicating that RUNX1 is an important 
transcription factor that positively and negatively regulates IL-17 expression. 
 
TGFβ and Retinoic acid 
 The intestinal microenvironment is unique in that it is constantly exposed to 
foreign food-borne antigen and the requirement of regulatory mechanisms controlling 
tolerance is probably greatest in this tissue. Intestinal epithelial cells are a rich source 
of TGFβ, which can, as discussed above, influence the generation of suppressive 
iTreg cells versus pro-inflammatory Th17 cells. It has been shown that the intestine, 
and lymphoid tissue associated with the intestines such as the mesenteric lymph nodes 
(MLN) and the lamina propria (LP) are preferred sites for the generation of iTreg 
cells (275, 296, 297). However, the constant exposure of immune cells to luminal 
antigens creates a chronic inflammatory environment, which should favor the 
generation of Th17 cells. Indeed, the lamina propria is one environmental niche that 
contains IL-17 producing cells even under homeostatic conditions (273). 
Nevertheless, under normal steady-state conditions, the intestines are not inflamed 
and immune responses are under control, primarily because iTreg cells tend to 
accumulate at this site. The Vitamin A metabolite, Retinoic Acid (RA), was found to 
be crucial for this balance, and it was shown that RA could inhibit TGFβ plus IL-6 
driven conversion of cells to the Th17 lineage, and promote the generation of iTreg 
cells (275, 296, 297). 
 
 The human body does not synthesize Vitamin A, and it is absorbed from the 
diet and metabolized to RA by various enzymes including alcohol dehydrogenases 
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 (ADH) and retinal dehydrogenases (RALDH) (298). Of the isoforms of RA, only the 
all-trans retinoic acid (ATRA) is found in vivo, which can bind to nuclear receptors, 
retinoic acid receptors (RARs) and retinoid X receptors (RXRs). These receptors can 
function as ligand-induced transcription factors that bind DNA at RA response 
elements (RARE). In addition to regulating iTreg and Th17 cell differentiation, RA 
can also influence IgA production at mucosal surfaces by regulating class switching. 
RA also induces migration and homing of B cells to the LP of small intestine. RA 
produced by MLN and Peyer’s Patch (PP) DCs can induce expression of gut homing 
receptors, α4β7 and CCR9 on T cells. In conjunction with TGFβ, RA can also 
regulate expression of the aEintegrin CD103 on T cells. 
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 Thesis Objectives and Summary 
 One of the main challenges for the immune system is to ensure that auto-
reactive T cells are kept in check in the periphery, and concomitantly, allow these 
cells to react to foreign antigen in an appropriate manner. T regulatory cells are 
critical regulators of this balance that prevents autoimmunity and allows the 
generation of a productive immune response. An understanding of the mechanisms 
utilized by Treg cells in maintaining this balance is useful from a clinical perspective 
in developing therapeutic and vaccination strategies for cancers and autoimmune 
diseases.  
 The major goal of my thesis research has been to understand the role of 
CTLA-4 and TGFβ in orchestrating Treg cell mediated regulation of peripheral 
tolerance. The data from these two studies are described in the following chapters. 
 
Chapter II: CTLA-4 functions in Treg cells and conventional cells to prevent fatal 
autoimmunity. 
 Based on the expression pattern of CTLA-4 in T cells, we can predict that 
CTLA -4 could exert immune regulation at three distinct phases of the immune 
response. 1. As naïve T cells enter cell cycle after TCR/CD28 signals, CTLA-4 
induction could moderate the threshold and magnitude of the T cell response. 2. 
CTLA-4 could act after T cells are fully activated to moderate clonal expansion and 
effector functions. 3. CTLA-4 on Treg cells could inhibit naïve T cell activation in a 
non-inflamed environment. To determine when and where CTLA-4 is required to 
maintain peripheral tolerance, we have generated mouse models of restricted CTLA-4 
expression. Analysis of these mice reveal a critical function for CTLA-4 in Treg cells 
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 to maintain peripheral homeostasis, as well as a function of CTLA-4 on conventional 
T cells to prevent autoimmune migration and tissue destruction. 
 
Chapter III: DAB2, a TGFβ signaling intermediate, is important for Treg cell 
function and for TGFβ responsiveness of conventional T cells. 
 In the search for FOXP3 target genes that may be important for Treg cell 
function, we have identified Dab2, a TGFβ signaling adaptor protein, as a molecule 
that is expressed exclusively in Treg cells in peripheral lymphocytes. We have 
investigated DAB2 function in Treg cells by utilizing conditional Dab2 deficient 
mice. Analysis of different conditional deletions of Dab2 suggests that DAB2 
functions at two stages to regulate T cell responsiveness and tolerance. First, DAB2 
expression in Treg cells is important to maintain normal Treg cell function in vivo 
and in vitro. Second, DAB2 functions in thymic precursor cells to program the TGFβ 
responsiveness of mature conventional T cells. 
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 CHAPTER II 
 
CTLA-4 functions in Treg cells and activated T cells to prevent multi-organ 
autoimmunity 
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 Introduction 
 Adaptive immunity requires T cell responses to foreign pathogens to be 
counterbalanced with the need to limit collateral destruction of the host’s own tissues. 
A pivotal balancing act involves negative co-stimulation, or co-inhibition, impacting 
peripheral T cells. Normally, naïve T cell activation requires signals transmitted by 
the TCR and the positive costimulatory molecule CD28 (153). However, 
costimulation is much more intricate than initially envisioned and an integration of 
stimulatory and inhibitory signals over the course of T cell activation determines the 
ultimate outcome of initial T cell encounter with antigens. A pair of homologous 
immunoglobulin-like receptors, CD28 and CTLA-4, best illustrates the dynamic 
interplay of costimulatory molecules. Although both recognize B7 ligands on antigen 
presenting cells (APCs) (161, 299), CD28 enhances T cell responses while CTLA-4 
limits them (187). B7 expression on APCs increases with inflammation (154) and it 
has been determined that CD28 is necessary for optimal naïve T cell activation and 
trafficking (300) coincident with the functional maturation of APCs while CTLA-4 
has been proposed to moderate T cell activation to prevent unchecked continuation of 
T cell immune responses (187).  
 
 There exists a firm consensus on CD28 function, but when and where CTLA-4 
acts to rein in T cell activation in vivo has been more elusive. There are two main 
reasons for this uncertainty. First, animal models to study CTLA-4 function during 
different phases of T cell activation and in distinct T cell subsets are lacking. The 
severe autoimmune lymphoproliferative disease of Ctla4-/- mice clearly demonstrated 
the importance of CTLA-4 in regulating T cell responses and pointed to a dominant 
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 role in naïve T cell homeostasis and tolerance to self (169, 301). But the dysregulation 
of T cells soon after birth and death of Ctla4-/- mice at 3-4 weeks of age did not permit 
a detailed dissection of CTLA-4 function. Second, unlike in conventional CD4+ T 
cells, CTLA-4 is constitutively expressed on FOXP3+CD4+ regulatory T (Treg) cells 
(191), in part because FOXP3 directs CTLA-4 transcription (121). Since FOXP3+ 
Treg cells dominantly control T cell self-tolerance (89) and Treg cell-deficient mice 
resemble Ctla4-/- mice in autoimmune disease progression (83), it has been speculated 
that the primary function of CTLA-4 is to affect Treg cell-mediated tolerance 
induction (191, 302). Consistent with this model we have shown that CTLA-4-
expressing Treg cells are necessary and sufficient to control Ctla4-/- T cell activation 
in vivo (Friedline R in press). However, this result did not rule out additional 
functions of CTLA-4 in other T cell subsets during T cell activation, and the relative 
importance of CTLA-4 signaling in cis (conventional T cell intrinsic) versus in trans 
(via Treg cells) in maintaining T cell homeostasis remains undefined.  
 
 Theoretically, there are three distinct phases of T cell activation when CTLA-
4 signaling can impose regulation: 1. As naïve T cells enter cell cycle after 
TCR/CD28 signals, CTLA-4 induction can moderate the threshold and magnitude of 
the T cell response. In vitro, we estimate this window of activity to be within 8-12 
hours after TCR engagement, after which point, T cells are committed to full 
activation (Jain N. and Chambers, C., unpublished observations). Some in vitro 
studies support the early function of CTLA-4 in T cell activation in the context of 
maximal TCR/CD28 signal induction (303). However, kinetics of induction of 
CTLA-4 in vivo (185, 304, 305) is not compatible with CTLA-4 action within a few 
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 hours after TCR engagement. 2. CTLA-4 acts after T cells are fully activated to 
moderate clonal expansion and effector functions (187). The majority of experimental 
data involving CTLA-4 manipulations in conventional T cells support this dampening 
effect of CTLA-4 subsequent to T cell activation. 3. CTLA-4 on Treg cells inhibits 
naïve T cell activation in non-inflamed environment. In T cell transfer models of 
colitis, blocking CTLA-4 on Treg cells using mAb results in the impairment of Treg 
cell-mediated prevention of colitis (191, 302, 306), and CTLA-4+ Treg cells can 
inhibit Ctla4-/- T cell activation in vivo (Friedline, R. et al. manuscript in press). These 
results indicate that CTLA-4 is essential for some aspects of Treg cell function. 
 
 To determine when and where CTLA-4 functions, viable mouse models where 
CTLA-4 expression can be temporally and spatially controlled are required. Here, we 
tested the activity of CTLA-4 in conventional T cells by generating mice expressing 
functional CTLA-4 in activated T cells, but not in Treg cells. This model was created 
using a CTLA-4 transgene (Tg) whose expression is driven by the Il2 promoter in 
Ctla4-/- mice. CTLA-4-less Treg cells were unable to inhibit aberrant naive T cell 
activation. Critically, while activated T cell-restricted CTLA-4 expression cannot 
prevent lymphoproliferation, it is sufficient to prevent activated T cell accumulation 
in non-lymphoid organs, thereby extending the life span of Ctla4-/- mice to over a 
year.  There are two tissues not protected by activated T cell restricted CTLA-4 
expression: the pancreas and gut. A late-onset enteritis eventually contributes to the 
death of the animals. Collectively, these results verify the functional link between 
CTLA-4 and Treg cells in the maintenance of T cell tolerance to self or environmental 
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 antigens, and reveal a function for CTLA-4 in conventional T cells to regulate the 
accumulation of aberrantly activated T cells in non-lymphoid tissues.  
 
RESULTS 
Il2 promoter driven CTLA-4 expression is restricted to activated T cells.  
 To determine spatial and temporal requirements of CTLA-4 in T cell subsets, 
we generated a transgenic mouse model of restricted CTLA-4 expression. Since the 
induction of Il2 gene transcription is tightly regulated and is one of the earliest events 
after T cell activation (104), we chose to use the Il2 promoter to drive a burst of 
CTLA-4 expression only at the initial phase of T cell activation, but not in naïve T 
cells. We generated CTLA-4 Tg mice, designated Il2pCtla4Tg, by cloning full-length 
Ctla4 cDNA downstream of the Il2 promoter and upstream of a CD2 locus control 
region (LCR) (Fig II-1A Top). A similar strategy has been used to faithfully report Il2 
gene transcription in a copy number dependent and integration-site independent 
manner (307). Four Tg founder lines were generated of which two were selected for 
further studies based on their optimal expression of CTLA-4. These were then 
backcrossed to Clta4-/- mice to generate Il2pCtla4TgCtla4-/- mice that were designed 
to express CTLA-4 only in activated T cells.  
 
 To establish the kinetics of TgCtla4 expression in T cells, we crossed the Il2p-
Ctla4TgCtla4-/- mice with 5C.C7TcrTgRag-/-Ctla4-/- mice to obtain a homogenous 
naïve T cell population. There was no detectable TgCtla4 mRNA expression in ex 
vivo naïve CD4+T cells as shown by RT-PCR (Fig II-1A Bottom). Upon activation 
with anti-CD3 and anti-CD28 mAbs, there was rapid up-regulation of TgCtla4  
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Figure II-1: Generation of Il2pCtla4TgCtla4-/- mice and characterization of Tg 
function. 
A. (Top) Restriction enzyme map of Il2pCtla4Tg construct. Full length (fl) CTLA-4 
cDNA was cloned 3` of the Il2 promoter and 5` of the human CD2 locus-control 
region (LCR). Restriction endonuclease sites S: Sal1, E: EcoR1, Xb: Xba1, N: Not1. 
(Bottom) Il2pCtla4Tg mice were crossed to 5C.C7Rag-/-Ctla4-/- mice. Naïve CD4+T 
cells from LNs of 5C.C7Il2pCtla4TgRag-/-Ctla4-/- mice were stimulated with plate-
bound anti-CD3 plus anti-CD28 Ab for indicated time periods. mRNA was isolated 
and 3-fold serial dilutions of cDNA were analyzed for expression of Il2 and Ctla4 
transgene (TgCtla4) by RT-PCR. Data are representative of two independent 
experiments. B. FACS sorted CD4+CD25- cells from wt and Il2pCtla4TgCtla4-/- mice 
were stimulated with either anti-CD3 plus anti-CD28 coated Sepharose beads for 24h 
and 72h. Total CTLA-4 expression on activated CD25+CD69+CD4+ T cells was 
determined by flow cytometry. Ctla4-/- CD4+T cells were used as a negative control 
for staining (filled histograms). C. CD4+CD25- cells from wt and Il2pCtla4TgCtla4-/- 
mice were stimulated with either anti-CD3 plus anti-CD28 Ab and control hamster 
IgG or anti-CD3 plus anti-CD28 and anti-CTLA-4 coated Sepharose beads. 
Frequency of activated CD4+CD25+ cells T cells was determined by flow cytometry 
at 24 hours post-stimulation. Data in B and C are representative of two independent 
experiments each.  
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 transcripts within the first 3 hours, which correlated with the kinetics of accumulation 
of endogenous Il2 mRNA.  
 
 To determine CTLA-4 protein expression, naive CD4+CD25- T cells were 
sorted from 3-4 weeks old Il2pCtla4TgCtla4-/- mice and activated in vitro. 
Intracellular (ic) TgCtla4 expression was detected in activated 
(CD44hiCD62LloCD69+) CD4+ T cells at 24 hrs that diminished by 72 hrs post-
activation (Fig II-1B). In contrast, activated wt CD4+ T cells accumulated CTLA-4 
protein over time. The functionality of TgCtla4 expression was confirmed, as cross-
linking CTLA-4 on cell surface using anti-CTLA-4 coated Sepharose beads resulted 
in comparably decreased activation, as seen by a reduction in the expression of 
activation marker, CD25, (Fig II-1C) on Il2pCtla4TgCtla4-/- and wt CD4+T cells. 
 
TgCtla4 expression in activated T cells is insufficient to prevent 
lymphoproliferation, but sufficient to prevent early onset fatal autoimmunity. 
 Ctla4-/- mice die by 3 weeks of age due to lymphoproliferation, aggressive 
multi-organ infiltration by activated T cells and consequent tissue damage (169, 301). 
Il2 promoter driven CTLA-4 expression prevented mortality and dramatically 
extended the life span of Ctla4-/- mice as ~50% of mice lived till 10-12 months of age  
(Fig. II-2A).  
 
 The survival benefit of TgCtla4 did not come about because peripheral naïve 
T cells were regulated properly. There was an increased proportion of activated 
(CD44hiCD62LnegIL-7Rlo) CD4+ T cells in peripheral LNs of Il2pCtla4TgCtla4-/-  
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Figure II-2: Activated T cell restricted expression of CTLA-4 delays lethality but 
cannot prevent lymphoproliferation. 
A.  wt (n=10, ♦), Ctla4-/- (n=10, ) and 2 founder lines of Il2pCtla4TgCtla4-/- (n=15, 
, ) mice were observed for signs of disease and mortality over the indicated 
months. Results are represented as percent survival, which was calculated as 100 x 
(number of surviving mice/total number of mice) at each time point. B. 
Representative flow cytometric dot plot showing expression of activation markers 
CD44 and CD62L on CD4+FOXP3- T cells in peripheral LNs of wt and 
Il2pCtla4TgCtla4-/- mice at 3 wks and 8 months of age and Ctla4-/- mice at 3 wks of 
age. Data are representative of at least three independent experiments with 2-3 mice 
per group. C. Frequency of CD4+FOXP3-CD44hiCD62Llo cells in the spleens of 7, 10 
and 21 days old wt, Il2pCtla4TgCtla4-/-, and Ctla4-/- mice. Data are representative of 
at least three independent experiments with 2-3 mice per group.  
(* p=<0.05, ** p=<0.001) 
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mice at 3 weeks of age, a trend that was detected as early as 10 days after birth (Fig. 
II-2B, C). By 8 months nearly all CD4+ T cells displayed an activated phenotype 
(Fig. II-2B). Further, these cells produced copious amounts of cytokines typical of 
activated/memory cells, such as IL-2, IFNγ, and TNFα (data not shown). The 
activated T cells were proliferating, since BrdU labeling experiments at 8 weeks of 
age showed that there was a 2-3 fold increase in the frequency of CD4+T cells that 
had incorporated the nucleotide analog in their DNA (Fig II-3A), that was mirrored 
by a significant increase in lymph node (LN) cellularity, starting at ~2-3 months of 
age (Fig II-3B). The expansion of lymphocytes was initially driven by an increase in 
CD4+T cell numbers (Fig II-3C), similar to the pattern in Ctla4-/- mice.  
 
 To account for the extended survival of Il2pCtla4TgCtla4-/- mice compared to 
Ctla4-/- mice in spite of aberrant naive T cell activation, we considered three non-
mutually exclusive possibilities. First, while TgCtla4 expression in T cells was 
globally affording protection against fatal autoimmunity, it was ineffective in 
preventing aberrant T cell activation due to a combined alteration in the kinetics and 
levels of CTLA-4 expression. Second, although Treg cells require IL-2 for their 
development (72, 308) and maintenance (309), they themselves transcribe very little 
Il2 (310), and further, FOXP3 represses Il2 gene transcription (121, 122). Hence, it 
was predicted that peripheral Treg cells in Il2pCtla4TgCtla4-/- mice would not 
express the TgCtla4 since IL-2 promoter is actively suppressed in Treg cells. Further, 
we have recently demonstrated that in mixed chimeras containing wt and Ctla4-/- T 
cells, CTLA-4+ Treg cells inhibit the activation of Ctla4-/- T cells in trans and that 
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Figure II-3: Activated T cell restricted expression of CTLA-4 cannot prevent 
lymphoproliferation. 
A. wt (8-10 wks old), Ctla4-/- (3-4 wks old) and Il2pCtla4TgCtla4-/- (8-10 wks old) 
mice were injected with bromo-deoxyuridine (BrdU) once every 12 hours for 2 days. 
Frequency of cycling CD4+ T cells in lymph nodes (LN), mesenteric lymph nodes 
(MLN) and spleen was determined by flow cytometric analysis of BrdU 
incorporation. Data are a mean of four mice per group. B. Total cellularity of pooled 
inguinal, axillary and brachial LNs in wt () and Il2pCtla4TgCtla4-/- () mice at 
different ages. Data are a mean of at least four mice per group at each time point. C. 
Representative flow cytometric dot plot showing frequency of CD4 and CD8 T cells 
in LN, MLN and spleen of wt and Il2pCtla4TgCtla4-/- mice at 3 wks and 8 months of 
age and Ctla4-/- mice at 3 wks of age. Data are representative of at least five 
independent experiments with 2-3 mice per group. 
(* p=<0.05, ** p=<0.001) 
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 normally, Treg cells may dominantly maintain the quiescence of naïve T cells 
(Friedline et al., J. Exp. Med. in press). Therefore, lack of CTLA-4 in the Treg cells 
was causing the aberrant naïve T cell activation in Il2pCtla4TgCtla4-/- mice, while the 
restricted TgCtla4 expression in activated T cells was inhibiting the disease 
progression directly. Third, it was possible that the Treg cells express low levels of 
CTLA-4 that are insufficient to regulate naïve T cell activation, but capable of 
moderating the self-destructive activities of aberrantly activated T cells incapable of 
expressing CTLA-4 normally.  
 
FOXP3+Treg cells from Il2pCtla4TgCtla4-/- mice are functionally impaired 
 To distinguish between these possibilities we first examined CTLA-4 
expression in T cell subsets of Il2pCtla4TgCtla4-/- mice and tested whether Treg cells 
in the mice are functional. In the thymus of Il2pCtla4TgCtla4-/- mice, TgCtla4 
expression pattern was similar to that of endogenous CTLA-4. TgCtla4 was expressed 
in the early αβ T cell lineage precursor cells, CD4-CD8-CD44-CD25+ (DN3), and the 
level of Tg expression was comparable to wt thymic precursors (Fig. II-4A). 
However, TgCtla4 was not expressed significantly in all other thymocyte subsets, 
except in CD4+SP FOXP3+ thymocytes where intracellular (ic) TgCtla4 was detected 
(Fig. II-4B) (see Discussion). In the periphery, CTLA-4 expression could be detected 
only in activated CD4+CD44hi T cells (Fig. II-4C). Importantly, FOXP3+ Treg cells 
did not express high amounts of ic CTLA-4 as compared to those from wt mice and 
no, or trace, cell surface CTLA-4 expression was observed on Treg cells (Fig. II-5C). 
In summary, the expression pattern of CTLA-4 in Il2pCtla4TgCtla4-/- mice indicated 
that the Tg was being regulated in vitro and in vivo as designed, since functional  
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Figure II-4: Expression of TgCtla4 in T cell subsets of Il2pCtla4TgCtla4-/- mice. 
A, B. Thymocytes from wt (6-12wks old), Ctla4-/- (3-4wks old) and 
Il2pCtla4TgCtla4-/- (6-12wks old) mice were analyzed for expression of intra-cellular 
CTLA-4 by flow cytometry. DN1: CD4-CD8-CD44+CD25-; DN2: CD4-CD8-
CD44+CD25+; DN3: CD4-CD8-CD44-CD25+; DN4: CD4-CD8-CD44-CD25-; DP: 
CD4+CD8+; CD8SP: CD4-CD8+; CD4SP: CD4+CD8-. Ctla4-/- thymocytes were used 
as a negative control for CTLA-4 expression (filled histogram). Data are 
representative of three independent experiments. C. CTLA-4 expression in peripheral 
T cell subsets from 6-12 wks old wt and Il2pCtla4TgCtla4-/- mice was determined by 
flow cytometry. Data are the average of Mean Fluorescence Intensity (MFI) of 
CTLA-4 expression determined over at least five independent experiments with 2-3 
mice in each group per experiment. For comparison, background CTLA-4 staining 
from Ctla4-/- CD4+T cells had MFI of 30. p-values indicated on graph. 
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Figure II-5: Characterization of Treg cells from Il2pCtla4TgCtla4-/- mice. 
A. Frequency of CD4+FOXP3+ Treg cells in wt (6-12 wks old), Ctla4-/- (3-4 wks old) 
and Il2pCtla4TgCtla4-/- (6-12 wks old) mice was determined by flow cytometry.  
Data are representative of at least five independent experiments with 3-4 mice in each 
group. B. Total LN cells from wt, Ctla4-/- and Il2pCtla4TgCtla4-/- mice were analyzed 
for the expression of FOXP3 by flow cytometry. FOXP3+ (unfilled histogram) and 
FOXP3- (filled histogram) cells were further compared for the expression of CD25, 
GITR, CD103 and CD5. Data are representative of at least five independent 
experiments with 3-4 mice in each group. C. CD4+FOXP3+ T cells from wt (Left) and 
Il2pCtla4TgCtla4-/- (Right) mice were analyzed for expression of surface CTLA-4. 
Ctla4-/- CD4+ T cells were used as a negative control for CTLA-4 expression (gray 
histogram). Numbers in FACS plots are the mean fluorescence intensity of CTLA-4 
staining normalized to Ctla4-/- control. 
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 CTLA-4 is expressed only in activated T cells in the periphery and not significantly in 
naive T cells and Treg cells. 
 
 To determine whether Treg cells from Il2pCtla4TgCtla4-/- mice are similar to 
those of Ctla4-/- mice we compared the developmental properties and function of Treg 
cells from these mice in detail. During development, there is an increased frequency 
of CD4+FOXP3+ T cells in Ctla4-/- mice, and there was also a similar 2-fold increase 
in the frequency of CD4+FOXP3+ cells in Il2pCtla4TgCtla4-/- mice (Fig. II-5A). This 
increase occurs as early as 7 days after birth in Il2pCtla4TgCtla4-/- mice, before overt 
CD4+ T cell activation (data not shown), indicating that it is unlikely a result of 
increased availability of growth factors like IL-2 in the milieu that enhance Treg cell 
production and maintenance. Phenotypically, Treg cells from Il2pCtla4TgCtla4-/- and 
Ctla4-/- mice were similar, except for CTLA-4 expression (Fig. II-5B). 
 
 CD4+CD25+ T cells from Ctla4-/- mice can suppress the proliferation of 
responder T cells in vitro. Similarly, Treg cells from Il2pCtla4TgCtla4-/- mice were 
also functional in vitro (data not shown), albeit to a lesser degree compared to wt Treg 
cells (Fig. II-6A). In vivo, however, Treg cells from Il2pCtla4TgCtla4-/- mice were 
defective. In an adoptive T cell transfer model of colitis, Treg cells from 
Il2pCtla4TgCtla4-/- or Ctla4-/- mice were not able to prevent colitis initiated by co-
injected wt naïve T cells. While wt Treg cells were able to efficiently regulate the 
colitogenic T cells and this cohort of T cell transferred hosts remained healthy (Fig. 
II-6B), the mice receiving Il2pCtla4TgCtla4-/- Treg cells succumbed to a wasting 
disease, displaying massive lymphocyte infiltration and significant epithelial 
99
020
40
60
80
100
0 15 30 45 60
%
 H
ea
lth
y
Time post-injection [Days]
A.
B.
Naive T only
Naive T + Il2pCtla4TgCtla4-/- Treg cells
Naive T + wt Treg cells
Naive T only
Naive T + wt 
Treg cells
Naive T +
 Il2pCtla4TgCtla4-/- 
Treg cells
10x
0
20
40
60
80
50000 25000 12500 0
Number of Treg cells added
%
 In
hi
bi
tio
n wt
Ctla4-/-
Il2pCtla4TgCtla4-/-
Figure II-6: Treg cells from Il2pCtla4TgCtla4-/- mice are functionally 
impaired in vitro and in vivo.
C.
100
Figure II-6: Treg cells from Il2pCtla4TgCtla4-/- mice are functionally impaired. 
A. Responder CD4+ effector T cells were co-cultured with varying numbers of sorted 
and pre-activated CD4+CD25+ cells from wt, Il2pCtla4TgCtla4-/- and Ctla4-/- mice. 
Cells were stimulated with plate bound anti-CD3 plus anti-CD28 and proliferation 
was measured by 3H thymidine incorporation at 65 hrs post-activation. % inhibition of 
proliferation was calculated by considering the proliferation of responder T cells in 
the absence of Treg cells as 100%. One of 3 independent experiments with similar 
results is shown. B, C. CD4+CD25+ Treg cells from wt, and Il2pCtla4TgCtla4-/- mice 
were transferred with wt CD4+CD25neg T cells into Rag1-/- mice to test their ability to 
prevent colitis. B. Mice were scored as “unhealthy” when first signs of illness 
including weight loss and mucosal inflammation around the eyes were observed. 
Frequency of healthy mice was plotted and data are representative of two independent 
experiments with 4-5 mice in each group. Rag1-/- mice receiving wt CD4+CD25- T 
cells alone were used as a control for colitis induction. ♦: Naïve T cell only, : Naïve 
T plus wt Treg cells, : Naïve T plus Il2pCtla4TgCtla4-/- Treg cells. C. 
Representative H&E stained sections of colons of Rag1-/- after transfer of T cells. 
Mice that received naïve wt T cells (Left panel) developed severe colitis, which was 
prevented by co-transfer of wt Treg cells (Middle panel). Mice constituted with naïve 
wt T cells and Il2pCtla4TgCtla4-/- Treg cells (Right panel) developed colitis, 
displaying substantial inflammatory infiltrates and significant epithelial hyperplasia 
with loss of goblet cells. However, the severity of colitis was milder as compared to 
mice receiving only naive wt T cells. Original magnification: 10X. 
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 hyperplasia with the loss of mucin secreting goblet cells in the colon (Fig. II-6C). 
This lack of regulatory activity was evident even when a 2-fold higher ratio of 
Treg:Teff was tested, indicating that the defect was not simply a matter of potency of 
suppression (data not shown). However, the progression of disease was delayed 
somewhat, compared to control mice receiving wt naïve T cells alone, suggesting that 
the CTLA-4-less Treg cells may have some residual function.  
 
 One caveat of the colitis assay was the possibility that the sorted Treg cells 
(CD25+CD4+) from CTLA-4-deficient mice may contain contaminating activated 
conventional CD4+ T cells that may accelerate the disease progression. There also 
exist conflicting results regarding the function of CTLA-4-deficient Treg cells in the 
colitis model. For these reasons, the colitis assay by itself may not accurately report 
the activities of Treg cells. To alleviate these concerns and to definitively test Treg 
cell function, we used the mixed BM chimera assay of trans regulation of Ctla4-/- T 
cells. In mice reconstituted with a mixture of wt and Ctla4-/- BM-derived cells, Ctla4-/- 
T cells are maintained in a normal un-activated state and wt Treg cells are necessary 
and sufficient for this regulation (Friedline et al. J. Exp. Med. in press). Hosts 
reconstituted with BM cells from Ctla4-/- or Il2pCtla4TgCtla4-/- mice alone are replete 
with activated (CD44+), proliferating T cells, with multi-organ tissue infiltration by 
activated T cells in the former, but not the latter (Fig.  II-7, Top left and data not 
shown).  
 
 To determine the functional competence of CTLA-4-less Treg cells in this 
model, T cell-depleted wt and congenically marked Il2pCtla4TgCtla4-/- BM cells 
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Figure II-7: Treg cells from Il2pCtla4TgCtla4-/- mice cannot prevent activation
 of Ctla4-/- lymphocytes in mixed bone marrow chimeras.
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Figure II-7: Treg cells from Il2pCtla4TgCtla4-/- mice cannot regulate Ctla4-/- T 
cells in mixed BM chimeras (BMCs).  
BMCs were generated in Rag1-/- mice by injecting T cell-depleted BM cells from 
either Ly5.1+Ctla4-/- or Il2pCtla4TgCtla4-/- mice (Top left, negative controls), or co-
injecting a mix of BM cells from wt and Ly5.1+Ctla4-/- mice (Top right, positive 
control), Ly5.1 wt and Il2pCtla4TgCtla4-/- mice (Bottom left) and Ly5.1 Ctla4-/- and 
Il2pCtla4TgCtla4-/- mice (Bottom right). 6-8 weeks after reconstitution, before some 
BMCs became fatally sick, mice were euthanized and LN cells were stained with Ly5 
congenic marker to determine contributions of each group to the peripheral 
lymphocyte compartment. Ly5.2+ and Ly5.2- CD4+ T cells were further analyzed for 
the expression of activation markers, CD44 and CD62L. Data are representative of 
two independent experiments with three mice in each group. 
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 were mixed at a 1:1 ratio and injected into sub-lethally irradiated Rag1-/- mice. In the 
presence of wt BM-derived T cells (~1:1 wth test T cells), Ctla4-/- or 
Il2pCtla4TgCtla4-/- T cells did not expand and remained mostly naïve (CD44lo), 
similar to wt T cells in the same mouse (Fig. II-7, Top right and bottom left). The 
result indicated that the aberrant T cell activation in Il2pCtla4TgCtla4-/- mice occurred 
because the Treg cells are defective in maintaining naïve T cell homeostasis.  
 
 To directly test whether CTLA-4-less Treg cells from Il2pCtla4TgCtla4-/- 
mice still retained the ability to prevent aberrantly activated T cells from infiltrating 
tissues, Il2pCtla4TgCtla4-/-: Ctla4-/- mixed chimeras were analyzed. 
Il2pCtla4TgCtla4-/- Treg cells failed to regulate the activation and expansion of Ctla4-
/- CD4+ T cells, as expected, and more tellingly, the chimeras rapidly succumbed to 
fatal lymphoproliferative disease with extensive T cell infiltration into vital organs 
(Fig. II-7, Bottom right and data not shown). These results demonstrated that Treg 
cells from Il2pCtla4TgCtla4-/- mice cannot prevent activation of Ctla4-/- T cells, and 
furthermore, they cannot stop aberrantly activated T cells from accumulating in non-
lymphoid organs.  
 
CTLA-4 expressing aberrantly activated T cells do not accumulate in most non-
lymphoid tissues 
 So far, we have shown that Treg cells from Il2pCtla4TgCtla4-/- mice express 
very low levels of CTLA-4, they are phenotypically indistinguishable from Ctla4-/- 
Treg cells, and are functionally impaired in vivo. Conversely, provision of wt Treg 
cells can completely prevent aberrant activation of Il2pCtla4TgCtla4-/- T cells. These 
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 results confirm that CTLA-4 is necessary for naïve T cell homeostasis and that the 
impaired peripheral Treg cells are unlikely to prolong the lifespan of 
Il2pCtla4TgCtla4-/- mice. Instead, while TgCtla4 expression in Tconv cells (Fig. II-
4C) is not the primary determinant of the activation state of naïve T cells, it appears 
capable of regulating aberrantly activated T cell pathogenesis.  
 
 To determine how activated Tconv cell-intrinsic expression of CTLA-4 
controls T cell homeostasis we first investigated why Il2pCtla4TgCtla4-/- mice do not 
succumb to early onset fatal autoimmunity. Analysis of cell surface expression of the 
apoptosis marker Annexin V showed that T cells were not increased in susceptibility 
to apoptosis (data not shown). Instead, in stark contrast to Ctla4-/- mice TgCtla4 
expression was preventing activated T cells from infiltrating into and/or persisting in 
non-lymphoid organs, as most tissues examined did not show extensive lymphocyte 
accumulation, even at 6-8 months of age (Fig. II-8).  
 
 As the mice aged there were two tissues where TgCtla4 expression did not 
provide protection: the small intestine and pancreas. In both tissues, there was 
extensive mononuclear cell infiltration, and in the pancreas, there were evidence of T 
cell infiltration of β-islet cells in older Il2pCtla4TgCtla4-/- mice (Fig. II-9). However, 
the mice were not hyperglycemic up to ~10 months of age (data not shown). The 
small intestine, but not the colon, showed diffused hyperplasia, increased plasma B 
cell and necrotic cell numbers in the mucosal epithelia, but limited epithelial cell 
damage (Fig. II-9B). Further, there was an increased CD4+ T cell frequency in the 
intestines and Peyer’s patches of old Il2pCtla4TgCtla4-/- mice (Fig. II-10A).  
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Figure II-8: Lack of non-lymphoid lymphocyte infiltration in Il2pCtla4TgCtla4-/- mice
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Figure II-8: Lack of non-lymphoid organ specific lymphocyte infiltration in 
Il2pCtla4TgCtla4-/- mice. 
Lymphocyte infiltration in wt (7 months old), Ctla4-/- (3-4 wks old) and 
Il2pCtla4TgCtla4-/- (7 months old) mice was determined by histology. Representative 
H&E stained sections of kidney, liver, lung and heart showed extensive lymphocyte 
infiltration only in sick Ctla4-/- mice. Original magnification: 10X. 
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Figure II-9: Organ-specific autoimmunity in Il2pCtla4TgCtla4-/- mice.
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Figure II-9: Organ specific lymphocyte infiltration in Il2pCtla4TgCtla4-/- mice. 
Lymphocyte infiltration in wt (7 months old), Ctla4-/- (3-4 wks old) and 
Il2pCtla4TgCtla4-/- (7 months old) mice was determined by histology. A. Pancreatic 
β-islets and B. small intestines were infiltrated with lymphocytes in old 
Il2pCtla4TgCtla4-/- mice. At least two sections/mouse and multiple fields were 
analyzed. Original magnification: 10X and 20x (for B) 
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Figure II-10: Altered intestinal homeostasis in Il2pCtla4TgCtla4-/- mice. 
A. Representative flow cytometric data showing frequency of CD4+T cells in Peyer’s 
Patches (PP) and intestinal intra-epithelial compartment (iIEL). Data are a mean on 
three independent experiments with 2-3 mice in each group. B. Total cellularity of 
MLNs at different ages in wt (), Ctla4-/- () and Il2pCtla4TgCtla4-/- () mice. Data 
are a mean of at least four mice per group at each time point. Ctla4-/- mice had MLN 
cellularity of 3.4x107 cells; S.D. 650,000. Bar graph depicts the MLN cellularity of 3 
weeks old wt, Ctla4-/- and Il2pCtla4TgCtla4-/- mice. 
(* p=<0.05) 
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  Accompanying the inflammation was a massive increase in the size of 
mesenteric LNs of 6-7 months old Il2pCtla4TgCtla4-/- mice (Fig. II-10B). The gut-
associated inflammation in Il2pCtla4TgCtla4-/- mice may be exacerbated by the 
decreased TgCtla4 expression in activated T cells in the small intestine (data not 
shown). It is likely that the enteritis leads to death of Il2pCtla4TgCtla4-/- mice since 
they can be maintained in good health beyond 10 months when fed antibiotic water 
(data not shown) that moderates the gut inflammation, and there are no significant 
infiltration of T cells into other tissues, even in Il2pCtla4TgCtla4-/- mice with full-
blown enteritis. 
 
 To begin to address the homing characteristics of Il2pCtla4TgCtla4-/- CD4+T 
cells, we examined integrin and chemokine receptor gene expression. There was 
increased expression of the gut-homing receptor CD103 on activated CD4+T cells 
from secondary lymphoid organs of Il2pCtla4TgCtla4-/- mice (Fig. II-11A). Further, 
while there was no change in the gut and pancreas homing receptor α4β7 integrin 
expression on LN cells, there was a marked increased frequency of cells expressing 
this receptor in the spleen, MLN and IELs of Il2pCtla4TgCtla4-/- mice (Fig II-11B). 
Strikingly, the expression of LN homing/retention receptor CCR7 that normally 
becomes downregulated during activation was maintained in the majority of CD44+ 
Il2pCtla4TgCtla4-/- T cells (Fig. II-11C). In contrast, activated Ctla4-/- T cells had 
downregulated CCR7 expression. These results indicate that one aspect of T cell 
activation that CTLA-4 regulates in a T cell-intrinsic manner is the modifications of 
aberrantly activated T cell trafficking to non-lymphoid organs. 
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Figure II-11: Altered expression of homing receptors on CD4+T cells in 
Il2pCtla4TgCtla4-/- mice. 
A, B. Expression of gut homing receptors CD103 (A) and α4β7 (B) on CD4+CD44hi 
activated T cells from peripheral LNs, MLN, spleen and iIELs of 2-3 months old wt 
and Il2pCtla4TgCtla4-/- mice as determined by flow cytometry. Data are 
representative of three independent experiments with 3-4 mice in each group. (C) 
Expression on CCR7 on CD4+CD25-CD44+ cells from peripheral LNs, MLN, and 
spleen of 6-8 months old wt and Il2pCtla4TgCtla4-/- mice and 3 weeks old Ctla4-/- 
mice as determined by flow cytometry. (Filled gray histogram: wt; Black histogram: 
Ctla4-/-; Red histogram: Il2pCtla4TgCtla4-/-). Data are representative of two 
independent experiments with 2-3 mice in each group. 
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 OX40-Cre mediated deletion of Ctla4 in FOXP3+ T cells followed by the loss of 
CTLA-4 in activated T cells results in fatal autoimmunity 
 To confirm that CTLA-4 expression in conventional activated T cells is 
necessary for preventing autoimmune tissue infiltration, we generated a mouse model 
amenable to conditional, sequential loss of CTLA-4 in FOXP3+ Treg cells, followed 
by loss in activated T cells. We generated mice in which the Cd2 promoter drives the 
expression of a “floxed” full-length Ctla4 Tg (flCtla4Tg; Fig. II-12A) in all T cells. 
flCtla4Tg mice were crossed to Ctla4-/- mice so that Ctla4 expression can be 
conditionally ablated. Interestingly, mice that were heterozygous for flCtla4Tg 
expression (Fig. II-12B) could not be maintained in a healthy state for more than 2 
months and had increased frequency of activated T cells in peripheral lymphoid 
organs (Fig. II-12C). However, flCtla4Tg+/+Ctla4-/- were healthy with a normal 
lifespan, suggesting that high CTLA-4 expression was required to maintain Ctla4-/- T 
cells in a naïve state.  
 To sequentially ablate Ctla4 in T cell subsets we employed OX40-Cre mice 
(311). OX40 is a late activation marker that is constitutively expressed on FOXP3+ 
Treg cells and is induced on conventional T cells by 36-48 hours post-activation 
(312). Expression of CRE from the OX40 promoter resulted in efficient deletion of 
the flCtla4Tg in nearly all CD4+FOXP3+ T cells by 7-10 days after birth (Fig. II-13A; 
Top row). As conventional T cells become activated by the loss of CTLA-4 on Treg 
cells (Fig. II-13B) they also lose CTLA-4 with slower kinetics, starting ~10 days of  
age, with complete loss of CTLA-4 expression by 2-3 weeks of age (Fig. II-13A; 
Middle row). Nearly half of CD4+FOXP3-CD44lo T cells from 
Ox40CreTg+flCtla4Tg+Ctla4-/- mice maintained the expression of CTLA-4 at 10 
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Figure II-12: Generation and characterization of flCtla4TgCtla4-/- mice.  
A. Full-length Ctla4 cDNA was cloned 3` of the Cd2 promoter. Lox P sites were 
introduced at 5` and 3` ends of Tg construct to generate flCtla4Tg+ mice. B. Levels of 
expression of flCtla4Tg in CD4+FOXP3+ T cells of 6-12 weeks old flCtla4Tg+/+Ctla4-
/- and flCtla4Tg+/-Ctla4-/- mice were determined by intra-cellular staining for CTLA-4. 
Ctla4-/- CD4+ T cells were used as a negative control for CTLA-4 expression (gray 
histogram). Numbers in FACS plots are the mean fluorescence intensity of CTLA-4 
staining normalized to Ctla4-/- control. C. CD4+FOXP3-T cells in spleens of Ctla4-/-
(3-4 wks old), flCtla4Tg+/+Ctla4-/- (6-12 wks old) and flCtla4Tg+/-Ctla4-/- (6-12 wks 
old) were analyzed for expression of activation markers, CD44 and CD62L. Data are 
representative of 2 independent experiments with at least 2 mice in each group. While 
flCtla4Tg+/+Ctla4-/- mice are viable, flCtla4Tg+/-Ctla4-/- succumb to fatal 
autoimmunity by 8-10 weeks of age. 
 
118
 daysof age.  CD44lo T cells that do not express CTLA-4 are most likely activated T 
cells that have initiated CRE expression, but have not yet up-regulated CD44 (Fig. II-
13A ; Bottom row, and data not shown). Consistent with the phenotype of 
Il2pCtla4TgCtla4-/- mice, ablation of CTLA-4 in FOXP3+ Treg cells resulted in 
conventional CD4+ T cell activation as shown by an increased frequency of 
CD44hiCD62Llo cells in secondary lymphoid organs, similar to Ctla4-/- mice (Fig. II-
13B). The aberrant T cell activation was detected as early as 10 days after birth (data 
not shown).  However, unlike Il2pCtla4TgCtla4-/- mice, Ox40CreTg+flCtla4Tg+Ctla4-
/- mice that sequentially lose CTLA-4 expression in Treg cells followed by the loss in 
activated conventional T cells succumbed to fatal autoimmunity and died by 4-6 
weeks of age (Fig. II-14A). Histological examination of non-lymphoid tissues 
revealed massive tissue infiltration in the liver, lung and heart of 
Ox40CreTg+flCtla4Tg+Ctla4-/- mice, indistinguishable from Ctla4-/- mice (Fig. II-
14B), suggesting that CTLA-4 expression in aberrantly activated conventional T cells 
can moderate and/or alter the course of autoimmune tissue destruction.  
 
DISCUSSION 
 CTLA-4 is expressed in both activated T cells and Treg cells; however, the 
relative contribution of CTLA-4 to the function and maintenance of these cells in 
controlling T cell homeostasis and activation remained undefined.  In this report, we 
describe a mouse model of T cell subset-restricted CTLA-4 expression and 
demonstrate for the first time, that CTLA-4 has dual function in activated T cells and 
Treg cells to maintain T cell homeostasis. Expression of an Il2-promoter driven 
TgCtla4 in Ctla4-/- mice results in functional CTLA-4 expression in activated T cells, 
119
A.
Ox40Cre-
flCtla4Tg-Ctla4-/-
13 9.5
5622
21 10
5316
86 3.7
5.34.8
66 5.3
1315
Ox40Cre+
flCtla4Tg+Ctla4-/-
Ox40Cre-
flCtla4Tg+Ctla4-/-
Ox40Cre-
flCtla4Tg-Ctla4+/-
Ox40Cre-
flCtla4Tg-Ctla4+/-
Ox40Cre-
flCtla4Tg+Ctla4-/-
Ox40Cre+
flCtla4Tg+Ctla4-/-
Ox40Cre+
flCtla4Tg+Ctla4-/-
CD4+
FOXP3+
CD4+
FOXP3-
CD44hi
CD4+
FOXP3-
CD44lo
CD44
C
D
62
L
79 85 10 4
65 70 20 0.5
93 92 43 11
CTLA-4
B.
Figure II-13: Sequential loss of flCtla4Tg expression in Treg cells followed
 by conventional activated T cells in Ox40Cre+flCtla4TgCtla4-/- mice
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Figure II-13: Sequential loss of flCtla4Tg expression in Treg cells followed by 
conventional activated T cells in Ox40Cre+flCtla4Tg+Ctla4-/- mice.  
A. OX40Cre mediated deletion of floxed flCtla4Tg substrate in T cell subsets was 
determined by intra-cellular staining for CTLA-4. CD4+ T cells in the spleens of 
Ox40Cre-flCtla4Tg+Ctla4+/- (1.5wks old), Ox40Cre-flCtla4Tg+Ctla4-/- (1.5wks old) 
and Ox40Cre+flCtla4Tg+Ctla4-/- (1.5wks and 2.5 wks old) were analyzed for the 
expression of FOXP3, CD44 and CTLA-4.  (Top row) CD4+FOXP3+ Treg cells, 
(Middle row) CD4+FOXP3-CD44hi activated conventional T cells, and (Bottom row) 
CD4+FOXP3-CD44lo conventional T cells. Ctla4-/- CD4+ T cells were used as a 
negative control for CTLA-4 expression (gray filled histogram). Data are 
representative of 2 independent experiments with at least 2 mice in each group. B. 
CD4+FOXP3-T cells in the spleen of 2.5 weeks old Ox40Cre-flCtla4Tg+Ctla4+/-, 
Ox40Cre-flCtla4Tg+Ctla4-/-, Ox40Cre-flCtla4Tg-Ctla4-/- and 
Ox40Cre+flCtla4Tg+Ctla4-/- were analyzed for expression of activation markers, 
CD44 and CD62L. Data are representative of 2 independent experiments with at least 
2 mice in each group. 
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Figure II-14: Fatal autoimmunity in mice lacking CTLA-4 expression in Treg cells.
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Figure II-14: Fatal autoimmunity in mice lacking CTLA-4 expression in Treg 
cells.  
A. Mortality rate of wt (n=8, ♦), Ctla4-/- (n=4, ), Ox40Cre-flCtla4Tg+/+Ctla4-/- (n=6, 
) and Ox40Cre+flCtla4Tg+/+Ctla4-/- (n=6, ) mice. Results are represented as 
percent survival, which was calculated as 100 x (number of surviving mice/total 
number of mice) at each time point. B. Histological analysis of H&E stained sections 
of liver, lung and heart from 3-4 wks old wt, Ctla4-/- and Ox40Cre+flCtla4Tg+Ctla4-/- 
mice. Extensive lymphocyte infiltration was seen in sick Ox40Cre+flCtla4Tg+Ctla4-/- 
and Ctla4-/- mice. At least two sections/mouse and multiple fields were analyzed. 
Original magnification: 10X. 
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 but not in FOXP3+ Treg cells and naïve T cells. CTLA-4-less Treg cells are 
functionally impaired in vivo and cause aberrant activation of T cells to self or 
environmental antigens, despite the fact that conventional T cells are capable of 
expressing TgCtla4 within hours of activation. Conversely, provision of wt Treg cells 
prevented aberrant Il2pCtla4TgCtla4-/- T cell activation. Strikingly, activated 
lymphocytes in adult Il2pCtla4TgCtla4-/- mice that can express CTLA-4 retain CCR7 
and do not home to and/or accumulate in peripheral non-lymphoid organs and cause 
tissue damage. In contrast, in Ox40CreTg+flCtla4Tg+Ctla4-/- mice, the loss of CTLA-
4 on Treg cells combined with a sequential loss of CTLA-4 in aberrantly activated T 
cells results in fatal autoimmunity that is similar to the disease observed in Ctla4-/- 
mice, with ~one month delay in death. Thus, CTLA-4 on Treg cells is required to 
prevent inappropriate naïve T cell activation against self and/or environmental 
antigens and CTLA-4 expression in activated T cells is necessary to limit the 
pathogenic effects of inappropriately activated T cells, perhaps by preventing the 
infiltration of aberrantly activated T cells into tissues in cis, providing, literally, a 
“brake” in pathogenic T cell mediated destruction of self-tissues. 
 
 It was formally possible that despite the defect in CTLA-4-less Treg cells in 
maintaining naïve T cell homeostasis, they are partly functional and are, in fact, 
responsible for preventing activated T cells from infiltrating non-lymphoid organs. 
This possibility was conclusively ruled out by the results from mixed BMC 
experiments composed of Il2pCtla4TgCtla4-/-: Ctla4-/- BM-derived cells, where 
extensive T cell infiltration into diverse tissues was evident, demonstrating that Treg 
cells from Il2pCtla4TgCtla4-/- mice are not able to prevent Ctla4-/- T cells from 
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 infiltrating non-lymphoid organs. Further, although it is formally possible that some 
trace CTLA-4 expression in adult Treg cells of Il2pCtla4TgCtla4-/- mice is a 
confounding factor, we have observed that the rescue of Ctla4-/- mice from fatal 
autoimmunity requires a relatively high level exogenous CTLA-4Tg expression in 
Treg cells. Even a 50% reduction in CTLA-4 expression level in Treg cells fails to 
prevent T cell activation and lymphoproliferation (Fig. II-12B, C). Hence, functional 
CTLA-4 in activated T cells is responsible for preventing aberrantly activated T cells 
from damaging self-tissues in Il2pCtla4TgCtla4-/- mice. It is important to emphasize, 
however, that this conclusion does not imply that CTLA-4-less Treg cells are 
completely non-functional. Treg cells from Ctla4-/- mice can suppress conventional T 
cell activation in vitro (data not shown and (313)) and there are some indications, 
albeit not universal, that these cells can function to inhibit colitogenic T cells in a T 
cell transfer model (221) and that they can delay the early fatality associated with 
Foxp3 null mutation (314). Conversely, mice lacking FOXP3 do succumb to rapid, 
fatal lymphoproliferative disease despite the fact that activated T cells can express 
CTLA-4 (315) suggesting that the absence of CTLA-4 on Treg cells is not 
functionally equivalent to the loss of Treg cells. Given the notion that Treg cells may 
utilize multiple effector mechanisms (316), including IL-10 (130) and TGFβ(235), to 
regulate T cell homeostasis and tolerance, it is not unexpected that ablation of CTLA-
4 in Treg cells do not make them inert. Hence, while both Foxp3-/- and Ctla4-/- mice 
die of an early lymphoproliferative disease, the causes are distinct: in the former it is 
the loss of FOXP3-dependent functions of Treg cells, whereas in the latter it is the 
combined effect of the loss of CTLA-4 in Treg cells and in activated T cells. In 
Il2pCtla4TgCtla4-/- mice CTLA-4-less Treg cells may afford a moderation in immune 
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 activation that allow Treg cell-independent function of CTLA-4 to take effect in vivo. 
However, other compensatory mechanisms cannot prevent naïve T cell activation in 
the absence of CTLA-4 on Treg cells and cannot control tissue destruction by 
aberrantly activated T cells. 
 
 Recently, the phenotype of conditional Ctla4-mutant mice (conditional KO, 
CKO, in BALB/c background) lacking CTLA-4 only in Treg cells (employing 
FOXP3-Cre Tg) was reported (222). These mice succumb to a delayed fatal 
lymphoproliferative disease and die by 7-10 weeks of age. This result strongly 
supports a major conclusion in our reports (Friedline et al. J. Exp. Med. in press and 
this work) derived from the analysis of several very different model systems that 
CTLA-4 functions centrally in Treg cells to regulate naïve T cell activation. Further, 
the 4-6 week survival benefit when CTLA-4 can still be expressed in Tconv cells of 
the CKO mice is also consistent with a role for CTLA-4 in non-Treg cells. However, 
an obvious question is why Il2pCtla4TgCtla4-/- mice survive so much longer. The 
disease course in Il2pCtla4TgCtla4-/-  mice is not simply a delay in pathogenesis since 
even in Il2pCtla4TgCtla4-/- mice suffering from fulminant enteritis, many other non-
lymphoid tissues are spared from T cell infiltration. Although this difference may be 
arising from the difference in genetic background (our mice are B6) or possible 
ablation of FOXP3 in other tissues of CKO mice that can cause accelerated death, we 
suspect that the most likely reason is the transient expression of TgCtla4 in FOXP3+ 
thymocytes in Il2pCtla4TgCtla4-/- mice (Fig. II-4B). These residual, transient 
FOXP3+ cells may moderate the pace of aberrant T cell activation, and more 
importantly, dampen overwhelming inflammation associated with Ctla4-/- or Foxp3-/- 
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 mice that may override the effects exerted by CTLA-4 expression in aberrantly 
activated T cells. This hypothesis is currently being tested. 
 
 This report does not address the mechanism with which CTLA-4 expression 
on aberrantly activated T cells can regulate their potential destructive actions. 
However, there is one other model system in which similar dual activity of CTLA-4 
has been suggested. In Ctla4-/- mice, expression of a CTLA-4 Tg lacking the 
cytoplasmic signaling domain of the protein resulted in aberrant T cell activation and 
lymphoproliferation (211). However, activated T cells did not accumulate in non-
lymphoid tissues and the mice were viable. Given that one major function of CTLA-4 
in conventional T cells is to inhibit CD28 signals (200), which has been shown in 
several situations to regulate homing of T cells (300), a straightforward interpretation 
is that CTLA-4 can compete with CD28 for B7 ligand binding on APCs, and that this 
mode of inhibition does not require biochemical signaling initiated from the CTLA-4 
cytoplasmic region. We propose that this CTLA-4-cytoplamic tail-independent 
inhibition of CD28 signaling in aberrantly activated conventional T cells is 
contributing to the lack of tissue infiltration in Il2pCtla4TgCtla4-/- mice. In contrast, 
the function of CTLA-4 in Treg cells to maintain naïve T cell homeostasis requires 
CTLA-4-cytoplasmic tail-mediated signals.  
 
 Collectively, we demonstrate a dual function of CTLA-4 in regulating T cell 
tolerance that can account for the pathologies observed in mice lacking normal 
expression of CTLA-4. CTLA-4 is absolutely required on Treg cells to regulate the 
aberrant activation of conventional naïve T cells to self or environmental antigens in 
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 the periphery in trans irrespective of whether or not conventional T cells can express 
CTLA-4. In addition, in cis, CTLA-4 expression in aberrantly activated T cells can 
modulate rampant autoimmune tissue destruction and alter the disease course, but this 
function in activated conventional T cells appears to require some moderation in the 
pace of aberrant T cell activation and is insufficient to completely protect all tissues in 
the animals as they age, since fatal enteritis eventually sets in. 
 
Materials and Method 
Mice 
The IL-2P/GFP/CD2 transgene construct was a kind gift from Casey Weaver (307). 
Following EcoR1 and Xba1 digestion, the 1.4kb full-length CTLA-4 cDNA construct 
from SKCwt5/10 was inserted in place of GFP in BOB1cwt10 plasmid containing IL-
2 transgene. The 9.6kB IL-2P/CTLA4/CD2 transgene was isolated from pIL-
2P(hs65TGFP)-hC2 following Not1 and Sal1 digestion and injected by Umass 
Transgenic Facility to generate transgenic mice. Transgene-positive founders were 
identified by PCR analysis. 4 different founder lines were established of which 2 were 
chosen for crossing with Ctla4+/- mice to generate Il2pCtla4TgCtla4-/- mice. Some 
mice were also crossed to 5C.C7TCRTgCtla4-/-Rag-/- mice to generate 
5C.C7TCRTg+Il2pCtla4Tg+Ctla4-/-Rag-/-. In addition, the 1.4kb full-length CTLA-4 
cDNA construct was inserted 3` of the Cd2 promoter (317) and Lox P sites were 
introduced at the 5` and 3` ends to generate floxed Cd2pflCtla4Tg+ (flCtla4Tg) mice 
(Supplemental Fig II-12A).  flCtla4Tg+  mice on the B6 background were then 
crossed with Ctla4+/- mice to generate flCtla4Tg+Ctla4-/- mice. Conditional deletion of 
Ctla4Tg in FOXP3+ T cells and activated T cells was achieved by crossing 
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 flCtla4TgCtla4-/- mice with OX40-Cre mice  (a kind gift from Dr. Nigel Killeen, 
UCSF). Rag1-/- and C57Bl/6 mice were obtained from Jackson Laboratories. All mice 
used in these experiments were housed in a specific pathogen-free rodent barrier 
facility. All experiments were approved by the University of Massachusetts Medical 
School Institutional Care and Use Committee.  
 
Antibodies, Flow cytometry and cell sorting 
Fluorescently labeled Abs specific to CD4, CD8a, CD44, CD62L, CD69, CTLA-4, 
CD103, CD5, BrdU, a4b7, and Ly5.2 were purchased from BD Pharmingen and Abs 
specific to FOXP3, CD25, IL-7R and GITR, were purchased from eBiosciences. 
Intra-nuclear FOXP3 and intracellular CTLA-4 stainings were performed according to 
the manufacturers’ protocol (eBiosciences and BD, respectively). Surface CTLA-4 
staining was performed at 370C for 30 minutes. All data were acquired on an EPICS 
XL cytometer (BD-Coulter, Hialeah, FL) or LSRII (BD), and analyzed using FlowJo 
software (Treestar, San Carlos, CA). Peripheral T cell subsets including CD4+CD25- 
conventional T cells and CD4+CD25+ Treg cells were sorted to greater than 95% 
purity using MoFlo (Cytomation) cell sorter.  
 
RT-PCR 
For reverse transcription-polymerase chain reaction (RT-PCR), total RNA was 
isolated from purified cells (Trizol Reagent, Invitrogen) and cDNA prepared using an 
Omniscript RT-PCR kit (Qiagen). For semi-quantitative RT-PCR (sqRT-PCR), 3-fold 
serial dilutions of cDNA were prepared. PCR primers used were: Il2-for 5`-TCA 
AGC TCT ACA GCG GAA GA-3` and il2-rev 5`-TGA AAT TCT CAG CAT CTT 
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 CCA A-3`; TgCtla4-for 5`-ATG GCT TGT CTT GGA CTC CGG AG-3` and 
TgCtla4-rev 5`-TCA GTT GAT GGG AAT AAA ATA AGG CT-3`; Actb-for 5`-
CTA GGC ACC AGG GTG TGA TGG-3` and Actb-rev 5`-TCT CTT TGA CAC 
GCA CGA-3`. 
 
In vitro T cell activation and proliferation 
Sorted CD4+CD25- T cells were activated with Sepharose beads coated with anti-CD3 
(500A2; eBiosciences) (0.5µg/ml), anti-CD28 (37N; eBiosciences) (1.0µg/ml) and 
either anti-hamster isotype control Ab or anti-CTLA4 (UC10.4F1; BD Biosciences) 
(5.0µg/ml) Ab in complete DMEM (10% FBS, 50µM 2-ME, 2mM L-glutamine, 
20mM Hepes, 0.1mM Non-Essential Amino Acids) for 72h. Beads were coated with 
Ab at 370C for 1h in sterile PBS.  
 
BrdU labeling and detection 
Mice received twice daily injections of 1mg of BrdU i.p. for two days before 
sacrifice. Cells were stained for surface markers as usual, fixed and then stained with 
anti-BrdU-FITC Ab (eBiosciences) as described in the accompanying article by 
Friedline et al.  
  
Colitis 
5 x 105 CD4+CD25- naïve T cells from wt mice were transferred to lymphocyte-
deficient (Rag1-/-) mice to induce colitis.  To test the function of Treg cells in 
preventing colitis, 2 x 105 CD4+CD25+ Treg cells from wt, Ctla4-/- and 
Il2pCtla4TgCtla4-/- mice were co-injected. Mice were weighed weekly and examined 
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 for signs of colitis and wasting. Mice were considered unhealthy if they displayed any 
of these signs: eye inflammation, scruffy coat, weight loss and loose stools. Mice 
were sacrificed and colons removed at 4-5 weeks after T cell reconstitution for 
histological examination.  
 
Mixed bone marrow chimeras (BMC) 
BM was flushed from the femurs and tibias of donor mice and depleted of CD4+ and 
CD8+ T cells using magnetic Dynal beads. 4 x 106 BM cells were injected into lightly 
irradiated (300 rads) Rag1-/- mice via the tail vein. Mice were bled periodically to 
determine reconstitution of the peripheral T cell pool. Mice were sacrificed and 
analyzed at >12 weeks post transfer. 
 
Histological examination 
Organs were removed and fixed in 10% formalin. Four microns paraffin embedded 
sections were cut and stained with hematoxylin and eosin (H&E). At least 4 sections 
and multiple fields were analyzed. 
 
Intestinal intra-epithelial lymphocyte (iIEL) preparation 
Intestinal IELs were prepared using discontinuous density gradient centrifugation. 
Briefly, small intestines were slit longitudinally and cut into 1 cm pieces after 
removing Peyer’s Patches and faecal matter. Intestines were incubated in 2% RPMI at 
370C with gentle stirring for 30 minutes. Tissues were transferred into 50ml conical 
tubes and shaken vigorously for 15 seconds. The cells were filtered over a steel mesh 
and then re-suspended in 3ml of 40% Percoll. The suspension was layered onto 70% 
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 Percoll and centrifuged at 300g for 30 minutes at 200C. The interface, which contains 
IELs, was removed and washed in complete RPMI. iIEL preparations routinely 
contained 75-80% viable cells. 
 
Statistical Analysis 
All data are representative of at least 3 independent experiments. P values were 
calculated using Student’s t-test. 
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 CHAPTER III 
Dab2 programs potential TGFβ responsiveness of T cells during early 
development and is required for Foxp3+ regulatory T cell function. 
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 Introduction 
 The importance of a reservoir of T cells capable of inhibiting the activities of 
potentially self-destructive effector T cells is now widely appreciated. The best 
studied among several different types of suppressor T cell subsets is the thymus-
derived regulatory CD4+T cell subset, called natural regulatory T (Treg) cells. These 
cells are distinguished from conventional T cells primarily based on their expression 
of CD25 (IL-2Rα) and the transcription factor FOXP3 (88), which can be induced in 
developing Treg cells by TGFβ. In humans and mice, mutations in the Foxp3 gene 
lead to fatal, early onset autoimmunity, mirroring the breakdown in T cell tolerance in 
TGFβ-deficient animals (87, 238).  
 
 FOXP3+ Treg cells can also be generated from naïve T cells in the presence of 
TGFβ in vitro (97) or with suboptimal TCR stimulation in vivo (319). TGFΒ-
dependent Foxp3 induction in T cells requires SMAD3, which acts in concert with 
other modulators, most notably NFAT that is activated by TCR signaling, to initiate 
and maintain Foxp3 transcription (115). SMAD recruitment and phosphorylation by 
the TGFβ receptor complex is controlled at multiple levels and there are a myriad of 
adaptors and inhibitors that fine-tune the kinetics, duration and nuclear residency of 
activated SMADs (320). Moreover, the quantity of TGFβ signals is a critical 
parameter controlling naïve CD4+ T cell differentiation, with high concentrations of 
TGFβ required to commit to the FOXP3+ Treg lineage and low concentrations of 
TGFβ leading to the generation of an alternate T cell subset producing pro-
inflammatory cytokines such as IL-17 termed Th17 cells (273). 
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  Several mechanisms for Treg cell-mediated suppression of effector T cell 
activation have been proposed, including the production of regulatory cytokines 
TGFβ (235), IL-10 (130) and IL-35 (135), and modifications of antigen presenting 
cells (APCs) such that they are rendered ineffective in activating T cells (321). An 
emerging theme in the mechanism of Treg-mediated suppression in vivo is that it is 
highly context-dependent and likely involves fail-safe, multiple effector components. 
This lack of dependence on a single, dominant means of immune suppression reflects 
a wide spectrum of conditions in which T cell homeostasis and quiescence must be 
maintained and reestablished subsequent to infection.  
 
 Treg cell-restricted expression of Foxp3 among lymphocytes and the absolute 
requirement for FOXP3 in Treg function have stimulated intensive investigations to 
determine FOXP3 target genes and proteins that are essential for Treg cell function. 
So far only a limited number of possible candidates have emerged: Phosphodiesterase 
3b (Pde3b) inactivates cAMP and its expression is inhibited by FOXP3 (101). 
Enforced over-expression of Pde3b in Treg cells leads to defects in their maintenance 
in vivo. Although the suppressive activities of Pde3b+ Treg cells have not been 
described, cAMPs have been suggested to be important effector molecules of Treg 
cells (144). IL-35 is a newly defined cytokine expressed selectively in Treg cells. It is 
composed of IL-12α and IL-27β, which is encoded by Ebi3, a FOXP3 target gene. 
Ebi3-/- and Il12a-/- mice do not develop spontaneous autoimmunity, but IL-35-
deficient Treg cells display impaired regulatory function in vitro and they are 
ineffective in curing established colitis in cell transfer assays in vivo (135).  
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  Here, we show that Dab2 is a target gene of FOXP3 that is critical for Treg 
cell function in vitro. Unlike previously identified targets of FOXP3 that are 
expressed in other peripheral lymphocyte subsets, Dab2 expression is restricted to 
CD4+ Treg cells. In non-lymphoid cells, Dab2 expression is regulated by the Vitamin 
A metabolite all-trans Retinoic Acid (ATRA) (322) and it has been implicated in 
several critical functions in cell development and transformation, by enhancing 
SMAD activation during TGFβ signaling (248, 323, 324), in GAP junction functions 
(325), and in clathrin coated pit-mediated endocytosis of cell surface receptors (326). 
Homozygous mutation of Dab2 results in early embryonic lethality (318), most likely 
as a consequence of defective signaling in the visceral endoderm by Nodal, a member 
of the TGFβ superfamily of cytokines. Analyses of mice with a T cell-restricted 
Dab2-deficiency show that they generate normal numbers of Treg cells, but these 
Treg cells are defective in function in vitro and in vivo. Dab2 is also expressed during 
thymic T cell development in the precursors in a Foxp3-independent manner. We 
provide evidence that the disruption of DAB2 function in the precursors, but not in 
later thymic developmental phases, including Treg cells, alters the TGFβ signaling 
properties of mature conventional T cells, indicating that TGFβ responsiveness in T 
cells is an inherited, programmable trait regulated by Dab2 at the precursor cell stage.  
 
Results 
Dab2 expression is restricted to Foxp3+ Treg cells and early thymic precursor 
cells. 
 To identify genes regulated by FOXP3, we infected an immature αβ T cell 
lineage thymoma cell line (CD4+CD8+, NFC) with a retrovirus expression vector 
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 containing Foxp3 cDNA. We then performed global gene expression profiling to 
determine genes whose expression was changed by the ectopic Foxp3 expression 
(data not shown). One gene among only a handful that was altered in expression in 
FOXP3+ NFC cells was Dab2 (Drosophila Disabled homolog-2, also called Doc2, 
differentially expressed in ovarian carcinoma 2), as illustrated by a confirmatory RT-
PCR assay (Fig. III-1A). Outside the hematopoietic compartment, Dab2 is widely 
expressed, especially in developing vasculature, placenta, adrenal gland, kidney and 
smooth muscle (327). Among hematopoietic cell subsets, Dab2 is expressed in 
platelets (328), murine macrophages (329), human lymphoid PB-BDCA4+ DCs 
(Novartis, http://wombat.gnf.org) and in the thymus (246). We found that thymic 
precursor cell subset DN3 (CD4-CD8-CD44-CD25+ Fig. III-1B) is the predominant 
population expressing Dab2 in the thymus, followed by DN4 (CD4-CD8-CD44-CD25-
) cells that express 10-30% of the amount detected in DN3 cells. Dab2 mRNA is 
detected at low levels in DP and is absent in CD8SP cells (Fig. III-1B and data not 
shown). Analysis of CD4SP (CD4+CD8-) cells sorted based on FOXP3 expression 
from the FOXP3-IRES-GFP reporter mice (285) showed that Dab2 expression in 
CD4SP thymocyte is restricted to FOXP3+ cells (Fig. III-1B).  
 
 In peripheral lymphocyte subsets, RT-PCR assays showed that Dab2 is 
exclusively expressed in the CD4+CD25+ Treg cells that are FOXP3+ (Fig. III-1C and 
data not shown). Dab2 is also expressed in TGFβ-induced FOXP3+ Treg cells in vitro 
and its expression is enhanced by RA, an inducer of Dab2 expression in non-
lymphoid cells (Fig. III-1D). In T cells, RA has been shown to synergize with TGFβ 
to promote Treg cell generation at the expense of inflammatory Th17 subset 
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Figure III-1: Foxp3 dependent and independent Dab2 expression in regulatory T 
cells and thymic precursor cells 
A. Semi-quantitative RT-PCR (sqRT-PCR) analysis of Dab2 expression (four-fold 
serial dilution of cDNA) in NFC cells that were infected with a control retroviral 
vector (MSCV-GFP) and a retroviral vector carrying the full-length Foxp3 cDNA 
(MSCV-Foxp3-IRES-GFP). Csrp2, Cysteine-rich protein 2, is a potential TGFβ-
regulated gene that has also been classified as a Treg cell signature gene. It is 
marginally induced in expression in conventional peripheral CD4+ T cells transduced 
with a Foxp3 expression vector. B. Real-time PCR analysis of Dab2 expression in 
thymic subsets: DN3, CD4-CD8-CD44-CD25+; DN4, CD4-CD8-CD44-CD25-; DP, 
CD4+CD8+; CD4SPGFP-, CD4+CD8-Foxp3-; CD4SPGFP+, CD4+CD8-Foxp3+. All 
data are normalized to Actb mRNA expression and are representative of 3 individual 
experiments. AU: Arbitrary Units C. RT-PCR analysis of Dab2 expression (one of 
five independent experiments) in peripheral CD4+ and CD8+ lymphocyte subsets, 
sorted by CD25 expression, from B6 and Dab2fl/fl:Cd2 mice. B6 Treg: sorted 
CD4+CD25+ T cells from B6 mice. D. FACS histograms showing Foxp3-GFP 
reporter expression in sorted CD4+GFP- naïve T cells stimulated with anti-CD3 and 
anti-CD28 in the presence or absence of TGFβ (2ng/ml) and all-trans retinoic acid 
(ATRA, 100nM); Real-time PCR analysis of Dab2 mRNA expression, normalized to 
Actb mRNA, in each stimulation condition. Data are representative of 3 individual 
experiments. AU: Arbitrary Units E. Chromatin-immunoprecipitation assay to 
determine FOXP3 binding to Dab2 gene regulatory element; four FOXP3 consensus 
binding sites were identified (circles), two upstream of exon 1 (Utr1, Utr2) and two in 
intron 1 (Int1.1, Int1.2). ChIP assay (one of two independent experiments) on 
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PMA/Ionomycin activated NFC-Foxp3 (F) and NFC-vector alone (V) cells using anti-
FOXP3 Ab showed FOXP3 binding only to Utr2 region (filled circle). The other three 
sites were not occupied by FOXP3. Anti-FOXP3 antibody binding to Pde3b locus 
was used as a positive control.  
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 production (296). These results collectively show that FOXP3 regulates Dab2 
expression in T cells. However, the expression of Dab2 in TN cell subsets that do not 
express Foxp3 (88) indicates that there may be other regulators of Dab2 expression in 
the thymus (330).  
 
 To determine whether FOXP3 directly regulates Dab2 transcription, 
chromatin immunoprecipitation (ChIP) experiments were performed. Relevant 
FOXP3 consensus binding sites in the regulatory sequences of Dab2 were selected 
based on conservation between the mouse and human Dab2 genomic loci. Among 
four such conserved consensus binding sites tested only one located in the 5’ 
untranslated region, ~2.3 kb upstream of the transcriptional site of the Dab2 gene, 
was found to be associated with FOXP3 in FOXP3+ NFC cells (Fig. III-1E). These 
results identify Dab2 as a potential direct target gene of FOXP3. 
 
Dab2 deficiency results in altered Treg cell function 
 The expression pattern of Dab2 in T cells combined with the known 
function of DAB2 as a positive regulator TGFβ signaling in non-lymphoid cells 
strongly suggested that DAB2 regulates TGFβ responsiveness of T cells and 
contributes to Treg cell function downstream of FOXP3. To determine the function of 
DAB2 in thymic precursor cells and in Treg cells, we generated mice lacking Dab2 
specifically in T cells in a developmental-stage controlled manner. We analyzed both 
Cd2 promoter-Cre Tg+ x Dab2fl/fl (referred to as Dab2fl/fl:Cd2) and Cd4 promoter-Cre 
Tg+ x Dab2fl/fl (Dab2fl/fl:Cd4) mice that delete the floxed Dab2 gene during early 
(CD3-CD4-CD8- TN thymocytes) and late (CD4+CD8+DP, αβ T cell lineage 
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 thymocytes) stages of intrathymic T cell development, respectively. In both 
conditional Dab2 knock-out (CKO) lines, Treg cells completely lacked Dab2 
expression (Fig. III-1C and data not shown).  
 
 We first assessed Dab2 function in Treg cells. Mice lacking DAB2 in Treg 
cells were healthy in appearance and did not suffer from overt autoimmunity even at 
10-12 months of age, suggesting that the mutant Treg cells were capable of 
maintaining peripheral T cell tolerance in unmanipulated mice. The development of 
Treg cells was relatively normal in Dab2fl/fl:Cd4 and in Dab2fl/fl:Cd2 mice. There was 
a 2-fold increase in the frequency of CD4+Foxp3+T cells in the thymus (Fig. III-2A) 
and spleen of Dab2fl/fl:Cd2, but not Dab2fl/fl:Cd4 mice (Fig III-2B). This relative 
enhancement of FOXP3+ cells in the CD4+ T cell subset in Dab2fl/fl:Cd2 mice 
increased as mice aged, with nearly half of the CD4+ T cells expressing FOXP3 by 9 
months of age (data not shown). However, at all ages the total numbers of FOXP3+ T 
cells were comparable to wt mice (data not shown), indicating a loss of other 
lymphocyte subsets rather than an increase in the production of Treg cells per se in 
Dab2fl/fl:Cd2 mice (see below). Phenotypically, Treg cells from both Dab2fl/fl:Cd2 and 
Dab2fl/fl:Cd4 mice appeared more activated, as indicated by a higher frequency of 
CD44 expression, compared to wt Treg cells (Fig. III-2C). DAB2 has been shown to 
bind to the clathrin-coated pit adaptor protein AP2, which regulates CTLA-4 
expression by endocytosis (326). However, we did not detect any changes in total or 
surface CTLA-4 expression in these Treg cells (Fig. III-2C). Further, other 
distinguishing cell surface markers of Treg cells, such as GITR and IL-7R (data not 
shown), were normal in expression on Dab2 CKO Treg cells, but a greater frequency 
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Figure III-2 Treg cell development and phenotype in Dab2fl/fl:Cd2 and 
Dab2fl/fl:Cd4 mice. 
A. A representative flow cytometric analysis of thymocytes from littermate wt, 
Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice for intracellular expression of FOXP3 in CD4+ T 
cells. B. A representative flow cytometric analysis of splenocytes from littermate wt, 
Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice for intracellular expression of FOXP3 in CD4+ T 
cells. C. Flow cytometric analysis of expression of CD44, CD62L, CD103, total 
CTLA-4 and surface CTLA4, on CD4+FOXP3+cells from wt and Dab2fl/fl:Cd2 
splenocytes. Shaded histograms represent CD4+FOXP3- cells 
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 of them expressed CD103 (Fig. III-2C), a TGFβ and ATRA regulated integrin 
molecule (297) and a marker of effector Treg cells that controls the homing of Treg 
cells to the gut mucosa (331). 
 
 Given that most proposed mechanisms of Treg function are not exclusively 
required to enforce T cell self tolerance in un-manipulated mice (316), the lack of 
overt disease in Dab2 CKO mice was not necessarily indicative of a lack of role for 
DAB2 in Treg cell function. Thus, we further assessed the functional competence of 
Dab2-deficient Treg cells using the standard assays. We first tested the ability of 
purified CD4+CD25+ Treg cells from Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice to suppress 
naïve T cell proliferation in vitro. Whereas wt Treg cells suppressed the proliferation 
of responder T cells in a Treg cell number-dependent manner, Treg cells from 
Dab2fl/fl:Cd2 mice were completely unable to suppress effector T cell proliferation. 
(Fig III-3A). A similar defect was observed with Treg cells from Dab2fl/fl:Cd4 mice 
(data not shown). 
 
To determine the mechanistic parameters that contribute to the defective function of 
Dab2-deficient Treg cells, we examined some of the potential candidates of Treg cell-
mediated immune suppression in vitro. Treg cells from Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 
mice produced normal amounts of IL-10 as measured by ELISA (Fig. III-3B) and 
RT-PCR, expressed comparable amounts of TGFβ and Ebi3 at the transcriptional 
level and expressed normal amounts of Granzyme B protein (data not shown). There 
were also no dramatic alterations in the expression of select TGFβ-regulated genes 
(Data not shown). Recently, it was shown that Treg cells suppress target cell 
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Figure III-3: Treg cells from Dab2-deficient mice are not functional in vitro 
A. Proliferation of responder CD4+ effector T cells co-cultured with varying numbers 
of sorted and pre-activated CD4+CD25+ cells from wt or Dab2fl/fl:Cd2 mice. Cells 
were stimulated with plate bound anti-CD3 plus anti-CD28 and proliferation was 
measured by 3H thymidine incorporation at 65 hrs post-activation. One of six 
independent experiments with similar results is shown. B. IL-10 production by anti-
CD3 plus anti-CD28 stimulated CD4+CD25+ cells from wt, Dab2fl/fl:Cd2 and 
Dab2fl/fl:Cd4 mice as measured by standard ELISA. One of two independent 
experiments with similar results is shown. C. CD4+T cells from Ly5.1 congenic mice 
were co-cultured with Calcein AM-loaded wt or Dab2fl/fl:Cd2 CD4+CD25+ Treg cells 
and stimulated with plate-bound anti-CD3 plus anti-CD28. Gap-junction function was 
assessed by determining the frequency of Calcein+Ly5.1+ cells at 16 hours of culture. 
Data are averaged over 3 independent experiments. D. Cytosolic cAMP 
concentrations in sorted CD4+CD25+ Treg and CD4+ CD25- conventional T cells 
from wt and Dab2fl/fl:Cd2 mice as measured by a standard cAMP ELISA. One of two 
independent experiments with similar results is shown. 
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 proliferation and activation by transferring cAMP through GAP junctions to effector 
T cells (144). Since DAB2 is known to interact with connexins that make up the GAP 
junctions (325), we tested whether Dab2-deficient Treg cells were poor suppressors in 
vitro because they had deficiencies in GAP junction-mediated intercellular 
communication (GJIC). We labeled Treg cells from wt and and Dab2fl/fl:Cd2 mice 
with a GAP junction transferable dye, Calcein AM, and co-cultured these with 
congenically marked wt responder cells. Dab2-deficient Treg cells were unable to 
transfer the dye as efficiently as wt Treg cells (Fig. III-3C). In addition Dab2-
deficient Treg cells expressed higher amounts of intracellular cAMP compared to wt 
Treg cells (Fig. III-3D). These results suggest that one impaired function in Dab2-
deficient Treg cells involves the GJIC, while other mechanisms of Treg cell-mediated 
suppression examined appeared largely intact. 
 
 Next, we determined the ability of purified Treg cells from Dab2fl/fl:Cd2 and 
Dab2fl/fl:Cd4 mice to control co-injected pathogenic naïve T cells when transferred 
into lymphopenic animals. In contrast to the complete lack of function of Dab2-
deficient Treg cells in vitro, they were as effective as wt Treg cells in preventing the 
induction of colitis by naïve T cells transferred to Rag1-/- mice (Fig. III-4A). 
However, in a more stringent model of Treg function, Dab2-deficient Treg cells were 
incapable of moderating already established colitis (332) (Fig. III-4B). While wt 
Tregs efficiently reversed colitis, both Dab2fl/fl:Cd2  and Dab2fl/fl:Cd4 Treg cells were 
incapable of regulating lymphocyte infiltration and accumulation in the colon (Fig. 
III-4C). However, while mice receiving Dab2-deficient Treg cells could not maintain 
health as compared to mice that received wt Treg cells, histological analysis of colons 
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Figure III-4: Dab2-deficient Treg cells are functionally impaired in vivo 
A. 4 x 105 sorted CD4+CD25- T cells with or without 2 x 105 sorted CD4+CD25+ cells 
from wt or Dab2fl/fl:Cd2 mice were i.v. injected into Rag1-/- recipients (n=4 for each 
group; one of three independent experiments with similar results is shown).  Mice 
were weighed and health was monitored weekly for visible signs of colitis, 
inflammation or wasting. Mice were euthanized if they lost more than 25% of starting 
weight. B. 5 x 105 sorted naïve CD4+CD25- CD45RBhi T cells were injected intra-
peritoneally (i.p.) into Rag1-/- recipients. Four weeks after transfer, 1 x 106 sorted 
CD4+CD25+ Treg cells from wt, Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice were i.p. 
injected and mice were weighed and health was monitored weekly for visible signs of 
colitis, inflammation or wasting. C. At 5 weeks after transfer of Treg cells, mice were 
euthanized and colons were prepared for histological analysis. Representative H&E 
stained sections of colons from mice that received naïve T cells only, naïve T plus wt 
Treg cells, naïve T plus Dab2fl/fl:Cd2 Treg cells and naïve T plus Dab2fl/fl:Cd4 Treg 
cells are shown. Original magnification is 10x. 
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 at 2 months after Treg cell transfer showed that Dab2-deficient Treg cells could 
partially control some aspects of colitis like mucin-cell depletion (data not shown).  
 
 To determine whether T cell response against pathogen was perturbed in 
Dab2fl/fl:Cd2 mice, they were challenged with LCMV (clone 13, whose clearance in 
mice is inhibited by IL-10 (333) or acutely infected with Leishmania major (334). 
The mutant mice resolved the infections relatively normally despite a dramatic 
difference in the number of T lymphocytes in Dab2fl/fl:Cd2  mice (data not shown) 
and in the case of LCMV infection, a delayed CD8 T cell activation and an impaired 
CD4 T cell mobilization (data not shown). Whether Treg cells are responsible for the 
altered immune response in the LCMV model will require further studies. 
Collectively, these results indicate that while DAB2 is essential for Treg cell-
mediated suppression of effector T cell proliferation in vitro, and may contribute to 
Treg cell-mediated immune modulation during infection, it is not absolutely required 
for Treg cell-mediated maintenance of T cell homeostasis and T cell tolerance in vivo. 
 
Altered lymphocyte development in Dab2fl/fl:Cd2 mice. 
 While Dab2 expression is restricted to Treg cells in the periphery, there is 
FOXP3-independent Dab2 expression in early T cell precursors in the thymus (Fig. 
III-1B). To determine the function of DAB2 in precursors, we reasoned that T cell 
defects seen in Dab2fl/fl:Cd2 mice but not in Dab2fl/fl:Cd4 mice would identify 
developmental stage-specific DAB2 function (Fig. III-5A). This comparison was 
made relatively straightforward because the only lymphocyte defect observed in 
Dab2fl/fl:Cd4 mice involved FOXP3+ Treg cells. In contrast, Dab2fl/fl:Cd2 mice 
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Figure III-5: Precursor stage specific deletion of Dab2 using Cd2CreTg+ and 
Cd4CreTg+ mice
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Figure III-5: Precursor stage specific deletion of Dab2 using Cd2CreTg+ and 
Cd4CreTg+ mice. 
A. Schematic of thymocyte development depicting the stages at which Cd2Cre and 
CD4Cre transgenes are expressed and delete flox’d target substrates. B. Real-time 
PCR analysis of Dab2 expression in sorted DN3 (CD4-CD8-CD44-CD25+) and DN4 
(CD4-CD8-CD44-CD25-) cells from Dab2 fl/fl:Cd4 and Dab2fl/fl:Cd2 mice. Data are 
normalized to Actb mRNA and are representative of three independent experiments. 
AU: Arbitrary Units. 
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 exhibited extensive alterations in T cell development and homeostasis, in addition to 
the common Treg cell defect.  
 
 We first confirmed that Dab2 expression was lost in the precursor cells of 
Dab2fl/fl:Cd2, but not in Dab2fl/fl:Cd4 mice. Real-time PCR analysis of DN3 and DN4 
thymocytes showed that the Dab2 mRNA is absent in Dab2fl/fl:Cd2 compared to 
Dab2fl/fl:Cd4 mice. (Fig. III-5B). Dab2 deletion at the thymic precursor stage resulted 
in subtle alterations in T cell development. The average total thymocyte number was 
consistently decreased by 50% in Dab2fl/fl:Cd2 mice relative to Dab2fl/fl:Cd4 or wt 
mice (Fig. III-6A), but the distribution of precursor and mature αβ T cells was 
relatively normal (Fig. III-6B, C). The absolute numbers of γδTCR+ was normal as 
their proportions among thymocytes increased (Fig. III-6D). However, one of the 
most notable effects of Dab2 deletion at the precursor stage was on the frequency and 
number of NKT cells which was significantly decreased (Fig. III-6D and data not 
shown). The Dab2 deficiency did not result in a significant increase in apoptosis of 
thymocyte subsets, as cell surface AnnexinV expression profiles of thymocytes from 
the CKO and LMC mice were similar (data not shown).  
 
 In the periphery, Dab2 deficiency resulted in decreased cellularity in the 
spleen and lymph nodes of Dab2fl/fl:Cd2, but not Dab2fl/fl:Cd4 mice (Fig. III-7). 
There was a significant decrease in the frequency of CD8+, and to a lesser extent 
CD4+ T cells in secondary lymphoid organs of Dab2fl/fl:Cd2 mice (Fig III-8A). The 
deficit largely arose from the loss of naïve T cells, as the number of activated 
(CD44hiCD62Llo) T cells was comparable to LMCs (Fig. III-8B). The decrease in 
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Figure III-6: Altered thymocyte development in Dab2fl/fl:Cd2 mice 
A. Total thymocyte numbers from 4-6 weeks old wt, Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 
mice. B. Thymocytes from wt, Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice were analyzed for 
expression of CD4 and CD8 markers by flow cytometry. C. Thymocytes from wt, 
Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice were analyzed for expression of CD44 and CD25 
markers on TN (CD4-CD8-CD3-) cells by flow cytometry. D. Thymocytes from wt, 
Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice were analyzed for expression of the γδ TCR by 
flow cytometry. E. Thymocytes from wt, Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice were 
analyzed for expression of TCRβ and CD1d tetramer by flow cytometry to identify 
NKT cells.  
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Figure III-7:  Dab2fl/fl:Cd2 mice have decreased cellularity of secodnary
 lymphoid organs compared to Dab2fl/fl:Cd4 mice.
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Figure III-7: Dab2fl/fl:Cd2 mice have decreased cellularity of secondary lymphoid 
organs compared to Dab2fl/fl:Cd4 mice. 
Total lymphocyte cellularity in peripheral lymph nodes (LN: inguinal, brachial and 
axillary), mesenteric lymph node (MLN) and spleen of 6-8 weeks old wt, 
Dab2fl/fl:Cd4 and Dab2fl/fl:Cd2 mice. p values are shown on each graph. 
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 peripheral lymphocyte number was not due to increased apoptosis of T cells in 
peripheral lymphoid organs, as measured by AnnexinV staining (data not shown).  
 
 Similar to Dab2fl/fl:Cd2 mice, Cd4Cre Tg+ TGFβRIIfl/fl (TGFβRIIfl/fl: Cd4) 
mice also have reduced frequencies of CD8+ T cells in the thymus and spleen, in 
addition to reduced frequencies of NKT cells in these organs(264, 265). Consistent 
with the decrease in NKT cell numbers in the thymus of Dab2fl/fl:Cd2 mice, the 
frequency of NKT cells in the spleen was also decreased more than 2-fold, leading to 
a ~4 fold reduction in their numbers in the spleen (Fig. III-8C). However, this 
decrease was not seen in Dab2fl/fl:Cd4 CKO mice (Fig. III-8C). These results 
indicated that Dab2 deficiency in thymic precursors, similar to the TGFβRII-
deficiency in αβ T cells starting at the CD4+CD8+ double positive thymocyte stage, 
led to the aberrant development and/or maintenance of naïve lymphocytes, CD8+ T 
and NKT cells. These results suggest that the developing T cells in Dab2fl/fl:Cd2 mice 
are likely impaired in TGFβ signaling. The defects are hematopoietic cell-intrinsic 
since in mixed bone marrow (BM) chimeras generated using irradiated Rag1-/- hosts 
reconstituted with 1:1 mixtures of T cell-depleted BM cells from Dab2fl/fl:Cd2 and wt 
mice the selective loss of NKT and CD8+ T cells was observed among donor cells 
originating from the Dab2-deficient T cell progenitors, but not among the partner wt 
cells. No alterations in T cell subset reconstitution were observed in Dab2fl/fl:Cd4 and 
wt mixed BM chimeras (data not shown). 
 
Altered TGFβ responsiveness of naïve conventional T cells from Dab2fl/fl:Cd2 
mice. 
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Figure III-8: Altered peripheral homeostasis of lymphocytes in Dab2 fl/fl:Cd2 
mice. 
A. Left; Representative flow cytometric dot plot showing frequency of CD4 and CD8 
cells in LN, MLN and spleen of wt and Dab2fl/fl:Cd2 mice. Right; Numbers of CD4+ 
and CD8+ cells in LN, MLN and spleen. B. Flow cytometry analysis of expression of 
CD44 and CD62L on CD4+ and CD8+ T cells in the spleen of wt and Dab2fl/fl:Cd2 
mice.  C. Numbers of CD1d tetramer+TCRβ+ (NKT) cells in the spleen of Dab2 
fl/fl:Cd4, Dab2fl/fl:Cd2 and wt LMC mice. Data in (A), (B), and (C) are representative 
of more than five independent experiments with 2-3 mice per group. p values are 
indicated on each graph (error bars, SEM) 
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  Given that conventional mature T cells do not express Dab2, and that 
Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice have similar alterations in Treg cells, the 
peripheral T cell defect in Dab2fl/fl:Cd2 mice is primarily due to the effect of Dab2 
deficiency originating from the precursors, and is independent of defects in Treg cells 
that are common to Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice nor can it prevented by wt 
Treg cells in the mixed BM chimeras. We reasoned that since DAB2 is an 
intermediate of the TGFβ signaling pathway shown to enhance SMAD2/3 activation 
(248), and Dab2fl/fl:Cd2 mice exhibit defects in lymphocyte subsets overlapping with 
those observed in TGFβRIIfl/fl:CD4 mice, the TGFβ responsiveness of conventional 
CD4+CD25- T cells from Dab2fl/fl:Cd2, but not Dab2fl/fl:CD4, mice may be altered. To 
test this we first examined whether the proliferation of naïve T cells from 
Dab2fl/fl:Cd2 mice was inhibited by TGFβ in vitro. CFSE-labeled naïve CD4+CD25- 
conventional T cells from wt, Dab2fl/fl:Cd2 and Dab2fl/fl:Cd4 mice were activated with 
anti-CD3 and anti-CD28, with or without TGFβ. While T cells from wt and 
Dab2fl/fl:Cd4 mice were inhibited by TGFβ in the culture (Fig. III-9A), that resulted 
in decreased cell recovery (data not shown), proliferation of T cells from Dab2fl/fl:Cd2 
mice was not affected by the addition of TGFβ.  
 
 TGFβ plays a pivotal role in regulating the balance between the generation of 
FOXP3+ Treg cells and pro-inflammatory Th17 cells (285, 286). TGFβ can direct the 
conversion of conventional murine CD4+ T cells into Foxp3 expressing anti-
inflammatory Treg cells in vitro, but in the presence of proinflammatory cytokine  
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Figure III-9: Altered TGFβ responsiveness of peripheral CD4+CD25- cells from 
Dab2fl/fl:Cd2 mice. 
A. Sorted and CFSE loaded CD4+CD25- conventional T cells from wt, Dab2 fl/fl:Cd4 
and Dab2fl/fl:Cd2 mice were activated with anti-CD3 plus anti-CD28 in the presence 
or absence of rTGFβ (2ng/ml).  Percent inhibition of proliferation by TGFβ was 
calculated using the formula ((%Divided-TGFβ - %Divided+TGFβ)/ %Divided-TGFβ)*100. 
One of three independent experiments is shown. B. Representative flow cytometric 
analysis of induced FOXP3 expression in sorted CD4+CD25- T cells from Dab2 
fl/fl:Cd4, Dab2fl/fl:Cd2 and wt LMC mice stimulated in vitro with TGFβ. One of five 
independent experiments is shown. C. Flow cytometric analysis of IL-17 and IFNγ 
production by TGFβ and IL-6 stimulated CD4+CD25- T cells from Dab2 fl/fl:Cd4, 
Dab2fl/fl:Cd2 mice and wt LMC mice. Cells were also stimulated under non-skewing 
conditions to establish baseline cytokine production. One of five independent 
experiments with similar results is shown. D. Flow cytometric analysis of FOXP3 
expression in TGFβ and ATRA stimulated CD4+CD25- cells from wt and 
Dab2fl/fl:Cd2 mice. E. Western blot analysis of SMAD2 phosphorylation in total 
splenocytes from wt and Dab2fl/fl:Cd2 mice stimulated with (+) and without (-) TGFβ 
for 1 hr at 37oC; ERK2, loading control. 
 
165
 such as IL-6, TGFβ can divert naïve CD4+ T cells to the Th17 lineage. We compared 
the ability of CD4+CD25- T cells from Dab2fl/fl:Cd2, Dab2fl/fl:Cd4, and  LMC mice to 
differentiate into these two lineages. CD4+CD25- T cells from Dab2fl/fl:Cd2 mice were 
inefficient at generating FOXP3+Treg cells when cultured TGFβ, while T cells from 
Dab2fl/fl:Cd4 mice were similarly responsive as wt T cells to TGFβ to induce FOXP3 
expression (Fig. III-9B). In contrast, CD4+ T cells from Dab2fl/fl:Cd2 mice were 
efficient in generating IL-17 producers when TGFβ and IL-6 were present in culture 
(Fig. III-9C). There was also a small but consistent increase in the frequency of Th17 
cells generated by Dab2fl/fl:Cd2 CD4+T cells as compared to Dab2fl/fl:Cd4 CD4+T 
cells. This indicated that the TGFβ signaling in T cells from Dab2fl/fl:Cd2 mice was 
inadequate to induce FOXP3 expression, but it was sufficient to differentiate naïve 
CD4+ T cells to the Th17 lineage and that the signaling pathway required for the 
inhibition of FOXP3 expression by proinflammatory cytokine IL-6 was also intact. 
The Dab2-deficient T cells were not generally altered in CD4+ T cell subset 
differentiation since they were normal in their ability to generate Th1 cells in a Th1-
skewing culture condition, and further, TGFβ signals required to inhibit Th1 
differentiation were also intact (data not shown). These results point to a specific 
defect in TGFβ signaling to induce Foxp3 expression in CD4+ T cells from 
Dab2fl/fl:Cd2 mice that had developed from precursors lacking Dab2.  
 
 The vitamin A metabolite ATRA has also been implicated in maintaining a 
balance between the generation of regulatory versus inflammatory T cell subsets by 
synergizing with TGFβ to block proinflammatory cytokine driven Th17 subset 
generation (296). While ATRA cannot induce Dab2 expression in the absence of 
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 TGFβ in naïve wt T cells (Fig. III-1D), it was possible that ATRA could enhance 
and/or bypass TGFβ signals leading to induction of FOXP3 that were altered in naïve 
CD4+ T cells from Dab2fl/fl:Cd2 mice. Indeed, the addition of ATRA along with 
TGFβ was able to overcome the aberrant TGFβ signaling in Dab2-deficient T cells to 
produce a normal proportion of FOXP3+ T cells (Fig. III-9D). Hence, the defect in T 
cells generated from Dab2-deficient precursors is due to impairment in TGFβ 
signaling, one which can be overcome by synergistic ATRA signals. These results 
also demonstrate that the inducible Dab2 expression in conventional T cells is not 
non-redundantly required for ATRA-mediated promotion of FOXP3+ T cell 
production.  
  
 Finally, since Dab2fl/fl:Cd2 conventional T cells were impaired in TGFβ 
signaling, we investigated the activity of TGFβ-activated nuclear effectors SMAD2 
and SMAD3 by examining their phosphorylation state in TGFβ treated T cell 
cultures. While wt CD4+ T cells cultured without TGFβ contained minimal amounts 
of phosphorylated SMAD2 protein, the basal level of SMAD2 (and SMAD3, data not 
shown) phosphorylation was higher in ex vivo T cells and CD4+ thymocytes from 
Dab2fl/fl:Cd2 mice (Fig. III-9E and data not shown). Within 30-60 min of TGFβ 
stimulation maximally elevated amounts of SMAD2 phosphorylation was detectable 
in CD4+ T cells from wt mice, but in the mutant T cells minimal TGFβ-dependent 
induction was observed. SMAD3 phosphorylation pattern in CD4+ T cells from 
Dab2fl/fl:Cd4 mice was comparable to those from LMCs (data not shown). These 
results indicate that the regulation of the receptor associated SMAD2/3 activation is 
aberrant in T cells that had differentiated from Dab2-deficient precursors.  
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Discussion 
 Dab2 is a FOXP3 target gene whose expression among peripheral 
lymphocytes is restricted to CD4+ Treg cells. We have shown that Dab2 is absolutely 
required for in vitro and in vivo suppression of effector T cells by Treg cells. 
Strikingly, DAB2 also has a unique, FOXP3-independent function in ensuring normal 
development and maintenance of TGFβ-dependent lymphocyte subsets and 
programming TGFβ responsiveness of conventional ab lineage T cells. By virtue of 
the restricted Dab2 expression in T cell precursors and the defects associated with its 
absence, it is apparent that the TGFβ signaling competence of mature T cells is set 
during their early intrathymic differentiation. The absence of Dab2 in thymic 
precursor cells results in impaired persistence of TGFβ-dependent CD8+ T cells and 
NKT cells in the periphery and the generation of mature conventional CD4+ T cells 
that are defective in TGFβ signaling.  We propose that DAB2 is necessary to calibrate 
TGFβ signaling during early T cell development since the impairment in TGFβ 
signaling is selective and appears to affect the processes requiring relatively strong 
TGFβ signaling, such as the induction of FOXP3+ T cells from naïve T cells (273). 
Further, the defect can be overcome by ATRA, a factor that normally enhances TGFβ 
signaling in T cells, indicating that the absence of DAB2-mediated calibration in the 
thymic precursors does not disable TGFβ signaling completely.   
 
 Given the FOXP3-dependent expression of Dab2 among mature lymphocytes 
and the critical function of Dab2 in setting TGFβ responsiveness during T cell 
development, one prediction was that Dab2 CKO mice would phenocopy the loss of 
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 Treg cells observed in mice with defective TGFβ signaling (Rubtsov and Rudensky, 
2007). However, Dab2 CKO mice maintained normal numbers of Treg cells, 
indicating that TGFβ signaling requirements are distinct in conventional T cells 
versus Treg cells. Further, Dab2 CKO mice are healthy suggesting that Dab2-
deficient Treg cells are functionally intact in vivo. Curiously, defects in Dab2-
deficient Treg cells are revealed in vivo only when these cells are purified and 
transplanted along with effector T cells into immunodefficient Rag-/- mice. In vitro, 
however, Dab2-deficient Treg cells cannot suppress conventional T cell proliferation. 
This dichotomy suggests that either the in vitro suppression relies on a very different 
mechanism than the in vivo Treg cell activities and/or that the latter involves multiple, 
possibly redundant, modes of immunosuppression. Data exist to support both 
possibilities. For instance, IL-10, TGFβ and CTLA-4 are not required for Treg cell-
mediated suppression of effector T cells in vitro (316), but each is variably required in 
different in vivo settings of immune suppression by Treg cells (130, 221, 235). None 
of these effectors appear to be aberrantly regulated in Dab2-deficient Treg cells. 
Conversely, while IL-35 is necessary for optimal Treg cell function in vitro, un-
manipulated Il35-/- mice exhibit normal T cell homeostasis (135). Dab2-deficient Treg 
cells express comparable amounts of FOXP3-regulated Ebi3 at the RNA level and 
they are functionally distinct from Ebi3-/- Treg cells, suggesting that IL-35 and DAB2 
belong to two independent regulatory pathways. Although the reduced GAP junction 
activities appear to be the only distinguishing feature of Dab2-deficient Treg cells that 
has previously been correlated with the impaired in vitro immune suppression, 
whether this is the cause of the Dab2-deficient Treg cell defect remains to be proven.  
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  Irrespective of the underlying mechanism of in vitro suppression, the 
relevance of DAB2 for Treg function in vivo remains to be determined.  There are at 
least three non-mutually exclusive explanations to account for the maintenance of T 
cell homeostasis in un-manipulated Dab2 CKO mice: One, biochemical processes 
regulated by DAB2 is not essential for in vivo Treg function. Two, DAB2-mediated 
function may only be critical in settings other than in homeostasis, such as during 
infection when relative TGFβ availability may be limiting. Three, other compensatory 
components can mask the effects of Dab2-deficiency, especially a myriad of Treg 
cell-intrinsic and cell-extrinsic TGFβ signaling modulators that have yet to be 
characterized in the lymphoid system. One appealing candidate for the latter is the 
ATRA signaling, which appears to be operational in Dab2-deficient T cells (Fig. III-
9D), and one that has been shown to synergize with TGFβ for enhancing Treg cell 
generation from naïve CD4+ T cells at the expense of pro-inflammatory Th17 
development.  ATRA can override the TGFβ signaling deficiencies in naïve CD4+ T 
cells generated from Dab2-deficient precursors to induce FOXP3+ T cells in vitro, and 
the normal function of Dab2-deficient Treg cells in vivo may also result from ATRA 
or other synergistic measures available to compensate for the intrinsic, suboptimal 
TGFβ or other DAB2-regulated activities in T cell subsets. The possibility that ATRA 
is masking the effects of Dab2-deficiency is currently being examined in Vitamin A 
and Dab2 double deficient mice. 
  
 One of the unexpected observations about DAB2 function is its involvement 
during early T cell development in calibrating TGFβ signaling competence of the 
mature T cell progenies. The TGFβ signaling defect observed in Dab2fl/fl:Cd2 mice 
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 only partly recapitulates the immune dysregulation in TGFβRIIfl/fl:CD4 mice (238, 
264, 265). While the loss of CD8+ T, NKT and naïve T cells and increased production 
of Th1 cytokine IFNγ (data not shown) are observed in both mouse mutant models, 
TGFβRIIfl/fl:CD4 mice are replete with activated T cells and they succumb to lethal 
autoimmune diseases that cannot be completely reversed by the infusion of wt Treg 
cells (264). An explanation for this difference is that the Dab2-deficiency alters the 
quality and perhaps the threshold of TGFβ signaling but it does not abrogate the 
TGFβ function in all cell types so that the generation and maintenance of TGFβ-
regulated T cell subsets such as Treg and Th1 cells in vivo and Treg cell-independent, 
TGFβ signaling-dependent maintenance of naïve T cell quiescence are relatively 
unperturbed.  
 
 The biochemical basis for the altered TGFβ signaling capacity originating in 
the T cell precursors of Dab2fl/fl:Cd2 mice is not addressed here, but it appears that 
the receptor-associated SMADs can be phosphorylated in Dab2-deficient T cells, 
suggesting that the defect lies downstream of the membrane proximal events. 
Although the increased amount of activated SMAD2/3 in non-TGFβ treated, ex vivo T 
cells from Dab2fl/fl:Cd2 mice (Fig. 4E) can be viewed as evidence for DAB2 as a 
negative regulator of TGFβ signaling, T cells that had developed from Dab2-deficient 
precursors are clearly not hyper-responsive to TGFβ in vivo or in vitro. In some 
cancer cells that are insensitive to TGFβ-mediated growth inhibition, hyperactivation 
of SMAD2/3 is also observed, indicating that enhanced basal SMAD2/3 
phosphorylation is not necessarily linked to enhanced TGFβ-responsiveness (335). 
Rather, the aberrant pattern of SMAD2/3 phopsphorylation in conventional T cells of 
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 Dab2fl/fl:Cd2 mice may indicate an adaptation by the TGFβ signaling defective T cells 
to be maintained in the periphery or a selective enrichment of the “adapted” T cells. 
Given the association of DAB2 with diverse intracellular processes in non-lymphoid 
cells, it is currently a major challenge to determine the repertoire of DAB2 activities 
in T cells and to characterize additional components of the TGFβ signaling cascade 
that may interact with DAB2. Hence, although convincing data exist to indicate that 
DAB2 positively controls TGFβ signaling during development and in diverse cell 
types (248, 249, 318, 323, 324), it remains formally possible that in T cells the 
apparent defects in TGFβ signaling may arise from alterations in other Dab2-
dependent pathways that can impact TGFβ signaling competence. Single cell tracking 
of Dab2 expression in the differentiating precursors and detailed biochemical studies 
of TGFβ signaling in the absence of Dab2 are required to definitively establish how 
Dab2 programs TGFβ signaling competence of mature T cells during their early 
intrathymic differentiation. 
 
 Collectively, DAB2 is modeled as a cell-intrinsic modulator of TGFβ 
signaling during T cell differentiation and selective expression of Dab2 in discreet 
cell subsets may permit cell lineage diversification based on the differential sensing of 
TGFβ. Consistent with the strength of TGFΒβ signaling as a decisive event in T cell 
differentiation it has been shown recently that low concentrations of TGFβ synergize 
with IL-6 to drive pro-inflammatory Th17 generation from naïve CD4+ T cells while 
high concentrations of TGFβ program anti-inflammatory Treg cell generation (273). 
The restricted FOXP3-regulated DAB2 expression in Treg cells may contribute to 
amplified, strong TGFβ signaling in a positive auto feedback loop. Additionally, 
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 naïve CD4+ T cells that had differentiated from Dab2-deficient precursors favor Th17 
generation at the expense of FOXP3+ Treg cells because they have reduced sensitivity 
to TGFβ. Importantly, ATRA can restore TGFβ signaling capacity of naïve CD4+ T 
cells generated from Dab2-deficient precursors, emphasizing the cooperative nature 
of these two signaling pathways in promoting Treg cell development and 
maintenance.  
 
Materials and Methods 
Mice 
Dab2fl/fl (B6 x 129) mice (318) were backcrossed 4 times onto B6 background. T cell 
specific deletion of Dab2 was obtained by crossing Dab2fl/fl mice with Cd2CreTg+ 
(317) and Cd4CreTg+ mice (336). Genotypes were determined by PCR analysis. Mice 
were analyzed at 6-8 weeks of age unless otherwise indicated. Foxp3eGFP reporter 
mice (285) were a kind gift from V. Kuchroo, provided by L. Selin. All mice used in 
these experiments were housed in a specific pathogen-free rodent barrier facility. All 
experiments were approved by the University of Massachusetts Medical School 
Institutional Care and Use Committee.  
 
Antibodies, Flow cytometry and cell sorting 
Fluorescently labeled antibodies specific to CD4, CD8a, NK1.1, CD44, CD62L, 
CTLA-4, CD103, IL-17, IFN-g and Granzyme B were purchased from BD 
Pharmingen and antibodies specific to Foxp3, CD25, CD127, GITR, CD3e and TCRb 
were purchased from eBiosciences. Intra-cellular staining for IL-17, IFN-g and Foxp3 
were performed according to the manufacturer’s protocol. PE conjugated a-gal-
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 ceramide tetramer was a kind gift from L. Berg (UMMS). All samples were acquired 
on an EPICS XL cytometer (BD-Coulter, Hialeah, FL) or LSRII (BD), and data were 
analyzed using FlowJo software (Treestar, San Carlos, CA). Ex vivo thymic subsets, 
peripheral T cell subsets including CD4+CD25- conventional T cells and CD4+CD25+ 
Treg cells were sorted to greater than 95% purity using MoFlo (Cytomation) cell 
sorter.  
 
Retroviral Infection 
NFC (CD4+CD8+, DP) thymoma cells were infected with a control MSCV retroviral 
vector containing GFP or with an MSCV retroviral vector carrying the full-length 
Foxp3cDNA cloned upstream of an IRES and GFP. Stable cell lines that express 
vector alone (V) and MSCV-Foxp3 (F) were generated by cell sorting and maintained 
in complete DMEM. 
 
RT-PCR and real-time PCR 
For reverse transciption-polymerase chain reaction (RT-PCR), total RNA was isolated 
from purified cells (Trizol Reagent, Invitrogen) and cDNA was prepared using an 
Omniscript RT-PCR kit (Qiagen). For semi-quantitative RT-PCR (sqRT-PCR), 5-fold 
serial dilutions of cDNA were used. PCR primers used are listed in Supplemental 
Data 1. For real-time PCR, cDNA was prepared as described, and amplification was 
performed using iQ SYBR Green supermix (BioRad). All data were normalized to 
Actb mRNA expression and represented as arbitrary units (AU). 
 
Chromatin Immunoprecipitation Assays 
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 Foxp3 over-expressing NFC cells (F) and vector control cells (V) were stimulated 
with PMA (50ngml) and Ionomycin (100ng/ml) at 37oC for 24 hours. ChIP assays 
were performed on 1 x 106 cells using the ChIP Assay Kit (Upstate Cell signaling 
Solutions, Charlottesville, VA). Immuno-precipitation was performed using anti-
FOXP3 antibody (Santa Cruz). The recovered DNA was dissolved in 20 ml of H2O 
and analyzed by PCR. PCR primers used were: Utr2-for 5’- GTA CAG TAA TTG 
GAT AGA CTT TCC-3’ and Utr2-rev 5’ GAG CAA GAG CTC CTG GCA GGC-3’; 
Utr1-for 5’-AGG CAA AGA ATA GTA TAA AAT TCT-3’ and Utr1-rev 5’- TCC 
AGC AAG CAA GGG AAG GTC ATT-3’; Int1.1-for 5’-CTG TGT ATC ATA TAT 
TTA CAT TAT-3’ and Int1.1-rev 5’- AGT GTT TCT CAA TCT CCC CAA TGC-3’; 
Int1.2-for 5’-CAT GAG TTC TGG AGA ACA AAA TTC-3’ and Int1.2-rev 5’-TGC 
TTG TGG ATA CAC GTA TCA AAG-3’; Pde3b-20-for 5-TTT GGG CCG CAT 
AGA GAA AA-3’ and Pde3b-20-rev 5’-CAG TGA ATC AGC AGC ACA A-3’. 
 
In vitro suppression assay 
Sorted CD4+CD25+ were activated in vitro with plate-bound anti-CD3 (0.5mg/ml; 
clone 500A2) and anti-CD28 (1.0mg/ml; clone 37N) in the presence of 100U/ml of 
rIL-2 in complete DMEM (10% FBS, 50uM 2-ME, 2mM L-glutamine, 20mM Hepes, 
0.1mM Non-Essential Amino Acids) for 48 hours. Post-stimulation, varying numbers 
of Treg cells were co-cultured with 5 x 104 freshly isolated CD4+T cells and 5 x 104 
irradiated splenocytes from B6 mice and activated with plate-bound anti-CD3 for 72 
hours. Cultures were pulsed with 1uCi 3H thymidine per well for the final 10-12 hours 
of culture and thymidine incorporation was analyzed on a scintillation counter. 
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 Calcein AM intercellular transfer and cAMP ELISA 
Sorted CD4+CD25+ Treg cells were loaded with Calcein as described in(144). Briefly, 
Treg cells (107/ml) were incubated with 1mM calcein AM at 37oC for 30 minutes in 
serum-free IMDM. After washing twice with IMDM, Tregs were co-cultured with 
Ly5.1+CD4+T cells and activated with plate-bound anti-CD3 (1mg/ml) and anti-CD28 
(2mg/ml) for 16 hours. Calcein transfer was detected on an LSRII (BD). To measure 
intracellular cAMP amounts sorted CD4+CD25+ and CD4+CD25- cells were washed 
in ice-cold PBS and lysed in 0.1NHCl and a cAMP specific ELISA was performed 
according to the manufacturer’s protocol (BioMol and Promega). 
 
In vitro T cell activation and proliferation 
Sorted CD4+CD25- T cells were activated with plate-bound anti-CD3 (0.5mg/ml) and 
anti-CD28 (1.0mg/ml) in complete DMEM for 72 hours. For proliferation assays, 
107cells/ml were labeled with 1mM CFSE (carboxyfluorescein diacetate succinimidyl 
diester; Molecular Probes) in PBS at 37oC for 15 minutes and then washed twice in 
complete DMEM. Proliferation was measured by analysis of the dilution of CFSE by 
flow cytometry. The following cytokines and antibodies were added for effector T 
cell skewing; Foxp3 induction: rTGFβ (2ng/ml; R&D), all-trans retinoic acid (ATRA) 
(100nM; Sigma); Th17: rTGFβ (2ng/ml), rIL-6 (20ng/ml; R&D), anti-IFNγ 
(10mg/ml; eBiosciences); Th1: rIL-12 (5ng/ml; R&D), anti-IL-4 (10mg/ml; BD 
Pharmingen). 
 
Western Blot 
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 CD4+ T cells or thymocytes from wt, Dab2fl/fl:Cd4 and Dab2fl/fl:Cd2 mice were 
stimulated as described in the presence or absence of rTGFβ (2ng/ml) for 30 minutes 
at 37oC. Cells were centrifuged and resuspended in lysis buffer (50mM Tris, pH7.5, 
300mM NaCl, 5mM EDTA, 1%NP-40, 0.1mM Na3VO4 and 1x protease inhibitor 
cocktail (Roche)). Lysates were resolved by SDS-PAGE and electroblotted onto 
nitrocellulose membranes using a BioRad semi-dry transblot apparatus. Western blot 
was performed using antibodies to phospho-Smad-2 (Chemicon International), 
phospho-Smad3 and ERK1/2 (Cell Signaling Technology). Blots were revealed with 
isotype-specific HRP-conjugated secondary antibodies (Sigma) followed by enhanced 
chemiluminescence detection (Pierce, Rockford, IL). 
 
Colitis induction and cure 
4 x 105 CD4+CD25- cells from wt mice were adoptively transferred to lymphocyte-
deficient (Rag1-/-) mice to induce colitis.  To test the function of Treg cells in 
preventing the colitis, 2 x 105 CD4+CD25+ regulatory T cells from wt, Dab2fl/fl:Cd4 
and Dab2fl/fl:Cd2 mice were co-injected. Mice were weighed weekly and examined 
for signs of colitis and wasting.  For colitis “rescue” experiments, 1x106 CD4+CD25+ 
regulatory T cells from wt or Dab2fl/fl:Cd2 mice were injected into Rag1-/- mice that 
had previously received 4x105  CD4+CD25- T cells. Mice were euthanized if >25% 
weight loss was observed. 
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 CHAPTER IV 
GENERAL DISCUSSION 
 
 The immune system has evolved several ways to keep auto-reactive T cells in 
check. Central tolerance operating in the thymus is one mechanism of deleting self-
reactive T cells. However, it is insufficient and additional mechanisms are required to 
ensure the integrity of host tissue and prevent autoimmunity in the periphery. Treg 
cells are critical in this aspect and dominant suppression of autoreactivity by these 
cells ensures peripheral T cell tolerance and immune homeostasis. This thesis 
elaborates the role of two mediators of Treg cell function: CTLA-4, a negative 
costimulatory molecule and DAB2, a TGFβ signaling intermediate. 
 It is widely accepted that CTLA-4 is an important negative regulator of T cell 
autoreactivity. Ctla4-/- mice display an aggressive autoimmune phenotype and die by 
3-4 weeks of age. However, the underlying defect for this dramatic loss in peripheral 
tolerance is unclear and it is still not known when CTLA-4 functions during T cell 
activation, whether it has distinct functions in T cell subsets, and what its functional 
repertoire is. Manipulation of CTLA-4 expression in vivo has been difficult. Because 
CTLA-4 is expressed on both Treg cells as well as activated conventional T cells, the 
effects of anti-CTLA-4 antibody treatment in vivo are complicated to interpret. 
However, anti-CTLA-4 antibodies are currently being tested to treat melanoma and 
prostrate cancer and are poised to come to clinics in the next few years. Although 
effective, the treatment is associated with severe side effects that include colitis and 
uveitis. Paradoxically, tumor regression occurs despite increased Treg cell numbers. 
CTLA-4 is constitutively expressed on Treg cells, and data from our lab and others 
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 have clearly shown that CTLA-4 on Treg cells is critical to prevent autoimmunity. 
Further, a recent study has suggested that blocking CTLA-4 on Treg cells by anti-
CTLA-4 treatment in vivo increases their proliferation but at the same time makes 
them less potent at suppression (337). Accordingly, the original idea of using anti-
CTLA-4 antibodies to remove the ‘block’ in T cell activation needs to be revised, and 
the cellular targets of anti-CTLA-4 antibody in vivo and their function remains to be 
identified.  
 Another approach has been to use RNAi mediated down-modulation of Ctla4 
transcripts in T cells in vivo. This results in an accelerated onset of diabetes in NOD 
mice as well as in NOD x B6.H-2g7 F1 mice that are normally resistant to diabetes. 
This phenotype is starkly different from that of Ctla4-/- mice that suffer from 
indiscriminate autoimmunity. Although the precise expression pattern of residual 
CTLA-4 expression in specific T cell subsets was not examined in this model, these 
results suggest that subtle modulation of CTLA-4 expression in T cells can yield 
distinct immunological outcomes. Indeed, differential levels of expression of CTLA-4 
protein (and isoforms) resulting from Ctla4 gene polymorphsims has been linked to 
susceptibility to several autoimmune diseases such as systemic lupus erythematosus 
(SLE), myasthenia gravis, Grave’s disease and Type 1 Diabetes.  
 The Ctla4-/- mouse stands witness to the fact that CTLA-4 is important for 
preventing self-reactivity of T cells- however it is not a very useful model to 
understand the mechanism of CTLA-4 control over peripheral tolerance, primarily 
because of the aggressive disease that begins very early in age. Viable mouse models 
that allow temporal and spatial control of CTLA-4 expression are required to 
determine the precise regulation of T cell reactivity by CTLA-4. To begin to address 
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 this issue, we have generated different mouse models in which CTLA-4 expression is 
restricted to distinct T cell subsets. Analyses of these mice reveal that CTLA-4 has 
dual and distinct function in activated T cells and Treg cells to maintain T cell 
homeostasis. We propose a model of CTLA-4 function in which CTLA-4 expression 
on FOXP3+ Treg cells is critical to prevent naïve conventional T cell activation in 
trans (Figure IV-1). In the absence of CTLA-4 expression on Treg cells, Tconv cells 
become aberrantly activated and proliferate. However, CTLA-4 expression on these 
activated T cells can moderate inflammation and autoimmune migration of these cells 
into tissues. Although this thesis does not directly address the mechanism by which 
CTLA-4 on Treg cells prevents autoimmunity of conventional T cells, we propose 
that one way is by modulation of antigen presenting cell (APC) function. In this 
model, CTLA-4 expressing Treg cells would efficiently engage B7 molecules on 
APCs and inhibit their capacity to activate Tconv cells. In the event of activation of 
Tconv cells to self-antigen, CTLA-4 expression on activated T cells would inhibit 
emigration into tissues most likely by altering expression of chemokine receptors on 
T cells. In preliminary experiments, we find that the expression of CCR7, a receptor 
essential for lymphocyte retention in lymph nodes and for egress from non-lymphoid 
tissues, is maintained on activated T cells that express CTLA-4 but not on Ctla4-/- T 
cells. This aspect of CTLA-4 function in regulating movement of activated T cells 
requires further investigation. 
 It is important to note here that all the data described in this study address 
CTLA-4 function in the context of ‘aberrant’ activation to self. Thus, during antigenic 
stimulation that is associated with inflammation, as in the case of an infection, for 
instance, CTLA-4 function may be very distinct and may involve regulation of 
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Figure IV-1: CTLA-4 controls aberrant self-reactivity and autoimmune tissue 
migration 
In a naïve mouse, CTLA-4 is primarily expressed on FOXP3+ Treg cells, with little to 
no expression on naïve conventional (Tconv) cells. Treg cells engage APCs that 
express low levels of B7-1/B7-2. Due to the higher affinity of CTLA-4 for B7-1/B7-2, 
they are preferentially ligated by CTLA-4 expressed on Treg cells. This delivers 
inhibitory signals into APCs that lead to the induction of immunosuppressive factors 
such as Indoleamine 2,3-dioxygenase (IDO) and TGFβ (Top Left). Modulation of 
APCs by Treg cells, in combination with the sequestration of B7-1/B7-2 molecules by 
CTLA-4, maintains peripheral tolerance, resulting in Tconv cells receiving only tonic 
TCR survival signals. In contrast, Treg cells lacking CTLA-4 are unable to condition 
APCs, and Tconv cells get aberrantly activated to self-antigen due to increased 
positive costimulation (Top Right). Once activated, however, an additional level of 
regulation is imposed on self-reactive Tconv cells by CTLA-4, which halts the 
migration of these T cells to non-lymphoid sites and prevents autoimmune pathology 
(Middle). As a result, while aberrantly-activated Ctla4-/- T cells can infiltrate tissues 
and cause their fatal destruction (Bottom), TgCtla4 expression only in activated T 
cells prevents this. 
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 proliferation and the ‘burst size’ of the T cell response, apoptosis of activated T cells 
and contraction of the immune response.   
 In addition to CTLA-4, we have identified Disabled-2 (DAB2) as another 
factor that is important for Treg cell function. In this study, we have shown that 
DAB2 is a FOXP3 target gene and its expression is restricted to FOXP3+ Treg cells in 
peripheral lymphoid organs. DAB2 function in Treg cells is essential for in vitro and 
in vivo suppression of conventional T cell reactivity. However, at odds with this 
important role for DAB2 in Treg cells is the fact that Dab2-conditional knockout mice 
do not suffer from any pathology resulting from aberrant Treg cell function. In fact, 
deficiencies in Dab2-deficient Treg cells are only revealed when Treg cell function is 
tested in models involving homeostatic proliferation. For instance, in the cure of 
colitis model, naïve T cells are injected into Rag-/- mice where they proliferate and 
induce colitis. In this model, Dab2-deficient Treg cells are unable to prevent disease. 
Similarly, in a mixed bone marrow chimera system, Treg cells generated from wt BM 
can control the activation and proliferation of Ctla4-/- T cells (this system is described 
in Chapter II). However, in a similar assay, Dab2-deficient Treg cells fail to control 
lymphoproliferation and disease (data not shown). Finally, in preliminary 
experiments, we have sub-lethally irradiated Dab2-conditional knockout mice to 
induce homoeostatic proliferation. Recent data from this experiment shows that while 
wt LMC mice remain healthy at 3 weeks post-irradiation, Dab2-conditional knockout 
mice are sick and are beginning to lose weight. The data are too preliminary to make 
any conclusions, but they support the previous observations that Dab2-deficient Treg 
cells may have a specific role in regulating homeostatic proliferation induced loss of 
tolerance of naïve T cells. 
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  While Dab2 is expressed in FOXP3+ Treg cells in the thymus and periphery, 
this expression is relatively lower compared to Dab2 expression in thymic precursor 
cells (Figure III-1B). One explanation for this is that the signals that regulate Dab2 
expression in Treg cells and thymic precursor cells are probably different. Dab2 
expression is most likely regulated by FOXP3 in peripheral lymphocytes, while Dab2 
expression in thymic precursor cells is clearly FOXP3 independent. Another 
possibility is that Dab2 expression may be restricted to a subset of FOXP3+ Treg cells 
that might have a specific role in the regulation of homeostatic proliferation described 
previously. Context-dependent regulation by Treg cells is not a new concept, and it 
has been shown that Treg cells utilize different effectors to control different aspects of 
tolerance. For instance, IL-10 is critical for the regulation at mucosal surfaces, while 
CTLA-4 is critical for inhibiting the initiation of T cell activation to self-antigen. 
However, so far, the existence of subsets of FOXP3+ Treg cells with distinct 
functionality has not been reported. To begin to address this, we have analyzed Dab2 
expression in Treg cells separated on the basis of expression of specific surface 
markers. In preliminary experiments, we sorted Foxp3eGFP+CD44hiCD62Lhi and 
Foxp3eGFP+CD44loCD62Lhi cells from Foxp3eGFP reporter mice. Real-time PCR 
analysis revealed that Dab2 expression was higher in the more ‘activated’ 
CD44hiCD62Lhi Treg cell population (data not shown). We are currently testing the 
significance of this difference in in vitro and in vivo assays. 
 
 A distinctive phenotype of Dab2-deficient conventional T cells is their altered 
responsiveness to TGFβ signals that regulate the conversion to FOXP3+ Treg cells. 
However, while the generation of the Treg cell lineage is impaired, Dab2-deficient 
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 conventional T cells can respond to TGFβ signals that regulate the conversion to the 
Th17 lineage. The molecular intermediates of the TGFβ signaling pathway that 
regulate differentiation to the FOXP3 versus the Th17 lineage are just beginning to be 
elucidated. Signaling from the TGFβR can activate both the SMAD pathway as well 
as a MAPK pathway leading to JNK phosphorylation. Although the SMAD3 and 
SMAD4 pathways appear to be essential for the conversion of conventional T cells to 
the FOXP3+ Treg cell lineage (280), whether the MAPK pathway of signal 
transduction from the TGFβR is differentially required for the commitment to the 
Th17 cell lineage is unknown.  DAB2 functions as an adaptor molecule in both these 
pathways (248, 249). Therefore, one likely explanation for the ability of Dab2-
deficient conventional cells to convert to Th17 cells could be because of an intact 
MAPK pathway that may be required for Th17 cell generation and an impaired 
SMAD pathway that is essential for FOXP3+ Treg cell generation. It remains to be 
determined if indeed the MAPK pathway of TGFβ signal transduction is intact in 
Dab2-deficient T cells. 
  
 The role of retinoic acid (RA) in regulating Treg cell function and effector T 
cell differentiation is beginning to be unraveled. Of interest is that RA can lift the 
specific defect of Dab2-knockout conventional T cells to convert to FOXP3+ Treg 
cells in the presence of TGFβ. Whether this is due to augmentation of TGFβ signals 
or by a TGFβ independent signaling pathway remains to be determined. Further, there 
are some indications that retinoic acid may by itself serve as a morphogen. The role of 
retinoic acid and DAB2 in the development of thymocytes and peripheral homoestasis 
is currently being investigated.  
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 One function of DAB2 is to serve as an adaptor protein to help SMAD 
proteins associate with TGFβRII. In macrophage cell lines and epithelial cells, DAB2 
functions as a positive regulator of TGFβ signals. Whether DAB2 performs similar 
functions in precursor cells in the thymus and Treg cells in the periphery is not 
known. One indication that DAB2 may have different effects in T cells is the fact that 
there is increased SMAD phosphorylation in the absence of DAB2. The function of 
DAB2 as an interpreter of TGFβ signals is being tested in in vitro over-expression 
studies. 
  
 Based on the data collected so far, we propose a model of DAB2 function in 
which Dab2 expression in thymic precursor cells programs the TGFβ responsiveness 
of mature T cells to TGFβ in the periphery (Figure IV-2). Further, DAB2 is a critical 
effector of Treg cell function and one mechanism by which DAB2 may regulate this 
is by the formation of Gap-Junctions and facilitating transfer of cAMP. 
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Figure IV-2: DAB2 programs TGFβ responsiveness of T cells in the thymus and 
controls Treg cell function 
A. DAB2 expression in DN3 (CD4-CD8-CD25+CD44-) cells in the thymus is 
necessary to program TGFβ responsiveness of mature T effector (Teff) cells in the 
periphery. In the absence of DAB2, the differentiation of Teff cells to FOXP3+ Treg 
cells in the presence of TGFβ is inhibited. However, retinoic acid (RA) can relieve 
this defect and restore normal TGFβ responsiveness.  
B. DAB2 expression in Treg cells is important for Treg cell control of Teff cell 
function. In the absence of DAB2, Treg cells are not functional. 
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